

INDEX

Volume Thirty-five — January through December 2001

The Annals of Pharmacotherapy

JANUARY	Pages 1-146	MAY	Pages 525-662	OCTOBER	Pages 1157-1310
FEBRUARY	Pages 147-276	JUNE	Pages 663-800	NOVEMBER	Pages 1311-1512
MARCH	Pages 277-402	JULY/AUGUST	Pages 801-978	DECEMBER	Pages 1513-1708
APRIL	Pages 403-524	SEPTEMBER	Pages 979-1156		

SUBJECT INDEX

A-B

Abacavir, hypersensitivity (L) 1291
Abciximab, before percutaneous coronary intervention (A) 602; for acute MI, with alteplase (A) 594, with reteplase (A) 594
Abortion, mifepristone with misoprostol (A) 707
Acetaminophen, effect on atherosclerosis (A) 1476; effect on blood alcohol level (A) 921; for atherosclerosis, clinical trials (A) 1477; mechanism of action (A) 1477; inhibition of orthodontic tooth movement (A) 114
N-Acetylcysteine, for veno-occlusive disease (A) 940
Acquired immunodeficiency syndrome, amphotericin B-induced seizures (CR) 1037
Acquired immunodeficiency virus, see also **Human immunodeficiency virus**; HIV-related medications, drug assistance programs by states (RR) 155
Acute renal failure, statin-fibrate induced (A) 909
Acute respiratory infections, management at private pharmacies, pediatric, Vietnam (IR) 1283
5-Adenyl-L-methionine, adverse events (A) 1420; associated with hyperhomocysteinemia (A) 1421; treatment of liver dysfunction and cholestasis (A) 1419; contraindications and precautions (A) 1421; dose-response correlation (A) 1420; dosing (A) 1422; drug interactions (A) 1421; efficacy studies (A) 1414; for depression (A) 1415; for gastroprotection (A) 1419; for osteoarthritis (A) 1417; patient counseling (A) 1422; pharmacokinetics (A) 1415; pharmacology (A) 1414
Adherence, see **Medication compliance**
Adrenocorticotrophic hormone, see **Corticotropin**
Adverse drug events, in geriatric homeless population (RR) 1166
Adverse drug reactions, abacavir, hypersensitivity (L) 1291; 5-adenyl-L-methionine, review (A) 1420; ACE inhibitors, review (A) 80; amoxicillin/clavulanate, hepatotoxicity (L) 1142, (L) 1677; amphotericin B, seizures, AIDS patient (CR) 1037, transient hypoparathyroidism (CR) 1042; angiotensin II receptor antagonists, review (A) 80; antiepileptics, hypersensitivity syndrome, children (RR) 533; antipsychotics, parkinsonism (CR) 435; antiretrovirals, glucose disorders (A) 343, gynecomastia (CR) 438; argatroban, review (A) 445; aspartame, fibromyalgia (CR) 702; atrovastatin, diaphragmatic muscle impairment (L) 1292; atypical antipsychotics, extrapyramidal syndromes, review (RR) 1517; bacillus Calmette-Guérin infections, therapy-related death (L) 963; benzylpenicillin, prolonged cholestasis (L) 783; bezafibrate, review (A) 1069; bromide, toxicity and pseudohyponatremia (A) 386; busulfan, idiopathic pneumonia syndrome (CR) 196; calcium carbonate, levthyroxine malabsorption (CR) 1578; carbamazepine, hypersensitivity syndrome, children (RR) 534, renal failure (CR) 560; carvedilol, hepatotoxicity (CR) 1364; cefonicid, eosinophilic hepatitis (L) 1699; celecoxib, gastroduodenal ulceration (L) 782; chemotherapy, idiopathic pneumonia (CR) 196; Chinese herbal medicine, review (A) 233; cilostazol, review (A) 52; ciprofloxacin, peripheral neuropathy (RR) 1540, seizures (CR) 1194; cisplatin, bradycardia (L) 641; citalopram, bradycardia and presyncope (CR) 1552; clomipramine, inducing serotonin syndrome after clozapine withdrawal (CR) 180; clozapine, burning mouth syndrome (CR) 874; clozapine, diabetic ketoacidosis, treatment with euglycemic clamp (CR) 1381; clozapine with haloperidol, neuroleptic malignant syndrome (L) 784; codeine phosphate, intravenous, seizures (CR) 1211; colchicine, neutropenia (CR) 192; colesvelam hydrochloride, severe gastrointestinal adverse events (A) 904; contrast media, acute renal failure, prevention with fenoldopam (A) 1278; cy-

clophosphamide, pulmonary fibrosis (CR) 894; cyproterone acetate, acute hepatitis (CR) 1053; dalteparin, hematoma (L) 643, retroperitoneal bleeding (L) 261; doxepin cream, anticholinergic toxicity (L) 505; enalapril, fatal hepatotoxicity (L) 1492; famotidine, switch from cimetidine, delirium (CR) 1045; fluconazole, pulmonary cryptococcosis, AIDS patient (L) 642, tonsade de pointes (A) 432; fluoropyrimidines with fluorouracil, review (A) 223; fluoropyrimidines, peripheral neuropathy (L) 1673, peripheral neuropathy (RR) 1540; fluorouracil, aphasia (L) 785; fluorouracil with fluoropyrimidines, review (A) 223; fluoxetine, manic switching (CR) 45; fluvoxamine, aggravating glaucoma (CR) 1565; fluvoxamine augmentation, increased mirtazapine serum concentrations (CR) 1221; fluvoxamine with mirtazapine, serotonin syndrome (CR) 1217, (L) 1672; gemcitabine, linear immunoglobulin A bullous dermatosis (CR) 891; glycoprotein IIb/IIIa receptor inhibitors, in heart failure (A) 603; haloperidol, extrapyramidal syndromes (RR) 1517; haloperidol with mirtazapine and risperidone, neuroleptic malignant syndrome (CR) 698; hemostatic medications, cardiac surgery, review (A) 1077, (A) 931; heparin, thrombocytopenia (A) 440, treatment with lepirudin (CR) 885; HMG-CoA reductase inhibitors, review (A) 909; hypertonic potassium chloride, bronchoconstriction, treatment with heparin (RR) 1161; Implanon, review (A) 332; indinavir, urologic effects (A) 749; indinavir with ritonavir, ingrown toenails (CR) 881, symptomatic hyperbilirubinemia (CR) 1391; interferon, homicidal ideations (L) 962, mood disorders, review (A) 489; interferon alfa, glucose disorders, HIV population (A) 344; interleukin, glucose disorders, HIV population (A) 344; isotretinoin, inflammatory bowel disease (CR) 1214, polycythemia (L) 964; levofloxacin, peripheral neuropathy (RR) 1540, seizures (CR) 1194; linezolid, review (A) 571; lipid amphotericin B, reduced toxicity (CR) 308, review (A) 209; lithium, exacerbation of stutter (L) 961, intoxication (CR) 560, severe acne (L) 961; lomefloxacin, peripheral neuropathy (RR) 1540; losartan, renal function (A) 80, megestrol, Cushing syndrome (CR) 1208, hyperglycemia, in HIV patients (A) 345; metformin, GI adverse effects, HIV population (A) 348; methotrexate, pancytopenia (CR) 1575; mifepristone, review (A) 710; mirtazapine, peripheral edema (L) 1494; monosodium glutamate, fibromyalgia (CR) 702; nateglinide, review (A) 1431; nefinavir, rash, in HIV patient (CR) 553; nimesulide, acute hepatitis (CR) 1049; NRTIs, mitochondrial toxicity (A) 346; NSAIDs, *Helicobacter pylori*-positive GI ulcers (A) 249, impairment of orthodontic tooth movement (A) 113; ofloxacin, peripheral neuropathy (RR) 1540, toxic epidermal necrolysis (CR) 1388; olanzapine, diabetes mellitus (CR) 563, diabetic ketoacidosis (CR) 1556, extrapyramidal syndromes (RR) 1517, hyperglycemic nonketotic coma (CR) 300, pancreatitis (L) 506, rhabdomyolysis (CR) 1020, weight gain (L) 1141; ophthalmic β -blockers, systemic adverse effects, review (A) 1633; opioids, constipation (A) 85, pruritus (A) 85; orlistat, review (A) 322; osetamivir, review (A) 66; pentamidine, pancreatic toxicity, HIV population (A) 345; phenobarbital, hypersensitivity syndrome, children (RR) 534; phenytoin, hypersensitivity syndrome (RR) 534; plasmapheresis, vancomycin removal (CR) 1400; protease inhibitors, diabetic ketoacidosis, treatment with metformin (CR) 877; protease inhibitors, glucose disorders, diabetes mellitus (A) 345, neurologic and gastrointestinal toxicity (A) 748; radiation therapy, myelopathy (CR) 188; rifampin with pyrazinamide, severe hepatitis (NC) 799; risperidone, extrapyramidal syndromes (RR) 1517, with mirtazapine and haloperidol, neuroleptic malignant syndrome (CR) 698; ritonavir, ingrown toenails (CR) 881, neurologic and GI effects (A) 748; ropivacaine, seizure (CR) 311; rosiglitazone, pulmonary edema (L) 123; sertraline, hyperglycemia (CR) 1371; sildenafil, review (RR) 285, review (A) 337; simvastatin with metoprolol, nightmares and sleep disturbances (L) 1292; statins

with fibrates, acute renal failure (A) 909, rhabdomyolysis (A) 909; stavudine, gynecomastia (CR) 439; sucralfate, aluminum toxicity, in renal failure (A) 360; tacrolimus, cardiomyopathy, transplant patients (RR) 985, review (A) 586; teneceplase, review (A) 1235; thrombolytic therapy, intracranial hemorrhage (A) 591; topiramate, epilepsy (RR) 176; trazodone, hepatotoxicity (CR) 1559; trimethoprim/sulfamethoxazole, toxic epidermal necrolysis (CR) 694; trovafloxacin, leukopenia (CR) 41; valacyclovir, aseptic meningitis (L) 128; vancomycin, hypersensitivity, desensitization protocols (A) 1458; veneporfin, review (A) 1595; vincristine with doxorubicin, ischemic heart disease (CR) 1403; vitamin B₆ with vitamin H, eosinophilic pleuropneumonitis (CR) 424; warfarin, subtherapeutic INR values (CR) 183; zanamivir, review (A) 66; zolpidem, delirium (CR) 1562
Alcohol, pharmacokinetics (A) 919; with OTC medications, effect on blood alcohol levels (A) 918
Alendronate, clinical efficacy (A) 1472; intermittent dosing (A) 1471
Allergic rhinitis, treatment with leukotriene receptor antagonists (A) 1274
Alopecia, postpartum (A) 255; treatment with vitamins B₆ and H, inducing eosinophilic pleuropneumonitis (CR) 424
Alopecia areata, treatment with tacrolimus (A) 585
Alprostadil, compared with sildenafil, mortality (L) 1143 (RR) 285
Alteplase, for acute MI, thrombolysis (A) 592, with abciximab (A) 594, with GP IIb/IIIa inhibitor (A) 593, with lamifiban (A) 594; for intraventricular hemorrhage (A) 1439; for post-hemorrhagic hydrocephalus, pediatrics (A) 1441; for veno-occlusive disease (A) 938
Alternative pharmacy, complementary, integrated (E) 959
Aluminum, toxicity, in end-stage renal disease (A) 360
Alzheimer disease, treatment with galantamine (A) 1406; treatment with mirtazapine (CR) 1024
Ambulatory care, antidepressant prescribing, Hispanic vs. non-Hispanic whites, primary care (RR) 419; antihypertensives with antithrombotics, after stroke (RR) 811; asthma patients, newness of drugs and use of HMO services (RR) 990; blood pressure monitoring, home monitors vs. mercury sphygmomanometers (RR) 817; compliance with metered-dose inhalers, self-reported vs. pharmacy claims data (RR) 997; diabetes, slowing of renal disease (A) 452; geriatrics, adverse drug events, homeless population (RR) 1166; incidence of gastroduodenal ulcers, during treatment with celecoxib, arthritis patients (RR) 829; nonprescription drugs, drug-related problems (RR) 1343; pharmacists' attitudes toward diabetes, involvement in diabetes education (RR) 841; polypharmacy, patient consultation (RR) 835; prescribing behavior, Lebanon (IR) 636; prescribing patterns, therapeutic implications for diabetic hypertension, Bahrain (RR) 1350; treatment of hypertension, physician's knowledge, attitudes, and practice (RR) 1173
American College of Cardiology, guidelines for acute MI (A) 589
American Heart Association, guidelines for amiodarone, treatment for ventricular arrhythmias (A) 1248
American Society of Clinical Oncology, guidelines for colony-stimulating factors, in leukemia (A) 104
American Thoracic Society, adherence to guidelines, treatment of community-acquired pneumonia (RR) 1180
Amikacin, antimicrobial resistance, switching studies (A) 1230; cycling with gentamicin, to control microbial resistance (A) 1228
Aminocaproic acid, for reduction of blood loss, in cardiac surgery, compared with aprotinin (A) 1079, compared with tranexamic acid (A) 1079, in hepatic surgery (A) 927, in prostate and thyroid surgery (A) 931

para-Aminosalicylic acid, pharmacokinetics, four dosing conditions (RR) 1332

Amiodarone, for ventricular arrhythmias, new American Heart Association guidelines (A) 1248; compared with bretylium (A) 1250; pharmacokinetic information (A) 1252

Amlodipine, for slowing of diabetic nephropathy, compared with cilazapril (A) 458; in coronary artery bypass graft, compared with diltiazem and nifedipine (A) 633

Amoxicillin/clavulanate, inducing hepatotoxicity (L) 1142, (L) 1677

Amphotericin B, adverse reactions, review (A) 209; dosing (A) 212; for *Candida lusitanae*, resistance (CR) 1570; for neonatal systemic candidiasis, lipid-based formulation (CR) 1032; for pulmonary aspergillosis, effect of three different lipid formulations (CR) 308; for stem cell transplant, lipid formulations practice guidelines (A) 206; for urinary tract infection, compared with fluconazole (A) 370; inducing hypomagnesemia and transient hypoparathyroidism, patient with β -thalassemia (CR) 1042; inducing seizures, AIDS patient (CR) 1037; pharmacoeconomics (A) 210

Ampicillin, for bronchitis (A) 578

Analgesia, opioids compared with ketorolac, in spine and joint procedures, impact on healthcare resources (RR) 1320

Anaphylaxis, vancomycin induced (A) 1458

Angioedema, serrtaline and trazodone overdose induced (CR) 1375

Angiotensin II receptor antagonists, adverse effects (A) 80; clinical trials (A) 73; compared with ACE inhibitors, clinical trials (A) 75; dosing (A) 81; for CHF, review (A) 71; for heart failure, with ACE inhibitors (A) 242; for slowing of renal disease, review (A) 457; pharmacology, compared with ACE inhibitors (A) 72; with ACE inhibitors, clinical trials (A) 78

Angiotensin receptor blockers, for chronic heart failure (A) 1070

Angiotensin-converting enzyme inhibitors, for chronic heart failure (A) 1069; for CHF, with angiotensin II receptor antagonists (A) 71, (A) 242; for CHF, with aspirin (A) 1653; for slowing of renal disease, review (A) 454; compared with angiotensin II receptor antagonists (A) 72

Anistreplase, for thrombolysis in acute MI (A) 592

Anthrax, prophylaxis among pregnant women (NC) 1692; recommendations for mail workers (NC) 1692

Antibiotics, see also **Antimicrobials**; clarithromycin, interaction with simvastatin, rhabdomyolysis (CR) 26; oxazolidinone, linezolid (A) 568

Anticoagulants, after stroke, community-based care (RR) 811; argatroban, prevention and treatment of thromboembolism, in heparin-induced thrombocytopenia (A) 440; dalteparin, in patients on warfarin with high risk of thrombosis (RR) 669; for acute MI (A) 607; for radiation-induced myelopathy (CR) 188; heparin-induced thrombocytopenia and renal failure, treatment with lepirudin and hemodialysis (CR) 885

Antidepressants, prescribing behavior, primary care, Hispanic vs. non-Hispanic whites (RR) 419

Antiemetics, ondansetron and granisetron (RR) 14

Antiepileptics, hypersensitivity syndrome, children (RR) 533

Antifibrinolytics, in cardiac surgery, reduce bleeding (A) 1075

Antifungals, intravenous itraconazole, review (A) 720

Antihypertensives, interaction with oralist (L) 1495; physicians' knowledge, of indications and contraindications (RR) 1175; with antithrombotics, after stroke, community-based care (RR) 811

Antimicrobial coating/bonding, intravascular catheters (A) 1255

Antimicrobial cycling, ceftazidime and piperacillin/tazobactam (A) 1228; gentamicin and amikacin (A) 1228; kanamycin and gentamicin (A) 1225; to control bacterial resistance (E) 1289; to reverse resistance trends (A) 1224

Antimicrobial resistance, gram-negative bacterial infections, switch from ceftazidime to ciprofloxacin (A) 1229; restriction of ceftazidime, increase susceptibilities of *Enterobacter* spp. (A) 1229; to antimicrobial coated/bonded or impregnated catheters (A) 1261

Antimicrobial switching, ceftazidime-resistant *Klebsiella* spp., switch to imipenem (A) 1229; clinical trials, to control microbial resistance (A) 1228; resistant *Klebsiella pneumoniae*, use of piperacillin/tazobactam and imipenem (A) 1228

Antimicrobials, see also **Antibiotics**; clinical trials, chronic obstructive pulmonary disease (A) 577; cycling studies, control of resistance (A) 1225; fluoroquinolones, spectrum of activity (A) 1085; for acute chronic obstructive pulmonary disease (A) 576; for *Bacillus anthracis*, prophylaxis among asymptomatic pregnant women (NC) 1692; limited fluoroquinolone reimbursement policy, impact on prescription claims (RR) 852; switching studies, control of resistance (A) 1228

Antioxidants, acetaminophen, for atherosclerosis (A) 1476; for acute MI (A) 609

Antiplatelet agents, for secondary prevention of ischemic stroke, aspirin (A) 1241, clopidogrel (A) 1243, dipyridamole (A) 1242, future directions (A) 1244, glycoprotein IIb/IIIa inhibitors (A) 1244, review (A) 1241; ticlopidine (A) 1243

Antipsychotics, inducing parkinsonism, treatment with zolpidem (CR) 435; olanzapine, inducing diabetes mellitus (CR) 563; understanding drug tolerability (O) 1659

Antiretrovirals, electronic adherence monitoring, barriers to use (RR) 1010; inducing glucose disorders (A) 343; inducing gynecomastia (CR) 438; protease inhibitors, drug concentration parameter (A) 746

Antithrombin-III, for veno-occlusive disease (A) 939

Antithrombotics, see **Thrombolytic therapy**; with antihypertensives, after stroke, community-based care (RR) 811

Antitumor necrosis factor α , for inflammatory bowel disease, in children (RR) 823

Aphasia, fluorouracil induced (L) 785

Aprotinin, for reduction of blood loss, in cardiac surgery, compared with aminocaproic acid (A) 1079, in hepatic surgery (A) 928, in orthopedic surgery (A) 930; in cardiac surgery, clinical trials (A) 1081

Archambault, George, tribute, 383

Argatroban, conversion to warfarin (A) 449; dosing (A) 449; for acute MI, with thrombolytic therapy (A) 444; for carotid stent placement (A) 444; for hemodialysis (A) 445; for heparin-induced thromboembolism, compared with danaparoid (A) 447, compared with lepirudin (A) 448; for ischemic stroke (A) 443; for percutaneous coronary angiography (A) 444; for peripheral occlusive disease (A) 444; for renal stent placement (A) 444; monitoring (A) 449; patient selection (A) 447; pharmacodynamics (A) 442; pharmacoeconomics (A) 449; pharmacokinetics (A) 441; pharmacology (A) 441; therapeutic issues (A) 447; with glycoprotein IIb/IIIa receptor antagonists (A) 442

t-Arginine, biochemical effects (A) 756; for cardiovascular diseases, review (A) 755, correction (L) 965; for heart failure (A) 761; for ischemic heart disease (A) 760; for peripheral vascular disease (A) 762; management of cardiovascular risk factors, diabetes (A) 759, hypercoagulability (A) 760, hyperlipidemia (A) 757, hypertension (A) 760, menopause (A) 760, smoking (A) 759

Arthritis, juvenile rheumatoid, pathophysiology (A) 465, traditional therapy (A) 465, treatment with etanercept (A) 464; treatment with celecoxib, incidence of gastroduodenal ulcers (RR) 829

Aspartame, inducing fibromyalgia (CR) 702

Aspirin, effect on blood alcohol level (A) 920; for acute MI, compared with clopidogrel (A) 597, with warfarin (A) 608; for CHF, with ACE inhibitors (A) 1653; for secondary prevention of ischemic stroke (A) 1241; in coronary stenting, compared with clostazolol (A) 1110

Asthma, ambulatory care, use of HMO services (RR) 990; β_2 -agonist recipients, treatment by national standards (RR) 682; induced by hypertonic potassium chloride, treatment with heparin (RR) 1161; compliance, metered-dose inhalers, self-reported vs. pharmacy claims data (RR) 997; drug utilization across time (RR) 992

Atenolol, with valsartan, fetal death (CR) 859

Atherosclerosis, treatment with acetaminophen (A) 1476; treatment with t-arginine (A) 755

Atopic dermatitis, treatment with tacrolimus (A) 583; treatment with topical tacrolimus (A) 943

Atorvastatin, compared/combined with colesvelam hydrochloride (A) 902; effect on fibrinogen (A) 238; inducing diaphragmatic muscle impairment (L) 1292; pharmacokinetics (A) 1099

Attention deficit hyperactivity disorder, children, treatment modalities (E) 1130; identification and diagnosis (E) 1131; pharmacotherapy (E) 1131

Atypical antipsychotics, inducing extrapyramidal syndromes (RR) 1517

Azole antifungals, interaction with statins, rhabdomyolysis (A) 1100

Bacillus anthracis, prophylaxis among asymptomatic pregnant women (NC) 1692; recommendations for mail workers (NC) 1692

Bacillus Calmette-Guérin, therapy-related death (L) 963

Bacterial resistance, prevention with antimicrobial cycling (E) 1289

β -Adrenergic antagonists, for acute MI (A) 600; for chronic heart failure (A) 1069; ophthalmic solutions, systemic adverse effects (A) 1633

Bahrain, prescribing patterns, therapeutic implications on diabetic hypertension (RR) 1350

Balloon tamponade, compared with octreotide, for variceal bleeding (A) 620

Beers criteria, for identification of adverse drug events, in homeless geriatric population (RR) 1166

Benzodiazepines, for insomnia, in hospitalized patients (A) 1451

Benzylicpenicillin, inducing prolonged cholestasis (L) 783

β_2 -Agonists, for asthma, drug utilization assessment by national standard (RR) 682

Bexarotene, adverse effects (A) 1060; chemical formula (A) 1057; clinical trials, in cutaneous T-cell lymphoma (A) 1058; contraindications (A) 1061; dosage (A) 1063; drug interactions, review (A) 1060; for cutaneous T-cell lymphoma (A) 1056; patient counseling (A) 1063; pharmacodynamics (A) 1058; pharmacokinetics (A) 1058; pharmacology (A) 1058; toxicology (A) 1058

Bezafibrate, for hyperlipidemia, in acute MI (A) 609

Bile acid sequestrants, colesvelam hydrochloride (A) 898; for lowering of cholesterol (A) 1599

Bipolar disorder, fluoxetine induced, manic switching (CR) 45; treatment with gabapentin (A) 1264

β -Lactams, pneumococcal resistance (A) 481

Blood alcohol level, affected by acetaminophen (A) 920; affected by aspirin (A) 920; affected by H_2 -receptor antagonists (A) 919

Blood loss, in hepatic surgery, aminocaproic acid (A) 927, aprotinin (A) 928, conjugated estrogens (A) 926, tranexamic acid

(A) 927; in orthopedic surgery, aprotinin (A) 930, desmopressin (A) 930, tranexamic acid (A) 928; in prostate and thyroid surgery, aminocaproic acid (A) 931, tranexamic acid (A) 931

Blood pressure, influenced by sildenafil (A) 338; accuracy of store-based monitors; home monitors compared with mercury sphygmomanometers (RR) 817, (L) 1676

Bol, Larry E, obituary (NC) 524

Book reviews, A Physician's Guide to Pain and Symptom Management in Cancer Patients 509; A Time to Die: The Place for Physician Assistance 265; Adverse Drug Reactions 1499; Best Evidence 5: Linking Medical Research to Practice 1679; Breast Cancer: A Practical Guide 1681; Breast Cancer: Its Link to Abortion and the Birth Control Pill 1682; Chemically Induced Birth Defects, 3rd Edition, Revised and Expanded 392; Communicating with Today's Patient: Essentials to Save Time, Decrease Risk, and Increase Patient Compliance 1298; Comprehensive Care of Schizophrenia: A Textbook of Clinical Management 1678; Controlled Drug Delivery: Designing Technologies for the Future 787; Culture of Death: The Assault on Medical Ethics in America 1498; Depression 966; Dyspepsia 966; Electronic Medical Records: A Guide for Physicians and Administrators 1500; Fundamentals of Complementary and Alternative Medicine, 2nd Edition 1145; Geriatrics at Your Fingertips, 2000 Edition 391; Gibaldi's Drug Therapy 2000: A Critical Review of Therapeutics 787; Handbook of Nonprescription Drugs, 12th Edition 391; Healing the Culture: A Commonsense Philosophy of Happiness, Freedom, and the Life Issue 1680; HIV 130; Management of the Child with a Serious Infection or Severe Malnutrition: Guidelines for Care at the First-Referral Level in Developing Countries 967; Medicinal Plants of the World, Volume 2: Chemical Constituents, Traditional and Modern Medicines 1297; On Being a Doctor 2: Voices of Physicians and Patients 966; Pathology and Therapeutics for Pharmacists: A Basis for Clinical Pharmacy Practice 648; Pharmacotherapy Casebook: A Patient-Focused Approach 130; Post-Traumatic Stress Disorder: Diagnosis, Management and Treatment 1145; Practical Decision Making in Health Care Ethics: Cases and Concepts, 2nd Edition 510; Proceedings of the 9th Congress on Pain: Progress in Pain Research and Management, Volume 16 647; Progress in Respiratory Research, Volume 31: New Drugs for Asthma, Allergy and COPD 1499; Realized Religion: Research on the Relationship Between Religion and Health 1681; Side Effects in Dermatology, 7th Edition 130; Sport and Exercise Pharmacology 1500; The Antimicrobial Drugs, 2nd Edition 509; The Hatherleigh Guide to Psychiatric Disorders, Part II 1678; The Patient Self-Determination Act: Meeting the Challenges in Patient Care 265; Tired - So Tired! And the "Yeast Connection" 1680; Tough Decisions: Cases in Medical Ethics, 2nd Edition 1299; Without Moral Limits 1299

Books received, 392, 511, 648, 788, 1146, 1501, 1683

Bradycardia, cisplatin induced (L) 641; citalopram induced (CR) 1552; treatment with intravenous theophylline, avoidance of pacemaker placement (CR) 303

Breast cancer, effect of phytoestrogens on growth (A) 1118; treatment with cyclophosphamide, inducing pulmonary fibrosis (CR) 894

Bretylium, compared with amiodarone, in ventricular tachyarrhythmias (A) 1250

Bromide, toxicity from overdose (L) 386

Bronchitis, antimicrobial therapy, for acute exacerbations (A) 576; chronic, treatment with fluoroquinolones (A) 1089

Bronchoconstriction, hypertonic potassium chloride induced, treatment with heparin (RR) 1161

Bulimia nervosa, treatment with ondansetron (A) 1270

Bupropion, after nicotine replacement therapy, in acute MI (A) 611; for depression, compared with selective serotonin-reuptake inhibitors (A) 1608

Burn injuries, treatment with morphine and its glucuronidated metabolites, pharmacokinetic comparison (CR) 1588

Busulfan, for idiopathic pneumonia syndrome, following myeloablative chemotherapy (CR) 196

C

Calcium carbonate, inducing levothyroxine malabsorption, in gastrointestinal disorders (CR) 1578

Calcium-channel antagonists, for slowing of renal disease, review (A) 457; in coronary artery bypass, radial artery grafts (A) 631

Canada, new integrated discharge prescription form, evaluation (CR) 953

Cancer, breast, phytoestrogens, effect on growth (A) 1118; colorectal, celecoxib, as adjunctive therapy (A) 1638; fibroblastic osteosarcoma, high-dose methotrexate (L) 1669; prostatic, treatment with flutamide, lack of methemoglobinemia (RR) 21

Candesartan, for CHF, compared with enalapril (A) 79, dose-finding trial (A) 75

Candida lusitanae, catheter-related sepsis, in a nonneutropenic woman (CR) 1570

Candidemia, intravenous fluconazole, impact of restriction policy (RR) 9; neonatal systemic, lipid-based amphotericin B (CR) 1032

Capacitabine, with fluorouracil, review (A) 219

Captopril, for CHF, with losartan (A) 76; for slowing of renal disease (A) 454

- Carbamazepine**, hypersensitivity reaction, children (RR) 534; inducing renal failure, resulting in lithium intoxication (CR) 560; interaction with ritonavir (L) 125
- Cardiac surgery**, reduction of bleeding, antifibrinolytics (A) 1075, desmopressin (A) 1080
- Cardiac toxicity**, erythromycin and verapamil induced (CR) 1396
- Cardiology**, acute MI, American College of Cardiology/American Heart Association, guidelines (A) 589; amiodarone, for ventricular tachyarrhythmias, new American Heart Association guidelines (A) 1248; angiotensin II receptor antagonists with ACE inhibitors, heart failure (A) 242; antihypertensives with antithrombotics, after stroke, community-based care (RR) 811; appropriateness of nitrate use, in general medical population (RR) 1339; blood pressure monitoring, home monitors compared with mercury sphygmomanometer (RR) 817; cardiac surgery, antifibrinolytics (A) 1075; cardiac surgery, desmopressin (A) 1080, cefuroxime serum concentrations, in coronary bypass graft patients (RR) 409; cholesterol-lowering agents, comparison of clinical outcomes (A) 1599; chronic heart failure, drug therapy (A) 1066; diltiazem as periprocedure anticoagulation, for patients on warfarin with high risk of thrombosis (RR) 669; glycoprotein IIb/IIIa antagonists, for acute coronary syndrome, risks and benefits (A) 472; HMG-CoA reductase inhibitors, affecting fibrinogen (A) 236; statin-fibrate combination therapy, review (A) 908; theophylline, for bradycardia (CR) 303
- Cardiomyopathy**, tacrolimus induced, in transplant patients (RR) 985
- Cardiovascular diseases**, management with L-arginine (A) 755
- Cardiovascular system**, adverse effects, ophthalmic β -blocker induced (A) 1633
- Carvedilol**, cost-effectiveness, results of the US Carvedilol Heart Failure Trials Program (RR) 846; for chronic severe heart failure (A) 601; inducing hepatotoxicity (CR) 1364
- Cefazolin**, bonded intravascular catheters, infection control (A) 1256
- Cefonicid**, inducing eosinophilic hepatitis (L) 1669
- Ceftazidime**, cycling with piperacillin/tazobactam, to control microbial resistance (A) 1228; gram-negative bacterial resistance, switch to ciprofloxacin (A) 1229; *Klebsiella pneumoniae* resistance, switch to imipenem (A) 1229
- Ceftriaxone**, intramuscular for childhood meningitis (CR) 36
- Cefuroxime**, continuous infusion serum concentrations, coronary bypass graft patients (RR) 409; serum concentrations, after continuous infusion, coronary bypass graft (L) 1295
- Celecoxib**, as adjunctive therapy for colorectal cancer (A) 1638; dosing (RR) 831; incidence of gastrointestinal ulcers, in arthritis patients (RR) 829; incidence of ulcers, compared with diclofenac (RR) 831, compared with ibuprofen (RR) 831, compared with naproxen (RR) 831; inducing gastrointestinal ulceration (L) 782; with clopidogrel, inducing intracerebral hemorrhage (CR) 1567
- Central nervous system**, adverse effects, ophthalmic β -blocker induced (A) 1633; staphylococcal infection, adjunctive treatment with rifampin (A) 765
- Cerebrovascular accident**, see also **Stroke**
- Cervastatin**, interaction with gemfibrozil, rhabdomyolysis (CR) 1016; pharmacokinetics (A) 1099
- Chemotherapy**, cisplatin, doxorubicin, and mitomycin, with ifosfamide (RR) 1548
- Chemotherapy**, antiemetics, ondansetron and granisetron (RR) 14; busulfan, inducing idiopathic pneumonia syndrome (CR) 196; cisplatin, doxorubicin, and mitomycin, with ifosfamide, stability for chemotherapeutic (RR) 1548; leukemia, colony-stimulating factors (A) 92; vincristine with doxorubicin, inducing ischemic heart disease (CR) 1403
- Chinese herbal medicine**, adverse effects (A) 233; formulations (A) 232; gastrointestinal disorders, review (A) 228; indications and diagnosis (A) 231; pharmacology (A) 232
- Chloramphenicol**, for bronchitis (A) 578
- Chlorhexidine-silver sulfadiazine**, coating for intravascular catheters, infection control (A) 1258
- Cholestasis**, celecoxib induced (L) 783; protection through S-adenosyl-L-methionine (A) 1419
- Cholesterol**, reduction, comparison of agents (A) 1599, with bile acid sequestrants (A) 1602, with fibrates (A) 1600, with HMG-CoA reductase inhibitors (A) 496, (A) 1602; with hormonal agents (A) 1603; with niacin (A) 1601
- Chronic heart failure**, drug therapy, ACE inhibitors (A) 1069, angiotensin receptor blockers (A) 1070, β -adrenergic antagonists (A) 1069, digoxin (A) 1069, endothelin receptor blockers (A) 1071, etanercept (A) 1071, loop diuretics (A) 1068, losartan (A) 1070, nesiritide (A) 1071, neurohormones (A) 1071, omapatrilat (A) 1071, spironolactone (A) 1070, involved tissues, (A) 1067
- Chronic obstructive pulmonary disease**, antimicrobial therapy, for acute exacerbations (A) 576
- Cidofovir**, for progressive multifocal leukoencephalopathy (A) 741
- Cilazapril**, for slowing of diabetic nephropathy, compared with amlodipine (A) 458
- Cilomilast**, lack of interaction with warfarin (RR) 1535
- Clofazimine**, adverse reactions (A) 52; dosing (A) 53; drug interactions (A) 53; in coronary stenting (A) 51; in intermittent claudication (A) 50, compared with pentoxifylline (A) 51; in intracoronary stenting, compared with aspirin (A) 1111, compared with ticlopidine (A) 1110, for prevention of thrombosis and restenosis (A) 1108, with aspirin (A) 1110, with probucol (A) 1111; pharmacoeconomics (A) 53; pharmacokinetics (A) 50; pharmacology (A) 49
- Cimetidine**, for acute peptic ulcer bleeding, compared with omeprazole (A) 735; switch to famotidine, delirium (CR) 1045
- Ciprofloxacin**, control of gram-negative bacterial infections, switch from ceftazidime (A) 1229; inducing peripheral neuropathy (RR) 1540; inducing seizures (CR) 1194; pharmacokinetics (A) 1087
- Cisapride**, interaction with digoxin, digoxin (L) 127
- Cisplatin**, inducing bradycardia (L) 641; with ifosfamide, stability for chemotherapeutic (RR) 1548
- Citalopram**, inducing bradycardia and presyncope (CR) 1552
- Clarithromycin**, interaction with simvastatin, rhabdomyolysis (CR) 26, with theophylline, effect of levofloxacin on theophylline clearance (CR) 691
- Clinical trials**, abciximab, before percutaneous coronary intervention (A) 602; ACE inhibitors with aspirin, for CHF (A) 1653; acetaminophen, for osteoporosis (A) 1477; S-adenosyl-L-methionine, for depression (A) 1415, for depression secondary to fibromyalgia (A) 1417, for liver dysfunction and cholestasis (A) 1419; for osteoarthritis (A) 1417, gastroprotective effects (A) 1419; alendronate, for osteoporosis (A) 1472; alteplase, for intraventricular hemorrhage (A) 1440, for veno-occlusive disease (A) 938; alteplase with abciximab, for acute MI (A) 594; alteplase with GP IIb/IIIa inhibitor, for acute MI (A) 593; amikacin, antimicrobial switching (A) 1230; aminocaproic acid, for hepatic surgery (A) 927, for prostate and thyroid surgery (A) 931; amiodarone, for ventricular tachyarrhythmia (A) 1251; amiodarone compared with bretylium, for ventricular tachyarrhythmias (A) 1250; amlodipine, for diabetic nephropathy (A) 458; amoxicillin, for bronchitis (A) 578; amphotericin B, lipid-based compounds (A) 208; ampicillin, for bronchitis (A) 578; angiotensin II receptor blockers combined with ACE inhibitors, for heart failure (A) 75, (A) 243; angiotensin II receptor blockers compared with ACE inhibitors, for heart failure (A) 75; antihypertensives with antithrombotics, after stroke, community-based care (RR) 811; antimicrobial cycling, ceftazidime and piperacillin/tazobactam (A) 1228, gentamicin and amikacin (A) 1228, kanamycin and gentamicin (A) 1225; antimicrobial resistance, restriction of ceftazidime, control of *Enterobacter* spp. (A) 1229; antimicrobial switching, from ceftazidime to ciprofloxacin (A) 1229, from ceftazidime to imipenem, restrict *Klebsiella* spp. (A) 1229, to control microbial resistance (A) 1228; antimicrobials, for chronic obstructive pulmonary disease (A) 577; antiretrovirals, electronic adherence monitoring (RR) 1010; antithrombin-III, for veno-occlusive disease (A) 939; apixitin, in cardiac surgery (A) 1080, in hepatic surgery (A) 928, in orthopedic surgery (A) 930; argatroban, review (A) 442; L-arginine, for diabetes (A) 759, for heart failure (A) 761, for hypercoagulability (A) 760, for hyperlipidemia (A) 756, for hypertension (A) 760, for ischemic heart disease (A) 760, for menopause (A) 760, for peripheral vascular disease (A) 762, for smoking-related problems (A) 759; aspirin, for acute MI (A) 597; atovaquone, effect on fibrinogen (A) 238; bexarotene, for cutaneous T-cell lymphoma (A) 1058; bezafibrate, for hyperlipidemia, in acute MI (A) 609; candesartan cilexetil, for CHF (A) 75; captopril, for slowing of renal disease (A) 454; carvedilol, cost-effectiveness, US Carvedilol Heart Failure Trials Program (RR) 847, in chronic severe heart failure (A) 601; celecoxib, treatment of arthritis, incidence of gastrointestinal ulcers (RR) 830; celecoxib compared with diclofenac, incidence of ulcers (RR) 831; celecoxib compared with ibuprofen, incidence of ulcers (RR) 831; celecoxib compared with naproxen, incidence of ulcers (RR) 831; chloramphenicol, for bronchitis (A) 578; cidofovir, in progressive multifocal leukoencephalopathy (A) 742; cilazapril compared with amlodipine, slowing of diabetic nephropathy (A) 458; cilostazol, in coronary stenting (A) 51, in intermittent claudication (A) 50, in intracoronary stenting, prevention of thrombosis and restenosis (A) 1109; cilostazol compared with aspirin, in intracoronary stenting (A) 1111; cilostazol compared with ticlopidine, in intracoronary stenting (A) 1110; cilostazol with aspirin, in intracoronary stenting (A) 1110; cilostazol with probucol, in intracoronary stenting (A) 1111; clopidogrel compared with ticlopidine, in intracoronary stenting (A) 598; clozapine, switch from brand-name drug to generic (RR) 282; colesvelam hydrochloride, review (A) 900; colesvelam hydrochloride combined with atorvastatin, for cholesterol reduction (A) 902; colesvelam hydrochloride compared/combined with atorvastatin, for cholesterol reduction (A) 902; colesvelam hydrochloride compared/combined with simvastatin, for cholesterol reduction (A) 902; conjugated estrogens, for reduction of blood loss, hepatic surgery (A) 926; corticosteroid, for acute gout (A) 366; diltiazem, for unstable angina and non-ST-segment MI (A) 604; diltiazem compared with unfractionated heparin, for unstable angina and non-ST-segment MI (A) 604; defibrotide, for prevention of veno-occlusive disease (A) 939; depression, religious coping (A) 354; desirudin compared with unfractionated heparin, for acute MI (A) 606; desmopressin, in cardiac surgery (A) 1080, reduction of blood loss, orthopedic surgery (A) 930; diltiazem, in coronary artery bypass graft (A) 632; diltiazem compared with amlodipine and nifedipine, in coronary artery bypass graft (A) 633; diltiazem compared with lisinopril, for slowing of diabetic nephropathy (A) 457; diltiazem compared with nifedipine, for slowing of diabetic nephropathy (A) 458; enalapril, for slowing of renal disease (A) 456; enalapril with losartan, for heart failure (A) 243, (A) 246; endoscopic therapy, for acute bleeding peptic ulcers (A) 735; enoxaparin compared with unfractionated heparin, for acute MI (A) 605; enoxaparin with unfractionated heparin, for unstable angina and non-ST-segment MI (A) 605; epifibrotide with unfractionated heparin, for acute coronary syndrome (A) 602; estrogen replacement therapy, for prevention of heart disease (A) 611; filgrastim, for adult lymphoblastic leukemia (A) 102, for adult myelogenous leukemia (A) 100, for pediatric lymphoblastic leukemia (A) 94; flucanazole, for urinary tract infection (A) 370; fluvastatin, for cholesterol reduction (A) 498; gabapentin, for bipolar disorders (A) 1264, for dementia (CR) 428; galantamine (A) 1408; gemfibrozil, for hyperlipidemia, in acute MI (A) 608; glutamine, for prevention of veno-occlusive disease (A) 937; hemostatic medications, for reduction of blood loss during surgery (A) 925; Implanon compared with Norplant, effectiveness (A) 331; indinavir, adverse effects (A) 749; indinavir compared with lamivudine and zidovudine, effect of drug concentrations (A) 747; indinavir compared with nevirapine, effect of concentrations (A) 747; infliximab, for inflammatory bowel disease, in children (RR) 824; infrastructure of pharmaceutical research, Japan (RR) 1122; intravenous tracheal intubation, for aspergillosis (A) 724, for blastomycosis (A) 725, for cryptococcal infection (A) 725, for febrile neutropenia (A) 725, for histoplasmosis (A) 725, pharmacokinetics (A) 723; irbesartan, for CHF (A) 75; irbesartan with ACE inhibitor, for heart failure (A) 246; isosorbide dinitrate, for coronary artery bypass graft (A) 633; lamifiban with alteplase or streptokinase, for acute MI (A) 594; lenograstim, for adult myelogenous leukemia (A) 96; lepirudin compared with unfractionated heparin, for acute MI (A) 606; leukotriene receptor antagonists, for allergic rhinitis (A) 1275; lidocaine, for ventricular tachyarrhythmias (A) 1251; linezolid, for resistant gram-positive cocci (A) 570; lisinopril, for slowing of renal disease (A) 455; lisinopril compared with diltiazem and furosemide/atenolol, for slowing of diabetic nephropathy (A) 457; lisinopril compared with nifedipine, for slowing of diabetic nephropathy (A) 459; losartan, for chronic heart failure, ELITE II (A) 1070, for CHF (A) 74; losartan compared with enalapril, for slowing of renal disease (A) 457; losartan with ACE inhibitor, for heart failure (A) 245; losartan with enalapril, for heart failure (A) 243; lovastatin, effect on fibrinogen (A) 239, for cholesterol reduction (A) 497; low-dose heparin, for prevention of veno-occlusive disease (A) 936; low-molecular-weight heparin, for prevention of veno-occlusive disease (A) 937; methylglutathione, effect on gastric emptying (A) 87, for morphine-induced pruritus (A) 89, reversing opioid-induced constipation (A) 88; mifepristone, efficacy (A) 709; molgramostim, for adult lymphoblastic leukemia (A) 103, for adult myelogenous leukemia (A) 98, for pediatric lymphoblastic leukemia (A) 94; montelukast, for allergic rhinitis (A) 1276; naloxone, for morphine-induced pruritus (A) 88, laxative effect (A) 87; naloxone with nalbuphine, for morphine-induced pruritus (A) 88; naproxen, for *Helicobacter pylori* eradication in patients with NSAID-induced gastric ulcers (A) 252; nateglinide, review (A) 1428; nateglinide compared with glyburide, for diabetes mellitus (A) 1429; nateglinide compared with repaglinide, for diabetes mellitus (A) 1430; nelfinavir compared with saquinavir, stavudine, and lamivudine, effect of drug concentrations (A) 746; niacin, for hyperlipidemia in acute MI (A) 608; nicardipine, for coronary artery bypass graft (A) 632; nicotine replacement, after MI (A) 611; nifedipine compared with isradipine, for slowing of diabetic nephropathy (A) 459; NSAIDs, for *Helicobacter pylori* eradication, review (A) 250; octreotide, for variceal bleeding (A) 621, compared with terlipressin and transdermal nitroglycerin (A) 620, compared with vasopressin (A) 620; omeprazole, for acute peptic ulcer bleeding (A) 734, for NSAID-induced ulcers with *Helicobacter pylori* present (A) 251; omeprazole compared with ranitidine, for acute bleeding peptic ulcers (A) 735; omeprazole compared with ranitidine, for NSAID-induced ulcers with *Helicobacter pylori* present (A) 251; ondansetron, for bulimia nervosa (A) 1271; opioid analgesics compared with ketorolac (RR) 1321; oral contraceptives, continuous use (A) 1480; orlistat, for weight loss (A) 315; oseltamivir, for influenza prophylaxis (A) 63, for influenza treatment (A) 64; oxytetracycline, for bronchitis (A) 578; penicillin, for bronchitis (A) 578; phenothrin with permethrin and piperonyl butoxide, for eradication of head lice (A) 110, phenytoin compared with normal saline, for decubitus ulcers (RR) 679; piperonyl butoxide with permethrin and phenothrin, for eradication of head lice (A) 110; polypharmacy, ambulatory care (RR) 836; pramipexole, for restless legs syndrome (A) 628; pravastatin, effect on fibrinogen (A) 239; procainamide compared with lidocaine, for ventricular tachyarrhythmias (A) 1249; prostaglandin E_2 , for prevention of veno-occlusive disease (A) 937; protease inhibitors, drug concentrations and effect (A) 746, influence on glucose and lipid metabolism, HIV population (A) 345; proton-pump inhibitors, for acute peptic ulcer bleeding (A) 732; publishing guidelines (E) 780; religion, adaptation to aging and disability (A) 353, effect on immune system function (A) 356; reteplase with abciximab, for acute MI (A) 594; ritonavir, adverse effects (A) 748; ritonavir compared with saquinavir, effect of drug concentrations (A) 747; rosiniprole, for restless legs syndrome (A) 629; saquinavir, interpatient variability, pharmacokinetics (A) 749; sargramostim, for adult myelogenous leukemia (A) 98; simvastatin, effect on fibrinogen (A) 239, for cholesterol reduction (A) 498; sotalol compared with lidocaine, for ventricular tachyarrhythmias (A) 1249; statin-fibrate combination therapy, review (A) 911; streptokinase with epifibrotide, for acute MI (A) 593; succrallate, effect on aluminum concentrations, in normal

renal function (A) 361, for renal failure/insufficiency (A) 362; sucrose analgesia, in neonates (A) 948; sulfasalazine, for radiation-induced gastrointestinal toxicity (RR) 807; tacrolimus, for alopecia areata (A) 585, for atopic dermatitis (A) 583, for psoriasis (A) 584, for pyoderma gangrenosum (A) 583, in solid-organ transplant (RR) 985, topical, atopic dermatitis (A) 944; teneceplase, for acute MI (A) 1234; tetracycline, for bronchitis (A) 578; TMP/SMX compared with amoxicillin and doxycycline, for bronchitis (A) 578; toprimate, tolerability, comparison of titration schedules (RR) 173; tranexamic acid, for reduction of blood loss, in hepatic surgery (A) 927, in orthopedic surgery (A) 928, in prostate and thyroid surgery (A) 931; unfractionated heparin, dose-finding trials, in acute MI (A) 599; urokinase, for intraventricular hemorrhage (A) 1442; ursodiol, for prevention of veno-occlusive disease (A) 937; valsartan with ACE inhibitor, for heart failure (A) 243; verteporfin (A) 1594; vitamin E, for prevention of heart disease (A) 609; warfarin, for acute MI (A) 607; warfarin with aspirin, for acute MI (A) 608; zafirlukast, for allergic rhinitis (A) 1275; zanamivir, for influenza prophylaxis (A) 59, for influenza treatment (A) 60

Clomipramine, inducing serotonin syndrome, after clozapine withdrawal (CR) 180

Clonazepam, inducing burning mouth syndrome (CR) 874

Clopidogrel, for secondary prevention of ischemic stroke (A) 1243; in intracranial stenting, compared with ticlopidine (A) 598; substitute for aspirin, in acute MI (A) 597; with celecoxib, inducing intracerebral hemorrhage (CR) 1567

Clozapine, converting from brand-name to generic (L) 1295 (RR) 281; inducing diabetic ketoacidosis, treatment with euglycemic clamp (CR) 1381; inducing nocturnal enuresis, tolterodine treatment failure (CR) 867; interaction with serratine, sudden cardiac death (CR) 862; unanticipated plasma concentrations (CR) 1028, (L) 1675; with haloperidol, inducing neuroleptic malignant syndrome (L) 784; with sertraline, inducing sudden cardiac death (L) 1671; withdrawal causing serotonin syndrome in association with clomipramine (CR) 180

Codine phosphate, intravenous, for sickle cell crisis in child, inducing seizures (CR) 1211

Coenzyme A, for hyperlipidemia, in acute MI (A) 608

Colchicine, for gout, inducing neutropenia (CR) 192

Coloesevelam hydrochloride, clinical trials (A) 900; compared/combined with atorvastatin (A) 902, lovastatin (A) 902, simvastatin (A) 902; drug interactions, review (A) 903; pharmacodynamics (A) 899; pharmacokinetics (A) 899; pharmacology (A) 899; safety profile (A) 902; severe gastrointestinal events (A) 904; therapeutic and economic issues (A) 903

Colony-stimulating factors, American Society of Clinical Oncology, guidelines (A) 104; for acute leukemia (O) 120, (A) 92

Colorectal cancer, celecoxib, as adjunctive therapy (A) 1638

Community pharmacy, compared with Internet pharmacy (SC) 116; integrated discharge prescription form (A) 953

Community-acquired pneumonia, adherence to guidelines, American Thoracic Society (RR) 1180

Compliance, see **Medication compliance**

Condoms, effectiveness, reduction of sexually transmitted diseases (O) 1136; prevention of sexually transmitted diseases (O) 1135

Congenital rubella syndrome, incidence in the US and Mexico, 1997-1999 (NC) 144

Congestive heart failure, angiotensin II receptor antagonists combined with ACE inhibitors (A) 78, compared with ACE inhibitors (A) 75; treatment with ACE inhibitors and aspirin (A) 1653

Consumer advertising, prescription drugs, evaluation of effect (L) 1494

Contraceptives, Implanon, review (A) 329; oral, debate over continuous use (A) 1480

Contrast media, inducing acute renal failure, prevention with fenoledipam (A) 1278

Coronary angioplasty, cilostazol, for prevention of thrombosis and restenosis, intracranial stenting (A) 1108

Coronary artery bypass graft, cefuroxime serum concentrations, after continuous infusion (L) 1295 (RR) 409; use of calcium-channel antagonists and nitrates (A) 631

Corrections, adequacy of sildenafil product information, French abstract (L) 786; azathioprine, effect on anticoagulant activity of warfarin (L) 1296; fenoledipam for prevention of contrast-media-induced renal failure (L) 1677; L-arginine in the management of cardiovascular diseases (L) 965; rhabdomyolysis and HMG-CoA reductase inhibitors (L) 1296; slowing the progression of renal disease in diabetic patients (L) 965

Corticosteroids, for acute gout (A) 365

Coumadin, switch to generic warfarin, subtherapeutic INR values (CR) 183

Critical care, hemostatic agents in cardiac surgery, antifibrinolytics (A) 1075; desmopressin (A) 1075; protin-pump inhibitors, for acute peptic ulcer bleeding (A) 730; sedation assessment, in critically ill adults (A) 1624

Crohn's disease, treatment with infliximab, pediatric (RR) 823

Cushing syndrome, induced by megestrol (CR) 1208

Cutaneous T-cell lymphoma, therapeutic options (A) 1061; treatment with bexarotene, review (A) 1056

Cyclooxygenase-2 inhibitors, celecoxib, for colorectal cancer, adjunctive therapy (A) 1638

Cyclophosphamide, inducing pulmonary fibrosis (CR) 894

Cyclosporin, interaction with St. John's wort (L) 124; interaction with statins, rhabdomyolysis (A) 1099

Cyproheptadine, for serotonin syndrome (CR) 870, (L) 1672

Cyproterone acetate, inducing acute hepatitis (CR) 1053

Cytochrome P450, therapeutic drug monitoring, clozapine plasma concentrations (CR) 1028

D-E

Daidzein, effect on breast cancer growth (A) 1118

Dalteparin, compared with unfractionated heparin, in unstable angina and non-ST-segment MI (A) 604; inducing hematoma, compartment syndrome (L) 643; inducing retroperitoneal bleeding (L) 261; periprocedure anticoagulation, for patients on warfarin with high risk of thrombosis (RR) 669

Danaparoid, for thromboembolism, heparin-induced thrombocytopenia (A) 447

D'Arcy, Patrick F., obituary (NC) 1510

Defibrotide, for veno-occlusive disease (A) 939

Delirium, disulfiram and ethanol induced (RR) 32; famotidine induced, after switch from cimetidine (CR) 1045; zolpidem induced (CR) 1562

Dementia, treatment with gabapentin, behavioral and psychological symptoms (CR) 427; with Lewy bodies, success with donepezil (CR) 202

Dentistry, NSAIDs, impairment of orthodontic tooth movement (A) 113

Depression, Alzheimer disease, treatment with mirtazapine (CR) 1024; successful coping with religion (A) 354; treatment with bupropion, compared with selective serotonin-reuptake inhibitors (A) 1608; treatment with 5-adenosyl-L-methionine (A) 1414

Dermatology, tacrolimus, for dermatologic disorders (A) 582

Desensitization, flunazepam, in AIDS patient (L) 642; nelfinavir (CR) 553; protocols for vancomycin (A) 1458

Desirudin, compared with unfractionated heparin, in acute MI (A) 606

Desmopressin, for reduction of blood loss, in cardiac surgery (A) 1075, in orthopedic surgery (A) 930

Desmethasone, prophylaxis of paxitaxel hypersensitivity (A) 1114

Diabetes mellitus, cardiovascular risk factor, management with L-arginine (A) 759; diabetic ketoacidosis, olanzapine induced (CR) 1556; euglycemic clamp, for clozapine-induced diabetic ketoacidosis (CR) 1381; nateglinide, approval for type 2 (A) 1426; olanzapine induced (CR) 563; olanzapine-induced hyperglycemic nonketotic coma (CR) 300; pharmacists' attitudes, involvement in diabetes education (RR) 841; prescribing patterns, therapeutic implications for diabetic hypertension, Bahrain (RR) 1350; protease inhibitor induced (A) 345; slowing of renal disease (A) 452; valsartan with atenolol, inducing fetal death (CR) 859

Diabetic ketoacidosis, olanzapine induced (CR) 1556; protease inhibitor induced, treatment with metformin (CR) 877

Diaphragmatic muscle impairment, atorvastatin induced (L) 1292

Diclofenac, compared with celecoxib, incidence of ulcers (RR) 831

Digoxin, for chronic heart failure (A) 1069; interaction with cisapride (L) 127

Diltiazem, for slowing of diabetic nephropathy, compared with lisinopril (A) 457, compared with lisinopril and furosemide/atenolol (A) 457, compared with nifedipine (A) 458; in coronary artery bypass graft, compared with amlodipine and nifedipine (A) 633

Diphtheria, shortage of vaccine (NC) 144; vaccine, update on supply (NC) 662

Dipyridamole, for secondary prevention of ischemic stroke (A) 1242

Direct thrombin inhibitors, bleeding rates, compared with unfractionated heparin (A) 607; for acute MI (A) 606

Disulfiram, interaction with ethanol, delirium (CR) 32

Diuretics, for chronic heart failure (A) 1068

Donepezil, for dementia with Lewy bodies (CR) 202

Dopamine, receptors blocked by risperidone, in schizophrenia treatment (RR) 1523

Dopamine agonists, for prevention of contrast media-induced acute renal failure (A) 1279; for restless legs syndrome (A) 627

Dosage form, continuous infusion, cefuroxime, coronary bypass surgery (RR) 409; intramuscular, ceftriaxone, meningitis (CR) 36; intravenous, flunazepam, impact of restriction policy (RR) 9; intravenous bolus, gentamicin, in children (RR) 1327

Dosing, alendronate, intermittent (A) 1471; amphotericin B (A) 212; angiotensin II receptor antagonists (A) 80; argatroban (A) 449; bexarotene (A) 1063; candesartan (A) 81; celecoxib (RR) 831; Chinese herbal medicine (A) 232; cilostazol (A) 53; colchicine (CR) 193; flunazepam, in urinary tract infection (A) 369; galantamine (A) 1412; HMG-CoA reductase inhibitors, cholesterol reduction (A) 496; Implanon (A) 334; intravenous itraconazole (A) 726; linezolid (A) 571; losartan (A) 81; mifepristone (A) 714; nateglinide (A) 1432; orlistat (A) 323; osetamivir (A) 66; para-aminosalicylic acid, pharmacokinetics under four dosing conditions (RR) 1332; protease inhibitors, adjustment for organ dysfunction (A) 750; ropivacaine (CR) 312; S-adenosyl-L-methionine (A) 1422; sildenafil, elderly (A) 340; teneceplase (A) 1237; verteporfin (A) 1596; zanamivir (A) 66

Doxepin, inducing anticholinergic toxicity, topical cream (L) 505

Doxorubicin, with toversol, stability for chemoembolization (RR) 1548; with vincristine, inducing ischemic heart disease (CR) 1403

Drug administration, gentamicin, safety of intravenous bolus in children (RR) 1327; levothyroxine, effect of administration time on serum TSH (RR) 529; mifepristone (A) 714; piperacillin and ticarcillin, stability in AutoDose infusion bags (RR) 1360

Drug formulation, intravenous itraconazole (A) 726

Drug funding, AIDS, HIV-related medications, by states (RR) 155

Drug information, consumer advertisement of prescription drugs (A) 1494

Drug Information Rounds, acetaminophen, effect on atherosclerosis (A) 1476; alendronate, intermittent dosing (A) 1471; angiotensin II receptor antagonists with ACE inhibitors, (A) 242; ACE inhibitors with aspirin (A) 1653; calcium-channel antagonists and nitrates, in coronary artery bypass grafts (A) 631; celecoxib, adjunctive therapy for colorectal cancer (A) 1638; cilostazol, for prevention of thrombosis and restenosis, in intracranial stenting (A) 1108; corticotropin, for acute gout (A) 365; dopamine agonists, for restless legs syndrome (A) 627; fenoledipam, for prevention of contrast media-induced acute renal failure (A) 1278; flunazepam, for urinary tract infection, dose recommendation (A) 369; gabapentin, for bipolar disorders (A) 1264; *Helicobacter pylori* eradication, effect on NSAID-induced gastrointestinal toxicity (A) 249; HMG-CoA reductase inhibitors, for cholesterol reduction, alternate-day dosing (A) 496; intravenous valproate, for status epilepticus (A) 1465; L-arginine, for cardiovascular diseases (A) 755; leukotriene receptor antagonists, for allergic rhinitis (A) 1274; metformin, for polycystic ovary syndrome (A) 1644; misoprostol, prevention of postpartum hemorrhage (A) 1648; NSAIDs, impairment of orthodontic tooth movement (A) 113; ondansetron, for bulimia nervosa (A) 1270; oral contraceptives, debate regarding continuous use (A) 1480; paxitaxel, prophylaxis for hypersensitivity reactions (A) 1114; permethrin and phenothrin, for head lice resistance (A) 109; phytoestrogens, effect on breast cancer growth (A) 1118; postpartum alopecia (A) 255; rifampin, for CNS staphylococcal infections, adjunctive therapy (A) 765; sulfacate, for renal failure (A) 360; sucrose analgesia, in neonates (A) 947; topical tacrolimus, for atopic dermatitis (A) 943; warfarin-Salvia *millierrhiza* interaction (A) 501

Drug interactions, ACE inhibitors-aspirin, review (A) 1653; acetaminophen-alcohol (A) 921; alcohol-acetaminophen (A) 921; alcohol-aspirin (A) 920; alcohol-H₂-receptor antagonists (A) 919; alcohol-OTC medications (A) 918; alcohol-sildenafil (A) 340; antihypertensives-orlistat (L) 1495; argatroban, review (A) 446; argatroban-aspirin (A) 446; argatroban-erythromycin (A) 446; argatroban-heparin (A) 446; argatroban-lidocaine (A) 447; argatroban-warfarin (A) 446; aspirin-ACE inhibitors (A) 1653; aspirin-alcohol (A) 920; aspirin-argatroban (A) 446; atenolol-valsartan (CR) 859; azole antifungals-statins (A) 1100; bexarotene, review (A) 1060; carbamazepine-ritonavir (L) 125; celecoxib-clopidogrel (CR) 1567; cerivastatin-gemfibrozil (CR) 1016; cilostazol-warfarin, no interaction (RR) 1535; cilostazol, review (A) 53; cimetidine-sildenafil (A) 339; cisapride-digoxin (L) 127; clarithromycin-simvastatin (CR) 26; clopidogrel-celecoxib (CR) 1567; clozapine-haloperidol (L) 784; clozapine-sertraline (CR) 862, (L) 1671; colesevelam hydrochloride, review (A) 903; cyclosporine-St. John's wort (L) 124; cyclosporine-statins (A) 1099; digoxin-cisapride (L) 127; disulfiram-ethanol (CR) 32; erythromycin-argatroban (A) 446; erythromycin-verapamil (CR) 1396; ethanol-disulfiram (CR) 32; fibrates-statins (A) 1099, review (A) 908; fluoroquinolones, review (A) 1087; fluoroquinolone-phenytoin (CR) 1367; fluvoxamine-mirtazapine (CR) 1217, (CR) 1221, (L) 1674; gemfibrozil-cerivastatin (CR) 1016; gemfibrozil-statins (A) 1099; H₂-receptor antagonists-alcohol (A) 919; haloperidol-clozapine (L) 784; haloperidol-mirtazapine/risperidone (CR) 698; heparin-argatroban (A) 446; HMG-CoA reductase inhibitors, review (A) 1096; Implanon, review (A) 334; lidocaine-argatroban (A) 447; linezolid, review (A) 572; *Lycium barbarum* L.-warfarin (CR) 1199; macrolides-statins (A) 1100; metoprolol-simvastatin (L) 1292; mifepristone, review (A) 711; mirtazapine/risperidone-haloperidol (CR) 698; mirtazapine-fluvoxamine (CR) 1217, (CR) 1221, (L) 1674; nateglinide, review (A) 1432; nefazodone-zopiclone (CR) 1378; nonnitrates antihypertensives-sildenafil (A) 339; orlistat, review (A) 323; orlistat-antihypertensives (L) 1495; osetamivir, review (A) 65; OTC medications-alcohol (A) 918; phenytoin-fluorouracil (CR) 1367; protease inhibitors-sildenafil (A) 339; ritonavir-carbamazepine (L) 125; ropivacaine-warfarin (CR) 1202; S-adenosyl-L-methionine, review (A) 1421; *Salvia millierrhiza*-warfarin (A) 501; sertraline-clozapine (CR) 862, (L) 1671; sildenafil, review (A) 339; sildenafil-alcohol (A) 340; sildenafil-cimetidine (A) 339; sildenafil-nonnitrates antihypertensives (A) 339; sildenafil-protease inhibitors (A) 339; simvastatin-clarithromycin (CR) 26; simvastatin-metoprolol (L) 1292; smoking-warfarin (L) 385; St. John's wort-cyclosporine (L) 124; statins-azole antifungals (A) 1100; statins-cyclosporine (A) 1099; statins-fibrates (A) 1099, (A) 908; statins-gemfibrozil (A) 1099; statins-macrolides (A) 1100; sulfasalazine-warfarin (L) 506; teneceplase, review (A) 1236; valsartan-atenolol (CR) 859; verapamil-erythromycin (CR) 1396; warfarin-argatroban (A) 446; warfarin-cilostazol, no interaction (RR) 1535; warfarin-*Lycium barbarum* L. (CR)

- 1199; warfarin-ropinirole (CR) 1202; warfarin-*Salvia miltiorrhiza* (A) 501; warfarin-smoking (L) 385; warfarin-sulfasalazine (L) 506; zanamivir, review (A) 63; zopiclone-nafazodone (CR) 1378
- Drug overdose**, sertraline with trazodone, serotonin syndrome (CR) 1375
- Drug safety**, argatroban (A) 445; celecoxib, incidence of duodenal ulcers (RR) 831; colesvelam hydrochloride (A) 902; etanercept, for juvenile rheumatoid arthritis (A) 468; fluoroquinolones (A) 1090; galantamine (A) 1411; gentamicin, intravenous bolus in children (RR) 1327; glycoprotein IIb/IIIa antagonists, risk of hemorrhage (A) 476; Implanon (A) 333; in pregnancy, FDA labeling system (O) 1485; intravenous itraconazole (A) 726; mifepristone (A) 712; nicotine replacement products, pregnancy categories (L) 1496; orlistat (A) 322; sildenafil (A) 340
- Drug Selection Perspectives**, neuraminidase inhibitors, zanamivir and oseltamivir (A) 57
- Drug utilization**, acute respiratory infection, private pharmacies, Vietnam (RR) 1283; appropriateness of nitrate use, in general medicine population (RR) 1339; β_2 -agonists, assessment of treatment by national standards (RR) 682; diabetic hypertension, prescribing patterns and therapeutic implications, Bahrain (RR) 1350; opioid analgesics compared with ketorolac, in hip and joint procedures (RR) 1320
- Drug-related problems**, nonprescription drugs, pharmacy interventions (RR) 1343
- Editorials**, see also **Opinions**; Alternative, Complementary, or Integrated Pharmacy, 959; Antimicrobial Cycling to Control Bacterial Resistance, 1289; Treatment of Attention Deficit Hyperactivity Disorder in Children, 1130; Pharmaceutical Industry-Health System Interface, 1661; Publication of Clinical Drug Trials (E) 780; Understanding Antipsychotic Drug Tolerability, 1659
- Education and training**, Cancer Prevention Fellowship Program, National Cancer Institute (NC) 976
- Educational Events**, 143, 275, 401, 523, 661, 797, 1155, 1309, 1510, 1691
- Emitefur**, review (A) 223
- Enalapril**, for CHF, compared with losartan (A) 75, with candesartan (A) 79; for diabetic nephropathy, compared with losartan (A) 457; for heart failure, with losartan (A) 243; for slowing of renal disease (A) 455; inducing fatal hepatotoxicity (L) 1492
- Endocrinology**, levothyroxine, effect of administration time on serum TSH, elderly (RR) 529
- Endoscopic therapy**, for acute bleeding peptic ulcers (A) 732
- Endothelial receptor blockers**, for chronic heart failure (A) 1071
- End-stage renal disease**, treatment with succalfate (A) 360
- Eniluracil**, with fluoroaracil, for tumor control (A) 220
- Enoxacin**, pharmacokinetics (A) 1087
- Enoxaparin**, for radiation-induced myelopathy (CR) 188; for unstable angina and non-ST-segment MI, compared with unfractionated heparin (A) 605
- Enteral nutrition**, effect on gastric pH (A) 1615; effect on gastrointestinal blood flow (A) 1616; effect on stress ulceration and hemorrhage (A) 1618; fluconazole, in postpyloric feeding tubes (A) 1492; for stress ulcer prophylaxis (A) 1614
- Enterobacter spp.**, resistance to ceftazidime, restriction policy (A) 1229
- Enterococcus spp.**, resistance to ceftazidime (A) 1228
- Enuresis**, clozapine induced, tolterodine treatment failure (CR) 867
- Epilepsy**, topiramate, for seizure reduction, optimum titration schedule (RR) 173
- Eptifibatide**, with streptokinase, for acute MI (A) 593; with unfractionated heparin, for acute coronary syndrome (A) 602
- Erectile dysfunction**, sildenafil compared with injectable alprostadil, mortality comparison (RR) 285; treatment with sildenafil, adequateness of product information (A) 337
- Erythromycin**, interaction with verapamil, complete atrioventricular block (CR) 1396
- Estradiol**, lotion for hair loss (A) 256
- Estrogen**, for cholesterol reduction (A) 1603; for prevention of heart disease (A) 610; for reduction of blood loss, in hepatic surgery (A) 926; soy proteins, effect on breast cancer growth (A) 1118
- Etanercept**, for juvenile rheumatoid arthritis, efficacy (A) 468, pharmacology (A) 467, safety (A) 468
- Ethanol**, see **Alcohol**, interaction with disulfiram, delirium (CR) 32
- Euglycemic clamp**, for clozapine-induced diabetic ketoacidosis (CR) 1381
- Excitotoxins**, diet-induced fibromyalgia (CR) 702
- Extrapyrindamine syndromes**, atypical antipsychotics induced (RR) 1517

F-G

- Familial adenomatous polypos**, adjunctive treatment with celecoxib (A) 1638
- Famotidine**, inducing delirium, after switch from cimetidine (CR) 1045
- Febrile neutropenia**, antimicrobial resistance, switching study (A) 1228
- Fellowships and Residencies**, Nebraska, Creighton University Cardiac Center 143

- Fenoldopam**, for prevention of contrast media-induced acute renal failure (A) 1278, correction (L) 1677
- Fetal death**, valsartan with atenolol induced (CR) 859
- Fibrates**, compared with statins, review (A) 908; for lowering cholesterol (A) 1600; interaction with statins (A) 1099
- Fibrinogen**, affected by HMG-CoA reductase inhibitors (A) 236; assay methods (A) 237; clinical importance (A) 237
- Fibrinolytic therapy**, for intraventricular hemorrhage (A) 1435
- Fibroblastic osteosarcoma**, treatment with high-dose methotrexate, drug monitoring (L) 1669
- Fibromyalgia**, induced by dietary excitotoxins (CR) 702
- Filgrastim**, for adult lymphoblastic leukemia (A) 102; for adult myelogenous leukemia (A) 100; for pediatric lymphoblastic leukemia (A) 95; pharmacoeconomics (A) 96
- Finley, Rebecca S**, received Sister M Gonzales — Duffy Lecture Award, from American Society of Health-System Pharmacists of Pennsylvania (NC) 1692
- Fluconazole**, desensitization, in AIDS patient (L) 642; for *Candida lusitana*, resistance to amphotericin B (CR) 1570; for urinary tract infection, compared with amphotericin B (A) 370; dose recommendation (A) 369; inducing torsade de pointes (CR) 432; intravenous, effect of restriction on patient outcomes (RR) 9; pharmacokinetics in trauma patients, postpyloric feeding tubes (L) 1492
- Fluoropyrimidines**, adverse effects, review (A) 223; capecitabine with fluorouracil (A) 219; emitefur with fluorouracil (A) 223; eniluracil with fluorouracil (A) 220; pharmacoeconomics (A) 223; S-1 compared with uracil/tegafur (A) 222; uracil/tegafur with fluorouracil (A) 221; with fluorouracil, for tumor control, review (A) 217
- Fluoroquinolones**, antimicrobial activity (A) 1088; associated with seizures (CR) 1194; bacterial resistance (A) 1086; clinical efficacy, treatment of bacterial infection (A) 1088; drug interactions (A) 1087; for bone and joint infections (A) 1090; for chronic bronchitis (A) 1088; for community-acquired pneumonia (A) 1089; for febrile neutropenia (A) 1090; for intra-abdominal infections (A) 1090; for nosocomial pneumonia (A) 1089; for respiratory tract infections (A) 1089; for urinary tract infections (A) 1088; inducing peripheral neuropathy (L) 1673, (RR) 1540; limited reimbursement policy, impact on antimicrobial prescription claims (RR) 852; mechanism of action (A) 1085; pharmacokinetics (A) 1086; pneumococcal resistance (A) 482; resistance of *Streptococcus pneumoniae* (NC) 1509; safety and tolerability (A) 1090; spectrum of activity (A) 1085; treatment of skin infections (A) 1090
- Fluorouracil**, inducing aphasia (L) 785; interaction with phenytoin (CR) 1367; pharmacoeconomics (A) 223; pharmacology (A) 218; with fluoropyrimidines, review (A) 217
- Fluoxetine**, for bipolar depression, manic switching (CR) 45
- Flutamide**, lack of methemoglobinemia (RR) 21
- Fluvastatin**, for cholesterol reduction (A) 498; pharmacokinetics (A) 1099
- Fluvosamine**, aggravating glaucoma (CR) 1565; augmentation increases serum mirtazapine, three- to fourfold (CR) 1221; with mirtazapine, inducing serotonin syndrome (CR) 1217, (L) 1674
- Food and Drug Administration**, labeling system, safety in pregnancy (A) 1485, (O) 1485; problems with current labeling, drugs in pregnancy (A) 1486; proposed labeling changes (NC) 402
- Formulary Forum**, argatroban, for prevention and treatment of thromboembolism, heparin-induced thrombocytopenia (A) 440; hexaretone, for cutaneous T-cell lymphoma (A) 1056; cilostazol, for intermittent claudication (A) 48; colesvelam hydrochloride, novel bile acid-binding resin (A) 898; galantamine, for Alzheimer disease (A) 1406; intravenous itraconazole, for fungal infections (A) 720; linezolid, for resistant gram-positive cocci (A) 566; mifepristone, for pregnancy termination (A) 707; orlistat, for weight loss (A) 314; 5-adenosyl-L-methionine, efficacy (A) 1414; tenecteplase, for acute MI (A) 1233; verteporfin, for age-related macular degeneration (A) 1593
- Formulation**, amphotericin B, lipid-based compounds (A) 207; Chinese herbal medicine (A) 232
- Fungal infection**, amphotericin B, stem cell transplantation (A) 206; neonates, treatment with lipid-based amphotericin B (CR) 1034; prophylaxis, lipid-based amphotericin B (A) 214
- Gabapentin**, for bipolar disorders, review (A) 1264; for dementia, behavioral and psychological symptoms (CR) 427
- Galantamine**, clinical trials (A) 1408; dosing (A) 1412; for Alzheimer disease, review (A) 1406; pediatric and geriatric considerations (A) 1411; pharmacoeconomics (A) 1411; pharmacokinetics (A) 1407; pharmacology (A) 1407; safety (A) 1411
- Gastroenterology**, gastrointestinal disorders, Chinese herbal medicine (A) 228; octreotide, for acute variceal bleeding (A) 618; proton pump inhibitors, for bleeding peptic ulcers, meta-analysis (RR) 1528; 5-adenosyl-L-methionine, for gastroprotection (A) 1419; sulfasalazine, for radiation-induced gastrointestinal toxicity (RR) 806
- Gatifloxacin**, pharmacokinetics (A) 1087
- Gemfibrozil**, inducing linear immunoglobulin A bullous dermatitis (CR) 891
- Gemfibrozil**, for hyperlipidemia, in acute MI (A) 608; with cerivastatin, inducing rhabdomyolysis (CR) 1016; with statins, inducing rhabdomyolysis (A) 1099
- General medicine**, mood disorders, interferon induced, review (A) 489; mortality, sildenafil compared with injectable alprostadil (RR) 285; religion, coping with serious medical illness (A) 352

- Generic drugs**, clozapine, converting from brand name to generic (L) 1295 (RR) 281; warfarin, switch from Coumadin to generic, subtherapeutic INR (CR) 183
- Genistein**, effect on breast cancer growth (A) 1118
- Gentamicin**, cycling with amikacin, to control microbial resistance (A) 1228; cycling with kanamycin (A) 1225; ophthalmic solutions, stability (L) 1293; safety of intravenous bolus administration, in children (RR) 1327
- Geriatrics**, adverse drug events, in homeless geriatric population (RR) 1166; hexaretone, special considerations (A) 1061; galantamine, for Alzheimer disease (A) 1411; prescription drug use, by type of diagnosis, healthcare utilization (RR) 1004; topical phenytoin, treatment of stage II decubitus ulcers (RR) 675
- Geriatrics/Gerontology**, medication adherence after hospital discharge, home health services (RR) 539
- Glaucoma**, aggravated by fluvoxamine (CR) 1565
- Glucose**, assessment of abnormalities, HIV-infected patients, treatment recommendations (A) 347; baseline evaluation, monitoring (A) 347; metabolism abnormalities, antiretroviral therapy induced (A) 344, associated with HIV and its drug therapy, review (A) 343; nonpharmacologic intervention (A) 347; pharmacologic interventions (A) 348
- Glutamine**, prevention of veno-occlusive disease (A) 837
- Glyburide**, compared with nateglinide (A) 1429
- Glycopeptides**, coating for intravascular catheters, infection control (A) 1257
- Glycoprotein IIb/IIIa antagonists**, abciximab (A) 602; adverse effects (A) 603; eptifibatide (A) 602; for acute coronary syndrome, risks and benefits, review (A) 472; for secondary prevention of ischemic stroke (A) 1244; pharmacoeconomics (A) 477; safety (A) 476; therapeutic efficacy, acute coronary syndrome (A) 474; tirofiban (A) 603
- Gonorrhea**, treatment alternatives to spectinomycin (NC) 976
- Gout**, risk factors (A) 365; treatment with colchicine, inducing neutropenia (CR) 192; treatment with colchicine (A) 365
- Granisetron**, converting iv ondansetron to po granisetron (RR) 14
- Gynecomastia**, induced by highly active retroviral therapy (CR) 438

H-I

- H₂-Receptor antagonists**, effect on blood alcohol levels (A) 919
- Haemophilus influenzae**, ceftriaxone for childhood meningitis (CR) 36
- Hair loss**, see **Alopecia**
- Haloperidol**, inducing extrapyramidal syndromes (RR) 1517; switch to risperidone, inducing neuroleptic malignant syndrome (CR) 698; with clozapine, inducing neuroleptic malignant syndrome (L) 784
- Hartzema, Abraham G**, accepting eminent scholar position, at University of Florida College of Pharmacy (NC) 1510, (NC) 662
- Head lice**, resistance (A) 109
- Health maintenance organizations**, utilization by asthma patients (RR) 990
- Healthcare utilization**, by type of diagnosis, elderly (RR) 1004
- Heart failure**, treatment with ACE inhibitors plus angiotensin II receptor blockers (A) 242; treatment with carvedilol, cost-effectiveness results, US Carvedilol Heart Failure Trials Program (RR) 846; treatment with L-arginine (A) 761
- Helicobacter pylori**, in NSAID-induced gastrointestinal toxicity, effect of eradication on healing, review (A) 249
- Hematology**, veno-occlusive disease, prevention and treatment (A) 935
- Hemorrhage**, postpartum, prevention with misoprostol (A) 1648
- Hemostatic medications**, adverse effects, review (A) 931; for reduction of blood loss during surgery (A) 925; in cardiac surgery, adverse effects (A) 1077, clinical trials (A) 1077, comparison of drugs, meta-analyses (A) 1077, pharmacoeconomics (A) 932, (A) 1081, rationale for use (A) 1076
- Heparin**, see also **Unfractionated heparin**; effects on hypertonic potassium chloride-induced bronchoconstriction (RR) 1161; for radiation-induced myelopathy (CR) 188; inducing thrombocytopenia, treatment with argatroban (A) 440; inducing thrombocytopenia and renal failure, treatment with lepirudin and hemodialysis (CR) 885; low-dose, for prevention of veno-occlusive disease (A) 936; low-molecular-weight, for prevention of veno-occlusive disease (A) 937, for non-ST-segment MI (A) 604
- Hepatic surgery**, hemostatic medications, for reduction of blood loss (A) 926
- Hepatotoxicity**, amoxicillin/clavulanate induced (L) 1142, (L) 1677; carvedilol induced (CR) 1364; cefnicidol induced (L) 1669; cyproterone acetate induced (CR) 1053; enalapril induced (L) 1492; nimesulide induced (CR) 1049; rifampin and pyrazinamide induced, treatment of latent tuberculosis infection (NC) 799; trazodone induced (CR) 1559
- Herbals**, for gastrointestinal disorders (A) 228; St. John's wort, interaction with cyclosporine (L) 124; *Lycium barbarum* L., interaction with warfarin (CR) 1199
- HIV**, see **Human immunodeficiency virus**
- HMG-CoA reductase inhibitors**, see **Hydroxymethylglutaryl reductase coenzyme A inhibitors**
- Home health services**, medication adherence, elderly patients after hospital discharge (RR) 539

Hopkins, William A Jr, Gloria Niemeyer Francke Leadership Mentor Award, Academy of Pharmacy Practice (NC) 276

Hormone replacement therapy, for cholesterol reduction (A) 1603; topical testosterone treatment, complicated by hypertension (CR) 1205

Hospital discharge, integrated prescription form, evaluation (IR) 953

Human immunodeficiency virus, see also, Acquired immunodeficiency syndrome; amphotericin B-induced seizures (CR) 1037; antiretroviral therapy, gynecostasia (CR) 438; electronic adherence monitoring, barriers to use (RR) 1010; gastrostomy tube placement, noncompliant children (RR) 414; glucose disorders, associated with HIV drug therapy (A) 343; HIV-related medications, coverage by states (RR) 155; nelfinavir desensitization (CR) 553; progressive multifocal leukoencephalopathy, treatment with zidovudine (A) 741; protease inhibitors, role of therapeutic drug monitoring (A) 745; pulmonary cryptococcosis, desensitization to fluconazole (L) 642; quality of life, disease-specific psychometric evaluation (RR) 546

Hydroxymethyl glutaryl coenzyme A reductase inhibitors, adverse reactions (A) 909; drug interactions, rhabdomyolysis (A) 1096, correction (L) 1296; effect on fibrinogen, atorvastatin (A) 238, lovastatin (A) 239, pravastatin (A) 239, simvastatin (A) 239; for cholesterol reduction (A) 1602; alternate-day dosing (A) 496

Hyperbilirubinemia, indinavir and ritonavir induced (CR) 1391

Hypercholesterolemia, statin-fibrate combination therapy (A) 908; treatment with colestevam hydrochloride (A) 898

Hypercoagulability, cardiovascular risk factor, treatment with L-arginine (A) 760

Hyperglycemia, HIV drug therapy induced (A) 343; olanzapine-induced nonketotic coma (CR) 300

Hyperhomocysteinemia, S-adenosyl-L-methionine induced (A) 1421

Hyperlipidemia, cardiovascular risk factor, management with L-arginine (A) 756; treatment for coenzyme A, in acute MI (A) 608

Hypersensitivity, abacavir (L) 1291; to paclitaxel, prophylaxis with dexamethasone (A) 1114

Hypertension, cardiovascular risk factor, treatment with L-arginine (A) 760; complicating testosterone therapy, topical administration (CR) 1205; physicians' knowledge, attitudes, and practice, ambulatory care (RR) 1173; prescribing patterns, therapeutic implications for diabetic hypertension, Bahrain (RR) 1350; treatment after stroke (RR) 811

Hypertonic potassium chloride, inducing bronchoconstriction, treatment with heparin (RR) 1161

Hypoglycemia, xeroderma induced (CR) 1372

Hypomagnesemia, amphotericin B induced, transient hypoparathyroidism, β -thalassaemic patient (CR) 1042

Hypoparathyroidism, due to amphotericin B-induced hypomagnesemia, patient with β -thalassaemia (CR) 1042

Ibuprofen, effect on orthodontic tooth movement, compared with acetaminophen and misoprostol (A) 114; incidence of ulcers, compared with celecoxib (RR) 831

Imipenem, for ceftazidime-resistant *Klebsiella pneumoniae* (A) 1229

Immunotherapy, with Bacillus Calmette-Guérin, therapy-related death (L) 963

Implanon, adverse drug reactions, review (A) 332; clinical trials (A) 330; compared with Norplant (A) 331; contraindications (A) 333; dosing (A) 334; drug interactions (A) 334; patient education (A) 334; pharmacokinetics (A) 330; pharmacology (A) 330; review (A) 329; safety in pregnancy and lactation (A) 333

Incidence, measles, rubella, and congenital rubella syndrome, US and Mexico (NC) 144

Indinavir, adverse effects (A) 749; compared with lamivudine and zidovudine, effectiveness (A) 747; compared with nevirapine (A) 747; interpatient variability, pharmacokinetics (A) 749; with ritonavir, inducing ingrown toenails (CR) 881, inducing symptomatic hyperbilirubinemia (CR) 1391

Indomethacin, orthodontic tooth movement inhibition (A) 114

Infection, prophylaxis, cefuroxime in coronary bypass graft (RR) 409; staphylococcal, treatment of CNS infections with rifampin (A) 765; treatment with fluoroquinolones, bone and joint (A) 1090, intraabdominal (A) 1090, respiratory tract (A) 1089, skin and skin structure (A) 1090, urinary tract (A) 1088; treatment with rifampin, brain abscesses caused by *Staphylococcus* spp. (A) 767, meningitis caused by *Staphylococcus aureus* (A) 767, *Staphylococcus epidermidis* in cerebrospinal fluid shunt (A) 766

Infectious diseases, AIDS, coverage of HIV-related medications by states (RR) 155; zidovudine, for progressive multifocal leukoencephalopathy (A) 741; community-acquired pneumonia, adherence to ATS guidelines, hospitalized patients (RR) 1180; fluoroquinolones, spectrum of activity (A) 1085; HIV disease, glucose disorders, associated with drug therapy (A) 343, quality of life, psychometric evaluation (RR) 546; intravascular catheters, antimicrobial coating/bonding and impregnation (A) 1255; intravenous fluconazole, impact of restriction policy on patient outcomes (RR) 9; latent tuberculosis infection, treatment with rifampin and pyrazinamide, inducing severe hepatitis (NC) 799; linezolid, for resistant gram-positive cocci (A) 566; lipid-based amphotericin B, stem cell transplant, practice guidelines (A) 206; peripheral neuropathy, fluoroquinolone induced (RR) 1540; pneumococcal resistance, treatment challenge (A) 480; protease inhibitors, role of therapeutic drug monitoring (A) 745; stability of piperacillin and ticarcillin, AutoDose infusion bags (RR) 1360

Inflammatory bowel disease, isotretinoin induced (CR) 1214; treatment with infliximab, pediatrics (RR) 823

Infliximab, for inflammatory bowel disease, in children (RR) 823

Influenza, activity in the US, 2000-2001 season (NC) 402; antiviral pharmacology (A) 58; prophylaxis, with oseltamivir (A) 57, with zanamivir (A) 57; resistance to zanamivir (A) 66; treatment, with oseltamivir (A) 57, with zanamivir (A) 57; vaccine delayed (NC) 1156; viral structure (A) 58

Ingrown toenails, indinavir and ritonavir induced (CR) 881

Insomnia, drug therapy, benzodiazepines (A) 1452, trazodone (A) 1454, zaleplon (A) 1452, zolpidem (A) 1452; etiology and assessment (A) 1449; nonpharmacologic approaches (A) 1450; pharmacologic approaches (A) 1451; treatment in hospitalized patients (A) 1449

Insulin, for hyperglycemia, in HIV patients (A) 348; resistance, in HIV patients taking protease inhibitors (A) 346

Intensive care, development of bedside sedation scale (L) 262

Interferon, inducing homicidal ideations (L) 962; inducing mood disorders, theoretical and practical considerations (A) 489

Interferon- α , in antiretroviral therapy, inducing glucose disorders (A) 344

Interleukin, inducing glucose disorders in HIV patients (A) 344

Internationally normalized ratio, increase after smoking cessation, during warfarin therapy (L) 385

Internet pharmacy, compared with community pharmacy (SC) 116

Intracerebral hemorrhage, celecoxib and clopidogrel induced (CR) 1567

Intracoronary stenting, cilostazol, for prevention of thrombosis and restenosis (A) 1108

Intravascular catheters, antimicrobial coating, chlorhexidine-silver compared with minocycline-rifampin (A) 1260; antimicrobial coating/bonding and impregnation, review (A) 1255; associated with bloodstream infections (A) 1256; cefazolin-bonded (A) 1256; chlorhexidine-silver sulfadiazine coated (A) 1258; glycopeptide-coated (A) 1257; minocycline-rifampin coated (A) 1260; silver-impregnated (A) 1257; teicoplanin-coated (A) 1257

Intraventricular hemorrhage, management with fibrinolytic therapy (A) 1435; treatment with alteplase (A) 1439, treatment with urokinase (A) 1442

Ioversol, with cisplatin, doxorubicin, and mitomycin, for stability in chemoembolization (RR) 1548

Irbesartan, for CHF, dose-finding trial (A) 75; for heart failure, with ACE inhibitor (A) 246

Iron, supplement, treatment of alopecia (A) 257

Ischemic heart disease, management with L-arginine (A) 761; vincristine and doxorubicin induced (CR) 1403

Ischemic stroke, antiplatelet agents for secondary prevention (A) 1241

Isoorbide dinitrate, in coronary artery bypass graft (A) 633

Isoorbide mononitrate, appropriateness of use, in general medicine population (RR) 1339

Isotretinoin, inducing inflammatory bowel disease (CR) 1214; inducing polycythemia (L) 964

Iradipine, compared with nifedipine, for slowing of diabetic nephropathy (A) 459

Itraconazole, clinical efficacy, trials (A) 724; cyclodextrins (A) 721; dosage and administration (A) 726; drug safety (A) 726; for aspergillosis (A) 724; for blastomycosis (A) 725; for cryptococcal infection (A) 725; for febrile neutropenia (A) 725; for histoplasmosis (A) 725; formulation (A) 726; pharmacokinetics (A) 722; pharmacology (A) 72; therapeutic and economic issues (A) 726

Ivermectin, eradication of head lice (A) 109

J-M

Japan, pharmaceutical research, infrastructure and development (IR) 1122

JC Virus, inducing progressive multifocal leukoencephalopathy, in HIV patients (A) 741

Kanamycin, cycling with gentamicin, to control microbial resistance (A) 1225

Ketoacidosis, induced by clozapine, treatment with euglycemic clamp (CR) 1381

Ketorolac, compared with opioid analgesics, in spine and joint procedures (RR) 1320

Klebsiella pneumoniae, resistance, switching studies (A) 1228

Labeling, argatroban (A) 449; FDA system regarding safety in pregnancy (A) 1486, (O) 1485; mifepristone (A) 713; problems with current FDA system, drugs in pregnancy (A) 1486; proposed changes by the FDA (NC) 402; tenecteplase (A) 1237

Lamifiban, with alteplase or streptokinase, in acute MI (A) 594

Lamivudine, compared with indinavir and zidovudine, effectiveness (A) 747; compared with nelfinavir, saquinavir, and stavudine, effectiveness (A) 746

Lebanon, ambulatory care, common prescriptions (IR) 636

Leogranastin, for adult myelogenous leukemia (A) 96

Lepirudin, for acute MI, compared with unfractionated heparin (A) 606; for heparin-induced thrombocytopenia and renal failure (CR) 885; for thromboembolism, compared with argatroban, heparin-induced thrombocytopenia (A) 448

Leukemia, adult acute lymphoblastic, colony-stimulating factors (A) 102; adult acute myelogenous, colony-stimulating factors (A) 96; efficacy of colony-stimulating factors (A) 92 (O) 120; pediatric acute lymphoblastic, mogamostim and filgrastim (A) 94

Leukoencephalopathy, progressive multifocal, treatment with zidovudine (A) 741

Leukotriene receptor antagonists, clinical trials (A) 1275; treatment of allergic rhinitis (A) 1274

Levofloxacin, effect on theophylline clearance, during theophylline and clarithromycin combination therapy (CR) 691; failure, in patient with pneumococcal pneumonia (CR) 687; inducing peripheral neuropathy (RR) 1540; inducing seizures (CR) 1194; pharmacokinetics (A) 1087

Levothyroxine, effect of administration time on serum TSH, elderly (RR) 529; malabsorption due to calcium carbonate, in gastrointestinal disorders (CR) 1578

Lidocaine, for ventricular fibrillation/pulseless ventricular tachycardia (A) 1251; for ventricular tachyarrhythmias, compared with procainamide (A) 1249, compared with sotalol (A) 1249

Linear immunoglobulin A bullous dermatitis, induced by gemcitabine (CR) 891

Linezolid, adverse effects (A) 571; clinical trials (A) 570; compared with vancomycin, effectiveness against gram-positive cocci (A) 569; dosing (A) 571; drug interactions, review (A) 572; pharmacokinetics (A) 572; pharmacokinetics (A) 569; treatment of resistant gram-positive cocci (A) 566

Lisinopril, for slowing of diabetic nephropathy, compared with diltiazem (A) 457, diltiazem and furosemide/atenolol (A) 457, nifedipine (A) 459; for slowing of renal disease (A) 455

Lithium, inducing exacerbation of stutter (L) 961; inducing severe acne (L) 961; intoxication, carbamazepine-induced renal failure (CR) 560

Liver dysfunction, cyproterone acetate, inducing acute hepatitis (CR) 1053; protection with S-adenosyl-L-methionine (A) 1419

Lomefloxacin, inducing peripheral neuropathy (RR) 1540; pharmacokinetics (A) 1087

Losartan, for chronic heart failure (A) 1070, for CHF, compared with captopril (A) 76, enalapril (A) 75; dose-finding trial (A) 74; with captopril (A) 78; for diabetic nephropathy, compared with enalapril (A) 457; for heart failure, with ACE inhibitor (A) 245, with enalapril (A) 243 (A) 246

Lovastatin, effect on fibrinogen (A) 239; for cholesterol reduction (A) 497; pharmacokinetics (A) 1099

Lycium barbarum L., interaction with warfarin (CR) 1199

Lymphoma, cutaneous T-cell, treatment with hexareotide (CR) 1056

Macrolides, interaction with statins, rhabdomyolysis (A) 1100; pneumococcal resistance (A) 482

Macular degeneration, age-related, treatment with verteporfin (A) 1593

Malabsorption, levothyroxine, due to calcium carbonate, in gastrointestinal disorders (CR) 1578

Malathion, eradication of head lice (A) 109

Marketing, managing the pharmaceutical industry-health system interface (E) 1661

Measles, elimination (NC) 144; incidence (NC) 144; incidence in the US and Mexico, 1997-1999 (NC) 144

Medicaid, β_2 -agonist recipients, assessment of treatment by national standards (RR) 682

Medication compliance, alendronate, intermittent dosing (A) 1471; elderly patients after hospital discharge, home health services (RR) 539; electronic adherence monitoring, barriers to use, HIV clinic (RR) 1010; gastrostomy tube, nonadherent HIV-infected children (RR) 414; protease inhibitors, depending on drug concentrations (A) 749, with metered-dose inhalers, self-reported vs. pharmacy claims data, ambulatory care (RR) 997

Megestrol acetate, inducing Cushing syndrome (CR) 1208; inducing hyperglycemia, HIV population (A) 345

Meningitis, intramuscular ceftriaxone in children (CR) 36; *Staphylococcus aureus*, treatment with rifampin (A) 767

Menopause, cardiovascular risk factor, management with L-arginine (A) 760

Metered-dose inhalers, compliance, self-reported vs. pharmacy claims data (RR) 997

Metformin, for hyperglycemia, in HIV patients (A) 348; for polycystic ovary syndrome (A) 1644; for protease inhibitor-induced ketoacidosis (CR) 877; for type 2 diabetes mellitus, compared with nateglinide (A) 1429; inducing gastrointestinal adverse effects, in HIV population (A) 348; no interaction with protease inhibitors (A) 348

Methotrexate, for rheumatoid arthritis, inducing pancytopenia (CR) 1575; high-dose, for fibrosarcoma/osteosarcoma (L) 1669

Methylaltrixone, for morphine-induced pruritus (A) 89; reducing constipation in opioid addicts (A) 88; reversing constipation (A) 87

Metoprolol, with simvastatin, inducing nightmares and sleep disturbances (L) 1292

Mifepristone, adverse effects, review (A) 710; clinical studies (A) 709; contraindications (A) 712; dosage and administration (A) 714; economic and therapeutic issues (A) 712; ethical perspective (O) 376; labeling issues (A) 713; patient counseling (A) 714; pharmacokinetics (A) 709; pharmacology (A) 708; psychological effects (O) 381; therapeutic controversies (O) 373; with misoprostol (A) 707

Minocycline-rifampin, coating of intravascular catheters, infection control (A) 1260

Mirtazapine, in Alzheimer disease, treatment of depression and comorbidities (CR) 1024; inducing peripheral edema (L) 1494; with fluvoxamine, inducing serotonin syndrome (CR) 1217, (L) 1674; with risperidone and haloperidol, inducing neuroleptic malignant syndrome (CR) 698

Misoprostol, compared with ibuprofen and acetaminophen, effect on orthodontic tooth movement (A) 114; prevention of postpartum hemorrhage (A) 1648; with mifepristone (A) 707

Mitomycin, with isoversol, stability for chemoembolization (RR) 1548

Molgramostim, for adult lymphoblastic leukemia (A) 104; for adult myelogenous leukemia (A) 98; for pediatric lymphoblastic leukemia (A) 94

Monosodium glutamate, inducing fibromyalgia (CR) 702

Montelukast, treatment of allergic rhinitis (A) 1276

Mood disorders, interferon induced, suggested mediators (A) 492, theoretical and practical considerations (A) 489; lithium induced, homicidal ideations (L) 961

Morphine, and its glucuronidated metabolites, in burn injuries, pharmacokinetics (CR) 1588

Mortality, sildenafil compared with injectable alprostadil (RR) 285, (L) 1143

Moxifloxacin, pharmacokinetics (A) 1087

Multiple drug use, various diagnoses, elderly (RR) 1004

Mumps, elimination (NC) 144

Mydriasis, concomitant with serotonin syndrome, treatment with cyproheptadine (CR) 873, (L) 1672

Myelopathy, radiation-induced, treatment with anticoagulation therapy (CR) 188

Myocardial infarction, American College of Cardiology/American Heart Association, treatment guidelines 1999 (A) 589; antithrombotic therapy for intracoronary stenting (A) 598; clopidogrel substituting aspirin (A) 597; non-ST-segment elevation MI, treatment strategies (A) 601; primary percutaneous coronary intervention, compared with thrombolysis (A) 595; role of estrogen replacement therapy (A) 610; role of smoking cessation (A) 611; thrombolysis plus glycoprotein IIb/IIIa receptor inhibitors (A) 592; thrombolytic therapy (A) 590; treatment of hyperlipidemia for coenzyme A (A) 608, with β -adrenergic receptor blockers (A) 600, with oral anticoagulants (A) 607, with teneclapase (A) 1233, with unfractionated heparin (A) 599; vincristine and doxorubicin induced (CR) 1403

N-O

Nahata, Milap C, elected Distinguished Scholar, National Academy of Practice in Pharmacy (NC) 524; elected President and Chairman, Board of Directors of the American Association of Colleges of Pharmacy (NC) 1156; received Howard Q Ferguson Memorial Lecture Award, from University of North Carolina School of Pharmacy (NC) 1692

Naloxone, for morphine-induced pruritus (A) 88; laxative effect (A) 88

Naproxen, compared with celecoxib, incidence of ulcers (RR) 831; for *Helicobacter pylori* eradication, NSAID-induced gastric ulcers (A) 252

Narcotics, inducing constipation and pruritus (A) 85; opioid analgesics compared with ketorolac (A) 1320

Nateglinide, adverse effects (A) 1431; clinical trials (A) 1428; compared with glyburide (A) 1429, repaglinide (A) 1429; dosing (A) 1432; drug interactions (A) 1432; patient counseling (A) 1432; pharmacokinetics (A) 1427; pharmacology (A) 1427; special populations (A) 1432; therapeutic controversies (A) 1432; with metformin (A) 1430

Nefazodone, interaction with zopiclone (CR) 1378

Nelfinavir, compared with saquinavir, stavudine, and lamivudine, effectiveness (A) 746; desensitization (CR) 553; dosage adjustment for organ dysfunction (A) 750

Neonates, sucrose analgesia, for minor procedures (A) 947

Nesiritide, for chronic heart failure (A) 1071

Neurohormones, for chronic heart failure (A) 1066, (A) 1071

Neuroleptic malignant syndrome, after switch from haloperidol to risperidone (CR) 698

Neurology, antiepileptic hypersensitivity syndrome, children (RR) 533; antiplatelet agents, for secondary prevention of ischemic stroke (A) 1241; fibrinolytic therapy, for intraventricular hemorrhage (A) 1435; topiramate for epilepsy, titration and tolerability (RR) 173

Neuropathy, pain, treatment with venlafaxine (CR) 557

Neutropenia, febrile, treatment with fluoroquinolones (A) 1090

Nevirapine, compared with indinavir (A) 747

New Drug Approval, nateglinide, for type 2 diabetes mellitus (A) 1426

New Drug Development, fluorouracil, with the new oral fluorinated pyrimidines (A) 217

New publications, see **Book reviews**

News and Comments, 144, 276, 402, 524, 662, 799, 976, 1156, 1310, 1509, 1692

Niacin, for hyperlipidemia, in acute MI (A) 608; for lowering cholesterol (A) 1601

Nicardipine, in coronary artery bypass graft (A) 632

Nicotine, replacement products, pregnancy categories (L) 1496; replacement therapy, after MI (A) 611

Nifedipine, for slowing of diabetic nephropathy, compared with diltiazem (A) 458, isradipine (A) 459, lisinopril (A) 459; in coronary artery bypass graft, compared with diltiazem and amlodipine (A) 633

Nimesulide, inducing acute hepatitis (CR) 1049

Nitrates, appropriateness of use, in general medicine population (RR) 1339; in coronary artery bypass graft (A) 631

Nitroglycerin, transdermal, compared with octreotide and terlipressin, for variceal bleeding (A) 620

Nonprescription drugs, drug-related problems, pharmacy interventions (RR) 1343; effect on blood alcohol levels (A) 918

Nonsteroidal antiinflammatory drugs, effect on incidence of colorectal cancer (A) 1638; impairment of orthodontic tooth movement (A) 113; inducing gastrointestinal toxicity, *Helicobacter pylori* eradication, review (A) 249

Norflaxacin, pharmacokinetics (A) 1087

Norplant, compared with Implanon (A) 331

Nucleoside analogs, with other antiretrovirals, inducing gynecoma (CR) 438

Nucleoside reverse transcriptase inhibitors, alterations in glucose metabolism, mitochondrial toxicity (A) 346

Nutrition, dietary excitotoxins, inducing fibromyalgia (CR) 702; management of veno-occlusive disease (A) 940

Obesity, treatment with orlistat, review (A) 314

Obstetrics/gynecology, Implanon, effectiveness, (A) 329; mifepristone, ethical perspective (O) 376, psychological effects (O) 381, therapeutic controversies (O) 373; misoprostol, prevention of postpartum hemorrhage (A) 1648

Octreotide, for variceal bleeding, as adjunctive therapy to sclerotherapy (A) 622, compared with balloon tamponade (A) 620, sclerotherapy (A) 621, somatostatin (A) 624, terlipressin and transdermal nitroglycerin (A) 620, vasopressin (A) 620

Ofloxacin, inducing peripheral neuropathy (RR) 1540; inducing toxic epidermal necrolysis (CR) 1388; pharmacokinetics (A) 1087

Olanzapine, in pregnancy (L) 1294; inducing diabetes mellitus (CR) 563, diabetic ketoacidosis (CR) 1556, extrapyramidal syndromes (RR) 1517, hyperglycemic nonketotic coma (CR) 300, pancreatitis (L) 506, rhabdomyolysis (CR) 1020, weight gain (L) 1141

Omapatrilat, in chronic heart failure (A) 1071

Onaprazole, clinical trials (A) 733; for acute peptic ulcer bleeding, compared with cimetidine (A) 735, compared with ranitidine (A) 734; for gastrointestinal ulcers, *Helicobacter pylori*-positive patients (A) 751, for *Helicobacter pylori*-positive NSAID-induced ulcers, compared with ranitidine (A) 251

Oncology, American Society of Clinical Oncology, guidelines for colony-stimulating factors (A) 104; antiemetics, converting from iv ondansetron to po granisetron (RR) 14; cisplatin, doxorubicin, and mitomycin, with isoversol, stability for chemoembolization (RR) 1548; colony-stimulating factors in acute leukemia (A) 92; fluorouracil with oral fluorinated pyrimidines (A) 217; flutamide, lack of methemoglobinemia (RR) 21; idiopathic pneumonia syndrome, following myeloablative chemotherapy (CR) 196; myeloablative chemotherapy, followed by idiopathic pneumonia syndrome, busulfan therapy (CR) 196; paclitaxel, for prevention of hypersensitivity reaction (A) 1114; stem cell transplant, lipid-based amphotericin B for fungal infection (A) 206; veno-occlusive disease, prevention and treatment (A) 935

Ondansetron, clinical trials, for bulimia nervosa (A) 1271; converting iv ondansetron to po granisetron (RR) 14; for bulimia nervosa (A) 1270

Ophthalmic β -blockers, systemic adverse effects, review (A) 1633

Ophthalmic solutions, β -adrenergic antagonists, systemic adverse effects (A) 1633; gentamicin, stability (L) 1293

Opinions, see also **Editorials**; Are Condoms Effective in Reducing the Risk of Sexually Transmitted Disease?, 1136; Colony-Stimulating Factors in Acute Leukemia, 120; Condoms and Sexually Transmitted Diseases, 1135; Mifepristone: Less Obvious Adverse Effects, 381; Mifepristone — A Boom or a Bust?, 376; Mifepristone — Controversy, Beliefs, and Politics — Issues for Everyone, 373

Opioid agonists, pharmacology (A) 86

Opioid antagonists, for opioid-induced constipation (A) 85; for opioid-induced pruritus (A) 85; methylnaltrexone, effect on gastric emptying (A) 86; naloxone (A) 86; naltrexone (A) 86

Opioids, inducing constipation and pruritus (A) 85; opioid analgesics, compared with ketorolac, in spine and joint procedures (RR) 1320

Oral contraceptives, continuous use, clinical trials (A) 1480; for postpartum alopecia (A) 256

Orlistat, clinical trials (A) 315; dosing (A) 323; drug interactions (A) 323; effectiveness (A) 325; for weight loss, review (A) 314; interaction with antihypertensive drugs (L) 1495; patient counseling (A) 324; patient selection (A) 323; pharmacoeconomics (A) 325; pharmacokinetics (A) 315; pharmacology (A) 315; safety and tolerability (A) 322; toxicology (A) 315

Orthopedic surgery, hemostatic medications, reduction of blood loss (A) 928

Oseltamivir, adverse effects (A) 66; dosing (A) 66; drug interactions, review (A) 65; influenza prophylaxis, clinical trials (A) 63; influenza treatment, clinical trials (A) 64; pharmacokinetics (A) 63

Osteoarthritis, treatment with S-adenosyl-L-methionine (A) 1417

Osteoporosis, treatment with alendronate, intermittent dosing (A) 1471

Over-the-counter medications, see also **Nonprescription drugs**; effect on blood alcohol levels (A) 918

Oxazolidinone antibiotics, antimicrobial activity (A) 568; pharmacology (A) 568

Oxytetracycline, for bronchitis (A) 578

P-R

Paclitaxel, inducing hypersensitivity reactions, prophylaxis with dexmethasone (A) 1114

Pain, childhood sickle cell anemia, treatment with intravenous codeine phosphate, inducing seizures (CR) 1211; neuropathic, treatment with venlafaxine (CR) 557

Pancytopenia, methotrexate induced, in patient with rheumatoid arthritis (CR) 1575

Parkinson disease, warfarin-ropinirole interaction (CR) 1202

Parkinsonism, antipsychotic induced, treatment with zolpidem (CR) 435

Patient counseling, hexarene (A) 1063; Implanon (A) 334; mifepristone (A) 714; nateglinide (A) 1432; nitrate use, appropriateness in general population (RR) 1339; orlistat (A) 324; polypharmacy, ambulatory care (RR) 835; S-adenosyl-L-methionine (A) 1422; teneclapase (A) 1237; verteporfin (A) 1596

Paviluzumab, for RSV prophylaxis, in high-risk infants, respiratory syncytial virus (RR) 1186

Pediatrics, antiepileptics, hypersensitivity syndrome (RR) 533; hexarene, special considerations (A) 1061; galantamine (A) 1411; gastrostomy tube placement, nonadherent HIV-infected children (RR) 414; gentamicin, safety of intravenous bolus administration (RR) 1327; inflammatory bowel disease, treatment with infliximab (RR) 823; intravenous codeine phosphate, inducing seizures, treatment of sickle-cell anemia (CR) 1211; neonatal systemic candidiasis, lipid-based amphotericin B (CR) 1032; sucrose analgesia, in newborn infants (A) 947; vaccination coverage levels, national, state, and urban area, small children (NC) 1310

Pellegrino, Edmund D, award for contributions to healthcare ethics, Sanford University (NC) 976

Penicillin, intravenous, for bronchitis (A) 578; resistance, *Streptococcus pneumoniae* (CR) 687

Pentamidine, inducing pancreatic toxicity, HIV patients (A) 345

Pentoxifylline, for intermittent claudication, compared with cilostazol (A) 51

Peptic ulcers, bleeding, treatment with proton pump inhibitors (RR) 1528

Percutaneous coronary intervention, compared with thrombolytic therapy, in acute MI (A) 595

Peripheral edema, mirtazapine induced (L) 1494

Peripheral neuropathy, fluoroquinolone induced (L) 1673, (RR) 1540

Peripheral vascular disease, management with L-arginine (A) 762

Permethrins, head lice resistance (A) 109

PharmACE, 137, 269, 397, 517, 655, 793, 971, 1149, 1305, 1505, 1687

Pharmaceutical industry, managing industry-health system interface (E) 1661

Pharmaceutical research, infrastructure and development, Japan (RR) 1122

Pharmaceutical standards, integrated discharge prescription form (A) 953

Pharmacist attitudes, toward diabetes, involvement in diabetes education (RR) 841

Pharmacodynamics, argatroban (A) 442; hexarene (A) 1058; colesvelam hydrochloride (A) 899; nateglinide (A) 1427; warfarin, lack of interaction with cilostazol (RR) 1535

Pharmacoeconomics, amphotericin B, lipid-based compounds (A) 210; argatroban (A) 449; cilostazol (A) 53; clozapine, generic drug compared with brand name (RR) 281; colesvelam hydrochloride (A) 903; filgrastim (A) 96; fluoroquinolones, limited reimbursement policy, impact on antimicrobial prescription claims (RR) 852; fluorouracil with fluoropyrimidines (A) 223; galantamine (A) 1411; glycoprotein IIb/IIIa antagonists (A) 477; hemostatic medications (A) 932; in cardiac surgery (A) 1081; intravenous fluconazole, effect of restriction policy on patient outcomes (RR) 9; intravenous itraconazole (A) 726; linezolid (A) 572; mifepristone (A) 712; orlistat (A) 325; prescribing practice, ambulatory care, Lebanon (RR) 636; respiratory syncytial virus, cost-benefit analysis, prophylaxis in high-risk infants (RR) 1186; sarngastin (A) 98; teneclapase (A) 1236; US Carvedilol Heart Failure Trials Program, cost-effectiveness results (RR) 846; verteporfin (A) 1595; zanamivir (A) 67

Pharmacoepidemiology, limited fluoroquinolones reimbursement policy, impact on antimicrobial prescription claims (RR) 852

Pharmacokinetics, S-adenosyl-L-methionine (A) 1415; alcohol (A) 919; para-aminosalicylic acid, four dosing conditions (RR) 1332; argatroban (A) 441; atorvastatin (A) 1099; hexarene (A) 1058; cerivastatin (A) 1099; cilostazol (A) 50; ciprofloxacin (A) 1087; colesvelam hydrochloride (A) 899; enoxacin (A) 1087; fluconazole, in postpyloric feeding tubes (L) 1492; fluoroquinolones (A) 1086; fluvastatin (A) 1099; galantamine (A) 1407; galiloxacin (A) 1087; Implanon (A) 330; intravenous itraconazole (A) 722; levofloxacin (A) 1087; linezolid (A) 569; lomefloxacin (A) 1087; losartan (A) 1099; morphine and its glucuronidated metabolites, in burn injuries (CR) 1588; moxifloxacin (A) 1087; nateglinide (A) 1427; nor-

floxacin (A) 1087; ofloxacin (A) 1087; orlistat (A) 315; oseltamivir (A) 63; praziquantel (A) 1099; protease inhibitors, role of therapeutic drug monitoring (A) 745; simvastatin (A) 1099; sparfloxacin (A) 1087; teniposide (A) 1234; trovafloxacin (A) 1087; verteporfin (A) 1594; zanamivir (A) 58

Pharmacology, 5-adenosyl-L-methionine (A) 1414; angiotensin II receptor antagonists compared with ACE inhibitors (A) 72; argatroban (A) 441; bexarotene (A) 1058; Chinese herbal medicine (A) 232; cilostazol (A) 49; colestyramine hydrochloride (A) 899; gabapentin (CR) 428; galantamine, for Alzheimer disease (A) 1407; Implanon (A) 330; intravenous itraconazole (A) 721; mifepristone (A) 708; nateglinide (A) 1427; orlistat, review (A) 315; oxazolidinone antibiotics (A) 568; teniposide (A) 1233

Pharmacy education, certificate program (RR) 293; continuing education (RR) 292; guide for pharmacotherapy research, writing manuscripts describing clinical trials (A) 770; mathematics test, preadmission indicator (RR) 167; pharmacists' attitudes toward diabetes, involvement in diabetes education (RR) 841; pharmacists' preferences, continuing education and certificate programs (RR) 289; publication rates, international comparison (L) 126

Phenobarbital, hypersensitivity syndrome, children (RR) 534
Phenothrin, with permethrin and piperonyl butoxide, eradication of head lice (A) 110

Phenytoin, compared with normal saline dressings, for decubitus ulcers (RR) 679; hypersensitivity syndrome, children (RR) 534; interaction with fluoroquinolones (CR) 1367; topical treatment, for stage II decubitus ulcers, elderly (RR) 675

Photosensitivity, photopatch testing, photosensitive drug eruptions (CR) 1584

Physicians' practice patterns, treatment of hypertension (RR) 1173

Phytoestrogens, effect on breast cancer growth (A) 1118

Ping wei san, Chinese herbal medicine (A) 228

Piperacillin, stability in AutoDose infusion bags (RR) 1360

Piperacillin/tazobactam, cycling with ceftazidime, to control microbial resistance (A) 1228

Piperonyl butoxide, with phenothrin and permethrin, treatment of head lice (A) 110

Placenta extract, treatment of hair loss (A) 256

Plasma exchange transfusion, inducing removal of vancomycin (CR) 1400

Platelet aggregation inhibitors, after stroke, community-based care (RR) 811

Pleuritic pericarditis, eosinophilic, from Vitamins B₆ and H (CR) 424

Pneumonia, community-acquired, adherence to ATS guidelines (RR) 1180; treatment with fluoroquinolones (A) 1089; idiopathic syndrome, following chemotherapy (CR) 196; pneumococcal, levofloxacin failure (CR) 687

Poliomyelitis, 2000-2001 season, Dominican Republic and Haiti (NC) 524

Polycystic ovary syndrome, treatment with metformin (A) 1644

Polyparmacy, patient counseling, ambulatory care (RR) 835

Postoperative analgesics, opioid analgesics compared with ketorolac, in hip and joint procedures (RR) 1320

Pravastatin, for restless legs syndrome (A) 628

Pravastatin, effect on fibrinogen (A) 239; pharmacokinetics (A) 1099

Pregnancy, *Bacillus anthracis* prophylaxis, in asymptomatic pregnant women (NC) 1692; categories of nicotine replacement products (L) 1496; drug safety, FDA labeling system (O) 1485; fetal death, valproic acid with atenolol (CR) 859; olanzapine (L) 1294; termination, mifepristone with misoprostol (A) 707

Prescribing, for diabetes mellitus, therapeutic implications for hypertension, Bahrain (RR) 1350; in ambulatory care, Lebanon (IR) 636; of antidepressants, Hispanic vs. non-Hispanic whites (RR) 419; selective, for atypical antipsychotics (RR) 1517; use of integrated discharge form, evaluation (A) 953

Primary care, prescribing behavior, antidepressants, Hispanic vs. non-Hispanic whites (RR) 419

Probuco, with cilostazol, in intracranial stenting (A) 1111

Procainamide, for ventricular tachyarrhythmias, compared with lidocaine (A) 1249

Product information, sildenafil, adequateness of information (A) 337

Progesterone, lotion, treatment of hair loss (A) 246

Prolactin, concentrations during risperidone therapy, schizophrenic population (RR) 1523

Prophylaxis, for *Bacillus anthracis*, among asymptomatic pregnant women (NC) 1692; for influenza, with oseltamivir (A) 57; with zanamivir (A) 57; for postpartum hemorrhage, with misoprostol (A) 1648; for stress ulcer, with enteral nutrition (A) 1614

Prostaglandin E₂, prevention of veno-occlusive disease (A) 937

Protease inhibitors, drug concentrations, compliance (A) 749; dosage adjustment for organ dysfunction (A) 750; interpatient variability, pharmacokinetic parameters (A) 749; resistance or synergy (A) 750; therapeutic effect (A) 746; toxicity (A) 748; funding by states (RR) 162; indinavir with ritonavir, inducing hyperbilirubinemia (CR) 1391; inducing diabetic ketoacidosis, treatment with metformin, HIV patient (CR) 877; inducing glucose disorders (A) 345; insulin resistance (A) 346; interpretation of drug concentrations (A) 751; pharmacokinetic parameters, predictors of response (A) 751; plasma concentrations, determination with assay (A) 751; role of therapeutic drug

monitoring (A) 745; target concentrations and therapeutic range (A) 751; therapeutic drug monitoring, utility (A) 752; with other antiretrovirals, inducing gynecostasia (CR) 438

Proton pump inhibitors, for bleeding peptic ulcers, meta-analysis (RR) 1528; for acute peptic ulcer bleeding, clinical trials (A) 732; recommendations (A) 737

Pseudoepileptiformity, from bromide intoxication (A) 386

Psoriasis, treatment with tacrolimus (A) 584

Psychiatry, bupropion, for depression, compared with selective serotonin-reuptake inhibitors (A) 1608; converting patients from brand-name clozapine to generic (RR) 281; extrapyramidal syndromes, with haloperidol, risperidone, olanzapine (RR) 1517; gabapentin, for dementia (CR) 427; neuroleptic malignant syndrome, switch from haloperidol to risperidone (CR) 698; olanzapine-induced hyperglycemic coma (CR) 300; schizophrenia, effects of risperidone on gonadal axis hormones (RR) 1523; treatment of insomnia, hospitalized patients (A) 1449

Psychometrics, quality of life in HIV disease, disease-specific instruments (RR) 546

Publishing, publication of clinical drug trials (E) 780; writing manuscripts describing clinical trials, guide for pharmacotherapeutic researchers (A) 770

Pulmonary fibrosis, induced by cyclophosphamide (CR) 894

Pulmonary/Allergy, antimicrobial therapy, for acute chronic obstructive pulmonary disease (A) 576; β_2 -agonist recipients, treatment by national standards (RR) 682; beparin, effects on hypertonic potassium chloride-induced bronchoconstriction (RR) 1161

Pyoderma gangrenosum, treatment with tacrolimus (A) 585

Pyrazinamide, with rifampin, inducing severe hepatitis, in treatment of latent tuberculosis infection (NC) 799

Quality of care, community-acquired pneumonia, adherence to treatment guidelines, American Thoracic Society (RR) 1180

Quality of life, disease-specific psychometric evaluation, HIV disease (RR) 546

Quinolones, see Fluoroquinolones

Radiation therapy, inducing acute gastrointestinal complications, treatment with sulfasalazine (RR) 806; inducing myopathy, treatment with anticoagulation drugs (CR) 188

Ranitidine, for acute peptic ulcer bleeding, compared with omeprazole (A) 251, (A) 734

Red Man syndrome, induced by vancomycin (A) 1458

Religion, coping with serious medical illness (A) 352; influence on health outcomes (A) 356; negative effects on health (A) 357; role in medical practice (A) 353; successful coping with depression (A) 354

Renal disease, additional treatment modalities (A) 461; combination therapy (A) 460; diagnosis (A) 453; pathophysiology (A) 452; slowing of progression, diabetic patients (A) 452; correction (L) 965; treatment with ACE inhibitors (A) 454; treatment with angiotensin II receptor blockers (A) 457; with calcium-channel blockers (A) 457

Renal failure, carbamazepine induced, causing lithium intoxication (CR) 560; contrast media induced, prevention with fenoldopam (A) 1278; from heparin-induced thrombocytopenia, treatment with lepirudin (CR) 885; treatment with succinylcholine (A) 360

Repaglinide, compared with nateglinide (A) 1429

Resistance, antimicrobial cycling, reversal of resistance (A) 1224; *Candida lusitanae*, resistance to amphotericin B (CR) 1570; fluconazole (CR) 1570; *Enterobacter* spp., resistance to ceftazidime (A) 1229; *Enterococcus* spp., resistance to cefazidime (A) 1228; treatment with linezolid (A) 567; febrile neutropenia, antimicrobial switching studies (A) 1228; gram-positive cocci, treatment with linezolid (A) 566; head lice, resistance to permethrin (A) 109; influenza virus, resistance to zanamivir (A) 66; *Klebsiella pneumoniae*, resistance to ceftazidime, switch to imipenem (A) 1229; to gentamicin (A) 1228; switching study (A) 1228; pneumococcal, treatment with β -lactams (A) 481, with fluoroquinolones (A) 482, with macrolides (A) 482; *Staphylococcus* spp., treatment with linezolid (A) 567; *Streptococcus pneumoniae*, resistance to fluoroquinolones (NC) 1509, resistance to levofloxacin (CR) 687, resistance to penicillin (CR) 687, review (A) 480; treatment with linezolid (A) 568; to amikacin, antimicrobial switching (A) 1230; to antimicrobial coated/bonded or impregnated catheters (A) 1261; to antimicrobials, cycling studies (A) 1225, switching studies (A) 1228; to fluoroquinolones (A) 1086

Respiratory syncytial virus, activity in the 1999-2000 season (NC) 276; prophylaxis in high-risk infants, cost-benefit analysis (RR) 1186

Respiratory syncytial virus immune globulin, for prophylaxis, in high-risk infants (RR) 1186

Respiratory tract infections, treatment with fluoroquinolones (A) 1089

Restless legs syndrome, treatment with dopamine agonists (A) 627

Retepase, for thrombolysis in acute MI (A) 592; with abiraterone, in acute MI (A) 594

Rhabdomyolysis, cervastatin and gemfibrozil induced (CR) 1016; clinical features (A) 1097; drugs interacting with statins (A) 1099; HMG-CoA reductase inhibitor induced, interactions (A) 1096, correction (L) 1296; olanzapine induced (CR) 1020; role of statins, drug interactions (A) 1098; statin and fibrin induced (A) 909

Rheumatoid arthritis, treatment with methotrexate, inducing severe pancytopenia (CR) 1575

Rifampin, as adjunctive therapy, for CNS staphylococcal infections (A) 765; for brain abscesses (A) 767; for cerebrospinal fluid shunt infections (A) 766; for staphylococcal meningitis (A) 767; with pyrazinamide, inducing hepatitis, in treatment of latent tuberculosis infection (NC) 799

Risperidone, for schizophrenia, effects on gonadal axis hormones (RR) 1523; inducing extrapyramidal syndromes (RR) 1517; inducing neuroleptic malignant syndrome, after switch from haloperidol (CR) 698

Ritonavir, adverse effects (A) 748; compared with saquinavir (A) 747; interaction with carbamazepine (L) 125; with indinavir, inducing ingrown toenails (CR) 881, inducing symptomatic hyperbilirubinemia (CR) 1391

Rodriguez de Bittner, Magaly, Merit Award, Academy of Pharmacy Practice and Management (NC) 276

Ropinirole, for restless legs syndrome (A) 629; interaction with warfarin (CR) 1202

Ropivacaine, inducing seizure (CR) 311

Rosiglitazone, associated with pulmonary edema (L) 123

Routes of administration, 5-adenosyl-L-methionine (A) 1420

Rubella, elimination (NC) 144; incidence (NC) 144

S-T

Salvia miltiorrhiza, interaction with warfarin (A) 502

Saquinavir, compared with nelfinavir, stavudine, and lamivudine, effectiveness (A) 746; compared with ritonavir (A) 747; interpatient variability, pharmacokinetics (A) 749

Sargramostim, chemotherapy, adult myelogenous leukemia (A) 98; pharmacoeconomics (A) 98

Schizophrenia, risperidone, effects on gonadal axis hormones (RR) 1523

Sclerotherapy, for variceal bleeding, compared with octreotide (A) 620

Sedation, bedside, development of a scale (L) 262

Sedation assessment, in critically ill adults (A) 1624; instruments (A) 1625

Seizures, induced by fluoroquinolones (CR) 1194; induced by intravenous codeine phosphate, pediatrics (CR) 1211

Selective serotonin-reuptake inhibitors, fluvoxamine, aggravating glaucoma (CR) 1565; for depression, compared with bupropion (A) 1608; sertraline, inducing hypoglycemia (CR) 1371; sertraline with trazodone, inducing serotonin syndrome (CR) 1375

Sepsis, catheter related, *Candida lusitanae*, treatment with fluconazole (CR) 1570

Serotonin, receptors blocked by risperidone, in schizophrenia treatment (RR) 1517

Serotonin syndrome, clomipramine induced, after clozapine withdrawal (L) 1143 (CR) 181; early management with cyproheptadine (CR) 870, (L) 1672; fluvoxamine and mirtazapine induced (CR) 1217, (L) 1674; sertraline and trazodone induced, overdose (CR) 1375

Sertraline, inducing hypoglycemia (CR) 1371; with clozapine, inducing sudden cardiac death (L) 1671, (CR) 862; with trazodone, overdose leading to serotonin syndrome (CR) 1375

Sexually transmitted diseases, prevention, effectiveness of condoms (A) 1136; use of condoms (O) 1135

Sildenafil, adequacy of product information (A) 337; French abstract correction (L) 786; adverse drug reactions (A) 337; compared with injectable alprostadil, mortality (RR) 285, (L) 1143; dosing, elderly (A) 340; drug interactions (A) 339; effect on blood pressure (A) 338; interaction with alcohol (A) 340, cimetidine (A) 339, nonfat antihypertensive (A) 339, protease inhibitors (A) 339 safety (A) 340

Silver, impregnation of intravascular catheters, infection control (A) 1257

Simvastatin, compared/combined with colestyramine hydrochloride (A) 902; effect on fibrinogen (A) 239; for cholesterol reduction (A) 498; interaction with clarithromycin, rhabdomyolysis (CR) 26; pharmacokinetics (A) 1099; with metoprolol, inducing nightmares and sleep disturbances (L) 1292

Smoking, cardiovascular risk factor, management with L-arginine (A) 759; cessation, increased INR in patient on warfarin (L) 385; nicotine replacement products, pregnancy categories (L) 1496; risk factor, coronary artery disease and acute MI (A) 611

Somatostatin, for variceal bleeding, compared with octreotide (A) 624

Sotalol, for ventricular tachyarrhythmias, compared with lidocaine (A) 1249

Soy protein, phytoestrogens, effect on breast cancer growth (A) 1118

Sparfloxacin, pharmacokinetics (A) 1087

Special Contribution, comparison of Internet and community pharmacies (A) 116; writing manuscripts describing clinical trials, guide for pharmacotherapeutic researchers (A) 770

Spectinomycin, for gonorrhea, alternatives (CN) 976

Sphygmomanometers, compared with home monitors, blood pressure monitoring (RR) 817, (L) 1676

Spiders, *Tegenaria agrestis* envenomation (VO) 1490

Spironolactone, for chronic heart failure (A) 1070

St. John's wort, interaction with cyclosporine (L) 124

Stability, cisplatin, doxorubicin, and mitomycin, with ioversol, for chemoembolization (RR) 1548; ophthalmic solutions, gentamicin (L) 1293; piperacillin and ticarcillin, in AutoDose infusion bags (RR) 1360

Staphylococcus aureus, treatment with rifampin, adjunctive therapy for CNS infection (A) 765

Staphylococcus epidermidis, treatment with rifampin, adjunctive therapy for CNS infection (A) 765

Statin-fibrate combination therapy, clinical trials (A) 911; inducing acute renal failure (A) 909; inducing rhabdomyolysis (A) 909; review (A) 908

Statins, compared with fibrates (A) 908; inducing rhabdomyolysis, review (A) 1096, with azole antifungals (A) 1100, with cyclosporine (A) 1099, with fibrates (A) 1099, with gemfibrozil (A) 1099, with macrolides (A) 1100; pharmacokinetics (A) 1099

Status epilepticus, treatment with intravenous valproate (A) 1465

Stavudine, inducing gynecomastia, other sexual symptoms (CR) 439

Stevens-Johnson syndrome, ofloxacin induced (CR) 1388; trimethoprim/sulfamethoxazole induced (CR) 694

Streptococcus pneumoniae, levofloxacin resistance (CR) 687; multidrug resistant, prevention and treatment (A) 485; resistance (A) 480; resistance to fluoroquinolones (NC) 1509

Streptokinase, for thrombolysis, in acute MI (A) 592

Stroke, ischemic, antiplatelet agents for secondary prevention (A) 1241; treatment with antithrombotics and antithrombotics, community-based care (RR) 811

Succalfate, for renal failure, review (A) 360; inducing aluminum toxicity (A) 361

Sucrose, for analgesia, in newborn infants (A) 947

Sulfasalazine, decreasing radiation-induced gastrointestinal toxicity (RR) 806; possible interaction with warfarin, factors (L) 506

Surgery, coronary artery bypass graft, infection prophylaxis with cefuroxime (RR) 409; systemic hemostatic medications, reducing surgical blood loss (A) 925

Sweden, nonprescription drugs, drug-related problems and pharmacy interventions (RR) 1343

Tacrolimus, adverse drug reactions (A) 586; for alopecia areata (A) 585; for atopic dermatitis (A) 583, (A) 943; for dermatologic disorders, review (A) 582; for psoriasis (A) 584; for pyoderma gangrenosum (A) 585; inducing cardiomyopathy, during transplantation (RR) 985

Tegenaria agrestis, envenomation (VO) 1490

Telocaplanin, coating for intravascular catheters, infection control (A) 1257

Tenecteplase, adverse effects (A) 1235; approved labeling and off-label uses (A) 1237; clinical trials (A) 1234; contraindications (A) 1236; dosage (A) 1237; drug interactions (A) 1236; for acute MI, review (A) 1233; for thrombolysis in acute MI (A) 592; geriatric use (A) 1236; patient counseling (A) 1237; pharmacokinetics (A) 1234; pharmacology (A) 1233; economic issues (A) 1236; toxicology (A) 1233

Terlipressin, for variceal bleeding, compared with octreotide and transdermal nitroglycerin (A) 620

Testosterone therapy, topical administration, complicated by hypertension (CR) 1205

Tetanus vaccine, shortage of (NC) 144, (NC) 662

Tetanus/diphtheria toxoids, shortage of (NC) 144

Tetracycline, for bronchitis (A) 578

Thalassemia, amphotericin B-induced hypomagnesemia, transient hypoparathyroidism (CR) 1042

Theophylline, clearance, effect of levofloxacin, during theophylline and clarithromycin combination therapy (CR) 691; intravenous, for sinus bradycardia, avoidance of pacemaker placement (CR) 303

Therapeutic controversies, angiotensin II receptor antagonists compared with ACE inhibitors, for CHF (A) 71; antimicrobial cycling, for reversal of resistance (A) 1224; argatroban compared with danaparol, for thromboembolism, heparin-induced thrombocytopenia (A) 447; argatroban compared with lepirudin, for thromboembolism, heparin-induced thrombocytopenia (A) 448; enteral nutrition, for stress ulcer prophylaxis (A) 1614; intravenous itraconazole (A) 726; mifepristone (O) 373, (A) 712; nateglinide (A) 1432; opioid antagonists, for opioid-induced adverse effects (A) 85; orlistat (A) 325; sildenafil, adequacy of product information (A) 337

Therapeutic drug monitoring, clozapine, plasma concentrations (CR) 1028; electronic adherence monitoring, barriers to use, HIV clinic (RR) 1010; methotrexate, for fibroblastic osteosarcoma (L) 1669; protease inhibitors (A) 745

Thiazolidinediones, for hyperglycemia, in HIV patients (A) 348

Thrombocytopenia, heparin-induced, treatment with lepirudin (CR) 885

Thromboembolism, prevention and treatment with argatroban, heparin-induced thrombocytopenia (A) 440

Thrombolytic therapy, compared with percutaneous coronary intervention, in acute MI (A) 595; comparison of agents (A) 592; for acute MI, contraindications (A) 590; for intracoronary stenting (A) 598; glycoprotein IIb/IIIa receptor inhibitors, for acute MI (A) 592; unfractionated heparin, for acute MI (A) 599

Thyroid hormones, treatment of alopecia (A) 256

Thyroid-stimulating hormone, serum concentrations, based on administration time, elderly (RR) 529

Ticarcillin, stability in AutoDose infusion bags (RR) 1360

Ticlopidine, for acute MI, substitute for aspirin (A) 598; for secondary prevention of ischemic stroke (A) 1243; in intracoronary stenting, compared with clostazolol (A) 1110, compared with clopidogrel (A) 598

Tirofiban, compared/combined with unfractionated heparin, in unstable angina or MI (A) 603

Titration, topiramate, for epilepsy, titration schedule (RR) 173

Tolerability, antipsychotics (O) 1659; orlistat, for weight loss (A) 322; topiramate, for epilepsy, comparison of titration schedules (RR) 173

Tolterodine, for clozapine-induced nocturnal enuresis, treatment failure (CR) 867

Topiramate, for epilepsy, titration and tolerability (RR) 173; for weight loss (L) 1141

Torsade de pointes, induced by fluconazole (CR) 432

Toxic epidermal necrolysis, ofloxacin induced (CR) 1388

Toxicology, hexarotene (A) 1058; orlistat (A) 315; tenecteplase (A) 1233

Tranexamic acid, reduction of blood loss, in hepatic surgery (A) 927, in orthopedic surgery (A) 928, in prostate and thyroid surgery (A) 931, in cardiac surgery; compared with aminocaproic acid (A) 1079

Transplantation, tacrolimus, inducing cardiomyopathy (RR) 985

Trazodone, for insomnia, in hospitalized patients (A) 1454; inducing hepatotoxicity (CR) 1559; with sertraline, inducing serotonin syndrome (CR) 1375

Tribute, George F Archambault JD ScD PharmD, 383

Trimethoprim/sulfamethoxazole, for bronchitis, compared with amoxicillin and doxycycline (A) 578; inducing toxic epidermal necrolysis (CR) 694

Troglitazone, inducing pulmonary edema (L) 123

Trovaflaxacin, inducing leukopenia (CR) 41; inducing peripheral neuropathy (RR) 1540; pharmacokinetics (A) 1087

Tyler, Varro E Jr, obituary (NC) 1310

U-Z

Ulcer, stress induced, prophylaxis with enteral nutrition (A) 1614

Ulcerative colitis, induced by isotretinoin (CR) 1214; treatment with infliximab, pediatric (RR) 823

Ulcers, gastroduodenal, celecoxib induced (L) 782, incidence during celecoxib treatment, arthritis patients (RR) 829; GI, NSAID induced, Helicobacter pylori eradication (A) 249; peptic, bleeding, treatment with proton-pump inhibitors (A) 730, treatment with proton pump inhibitors (RR) 1528; stage II decubitus, topical treatment with phenytoin, elderly (RR) 675

Unfractionated heparin, for acute MI, compared with desirudin (A) 606, compared with lepirudin (A) 606, with epifibatide and alteplase (A) 599; for unstable angina and non-ST-segment MI, compared with alteplase (A) 604, with enoxaparin (A) 605

United States Pharmacopeia, warfarin, uniformity specifications, tablet strength (CR) 184

Uracil/tegafur, with fluorouracil, review (A) 221

Urinary tract infection, treatment with fluconazole, dose recommendation (A) 369; treatment with fluoroquinolones (A) 1088

Urokinase, for intraventricular hemorrhage (A) 1442; for post-hemorrhagic hydrocephalus, pediatric (A) 1445

Ursodiol, for prevention of veno-occlusive disease (A) 937

Vaccination, coverage levels, national, state, and urban area, small children (NC) 1310

Vaccines, influenza vaccine delayed (NC) 1156

Valacyclovir, associated with aseptic meningitis (L) 128

Valproate, for status epilepticus, adult experience (A) 1466, pediatric experience (A) 1466; intravenous, treatment of status epilepticus (A) 1465

Valsartan, for CHF, with ACE inhibitors, digoxin, and diuretics (A) 79; for heart failure, with ACE inhibitor (A) 243; with atenolol, inducing fetal death (CR) 859

Vancomycin, compared with linezolid, effectiveness against gram-positive cocci (A) 569; hypersensitivity, approach with desensitization protocols (A) 1458; in plasma exchange transfusion, removal from plasma (CR) 1400

Variceal bleeding, diagnosis and management (A) 619; traditional medications (A) 619; treatment recommendations (A) 623; treatment with octreotide (A) 618

Varro E Tyler Jr, obituary 1310

Vasopressin, compared with octreotide, for variceal bleeding (A) 620

Venlafaxine, for neuropathic pain (CR) 557

Veno-occlusive disease, clinical features (A) 936; nutritional management (A) 940; pathophysiology (A) 935; prevention, glutamine (A) 937, low-dose heparin (A) 936, low-molecular-weight heparin (A) 937; prostaglandin E₂ (A) 937, ursodiol (A) 937; risk factors (A) 936; treatment, alteplase (A) 938, antithrombin-III (A) 939, defibrotide (A) 939

Ventricular tachyarrhythmias, treatment with amiodarone, new American Heart Association guidelines (A) 1248

Verapamil, interaction with erythromycin, complete atrioventricular block (CR) 1396

Verteporfin, adverse events (A) 1595; dosing (A) 1596; for age-related macular degeneration (A) 1593; pharmacoeconomics (A) 1595; pharmacokinetics (A) 1594; pharmacology (A) 1594

Viagra, for erectile dysfunction, appropriateness of product information (A) 337

Vietnam, management of childhood acute respiratory infections, private pharmacies (RR) 1283

Vincristine, with doxorubicin, inducing ischemic heart disease (CR) 1403

VIP News, Abraham G Hartzema, accepting eminent scholar position, University of Florida College of Pharmacy (NC) 662, (NC) 1510; Edmund D Pellegrino, award for contributions to healthcare ethics, Sanford University (NC) 976; Magaly Rodriguez de Bittner, Merit Award, Academy of Pharmacy Practice and Management (NC) 276; Milap C Nahata, Howard Q Ferguson Memorial Lecture Award, University of North Carolina School of Pharmacy (NC) 1692, elected Distinguished Scholar, National Academy of Practice in Pharmacy (NC) 524, elected President and Chairman, Board of Directors of the American Association of Colleges of Pharmacy (NC) 1156; Patrick F D'arcy, obituary (NC) 1510; Rebecca S Finley, Sister M Gonzales — Duffy Lecture Award, Health-Systems Pharmacists of Pennsylvania (NC) 1692; Varro E Tyler Jr, obituary (NC) 1310; William A Hopkins Jr, Gloria Niemeyer Francke Leadership Mentor Award, Academy of Pharmacy Practice (NC) 276

Visual observations, *Tegenaria agrestis* envenomation (VO) 1490

Vitamin B₆, with vitamin H, inducing eosinophilic pleuropneumonitis (CR) 424

Vitamin E, for veno-occlusive disease (A) 935; lowering risk of heart disease (A) 609

Vitamin H, with vitamin B₆, inducing eosinophilic pleuropneumonitis (CR) 424

Warfarin, conversion from argatroban (A) 449; for acute MI (A) 607; for radiation-induced myelopathy (CR) 188; increased INR from smoking cessation (L) 385; interaction with *Lycium barbarum* L. (CR) 1199, ropinirole (CR) 1202, *Salvia miltiorrhiza* (A) 501, sulfasalazine, factors (L) 506; lack of interaction with cilomilast (RR) 1535; plus aspirin, in acute MI (A) 608; prevention of thromboembolic complications, dalteparin for periprocedure anticoagulation (RR) 669; switch from Coumadin to generic, subtherapeutic INR values (CR) 183

Weight loss, principles (A) 315; with orlistat (A) 314; with topiramate (L) 1141

Zafirlukast, for allergic rhinitis (A) 1275

Zaleplon, for insomnia, hospitalized patients (A) 1452

Zanamivir, adverse effects (A) 66; dosing (A) 66; drug interactions (A) 63; influenza prophylaxis (A) 59; treatment, clinical trials (A) 60; pharmacoeconomics (A) 67; pharmacokinetics (A) 58; resistance (A) 66

Zidovudine, compared with didanosine and lamivudine, effectiveness (A) 747

Zolpidem, for antipsychotic-induced parkinsonism (CR) 435; for insomnia, in hospitalized patients (A) 1452; inducing delirium (CR) 1562

Zopiclone, interaction with nefazodone (CR) 1378

AUTHOR INDEX

A-B

Abanozu, Seher (coauthor) see Tutluoglu, Bülent, 1161

Abdel-Rahim, Maged M (coauthor) see Mayer, Michael I, 1548

Abdel-Rahman, Susan M (coauthor) see Masters-Harte, Lory D, 947

Abel, Steven R (coauthor) see Messmer, Karen J, 1593

Abraham, Prasad E (author) Neflinavir Desensitization (CR) 553

Abul-Ezz, Sameh R (coauthor) see Barone, Gary W, 124

Adam, Rodney D (coauthor) see Pokuquinn, Charles A, 1332

Adson, David E (author) An Unusual Presentation of Sertraline and Trazodone Overdose (CR) 1375

Aguilar-Castillo, Maria J (coauthor) see Serrano-Castro, Pedro Jesus, 785

Ahmad, Hussain (coauthor) see Pietrucha-Dilanchian, Paula, 1570

Akbulut, Sabiye (coauthor) see Cakmakci, Ayse, 954

Akkerman, Shawn R (author) book review, 130

Aksakal, A Burhan (coauthor) see Ortiz, Pinar, 961

Al Khaja, Khalid AJ (author) Prescribing Patterns and Therapeutic Implications for Diabetic Hypertension in Bahrain (RR) 1350

Al Mohaimed, Sulaiman A (coauthor) see Zolezzi, Monica, 1211

Alardo, Jean-Pierre (coauthor) see Bischoff, Dorothee Y, 311

Alderman, Christopher P (author) Possible Interaction of Zopiclone and Nefazodone (CR) 1378; (author) Understanding Antipsychotic Drug Tolerability (E) 1659

Aldridge, Martha A (author) Colesevelam Hydrochloride: A Novel Bile Acid-Binding Resin (A) 898

Alfaro, Cara I (author) Unanticipated Plasma Concentrations in Two Clozapine-Treated Patients (CR) 1028

Al-Humaidan, Abdullah S (coauthor) see Aruna, Augustine S, 1037

Al-Jaziri, Abdulrazq S (coauthor) see Cawley, Michael J, 303

Allebeck, Peter (coauthor) see Westerlund, LO Tommy, 1343

Almagro, Manuel (coauthor) see Del Pozo, Jesús, 891

Alonso, Janette (coauthor) see Wagner, Mary L, 1176

Alpert, Joseph S (coauthor) see Hise, Daniel M, 1163

Al-Safi, Saafan (author) Correction: Effect of Azathioprine on the Anticoagulant Activity of Warfarin (L) 1296

AL-Samarrai, Shatha A (coauthor) see Aruna, Augustine S, 1037

Altundag, Özden (author) Recurrent Asymptomatic Bradycardia Episodes After Cisplatin Infusion (L) 641

Amankwa, Kwadwo (coauthor) see Amsden, Guy, 480

Amonkar, Mayur M (coauthor) see Scott, Virginia G, 289

Ampel, Neil M (coauthor) see Wendel, Christopher S, 1010

Amsden, Guy W (author) Pneumococcal Resistance: The Treatment Challenge (A) 480

Anderson, Carolyn (coauthor) see Vander Zanden, Jeanne A, 1633

Andrade, Raul J (author) Benzylpenicillin-Induced Prolonged Cholestasis (L) 783

Andrews, Carlota O (author) Fibrinolytic Therapy in Intraventricular Hemorrhage (A) 1435

Angood, Peter B (coauthor) see Mitropoulos, Fotios A, 41

Antila, Sami AK (author) Fluvoxamine Augmentation Increases Serum Mirtazapine Concentrations Three- to Fourfold (CR) 1221

Arnold, Alana D (coauthor) see Quilitz, Rod Everett, 206

Arrehola-García, Juan D (coauthor) see Calvo-Romero, José María, 1403

Aruna, Augustine S (author) Amphotericin B-Induced Seizures in a Patient with AIDS (CR) 1037

Ashcroft, Darren M (author) Upper Gastrointestinal Ulceration in Arthritis Patients Treated with Celecoxib (CR) 829

Atis, Sibel (coauthor) see Tutluoglu, Bülent, 1161

Avila, Juan R (coauthor) see Fetrow, Charles W, 1414

Avni, Yona (coauthor) see Scheby, Ron, 1143

Avram, Anca M (author) Euglycemic Clamp Study in Clozapine-Induced Diabetic Ketoacidosis (CR) 1381

Avraps, Mary Beth A (author) Development of an ICU Bed-side Sedation Scale (L) 262

Azaz-Livshits, Tanya L (coauthor) see Goldschmidt, Neta, 1396

Azimi, Anita R (coauthor) see Erickson, Steven R, 997

Bagheri-Charabian, Haleh (coauthor) see Solem, Patrick, 1292

Bain, Kevin T (author) Linezolid for the Treatment of Resistant Gram-Positive Cocci (A) 566

Bair, Jennifer D (author) Warfarin and Ropinirole Interaction (CR) 1202

Baker, Daniel E (coauthor) see Levien, Terri L, 1426

Baker, William H (coauthor) see Abraham, Prasad E, 553

Baldwin, Steven N (author) Correction: L-Arginine in the Management of Cardiovascular Diseases (L) 965; (coauthor) see Cheng, Judy WM, 755

Barkley, Gregory L (coauthor) see Zarowitz, Barbara J, 1661

Barone, Gary W (author) Reply: Drug-Herb Interaction (L) 124

Barreuther, Alan D (author) book review, 1499

Bartels, Cathy L (author) Head Lice Resistance: Itching That Just Won't Stop (DIR) 109

Bates, Duane E (author) Possible Celecoxib-Induced Gastrointestinal Ulceration (L) 782

Baty, Vincent (author) BCG Therapy-Related Death and Previous Pelvic Radiation (L) 963

Bauwens, Steven F (author) book review, 391

Beauregard, Gilles (coauthor) see Perreault, Sylvie, 1588

Becker, Hermann (coauthor) see Schulz, Martin, 21

Begle, Robert L (coauthor) see Avripas, Mary Beth A, 262

Bell, Edward F (coauthor) see Schrand, Linda M, 1186

Bellavance, Francois (coauthor) see Perreault, Sylvie, 1588

Bellot, Vincente (coauthor) see Andrade, Raul J, 783

Benavides, Ray (coauthor) see Alfaro, Cara L, 1028

Ben-Yehuda, Arie (coauthor) see Goldschmidt, Neta, 1396

Besse, Lysanne (coauthor) see Paquette-Lamontagne, Nicolas, 1953

Bessmertny, Olga (author) Antiepileptic Hypersensitivity Syndrome in Children (A) 533

Biffi, Mauro (coauthor) see Boriani, Giuseppe, 1292

Bilgrami, Syed FA (author) Idiopathic Pneumonia Syndrome Following Myeloablative Chemotherapy and Autologous Transplantation (CR) 196

Bincsik, Arlene K (coauthor) see James, Christopher W, 882

Bingham, Andrea (coauthor) see McCune, Jeannine S, 14

Binh, Nguyen Thanh (coauthor) see Chuc, Nguyen Thi Kim, 1283

Bishara, Jihad (author) Amphotericin B — Not So Terrible (CR) 308

Bischoff, Dorothee Y (author) Seizure Induced by Ropivacaine (CR) 311

Biton, Victor (author) Topiramate Titration and Tolerability (RR) 173

Bizzarri, Claudio (coauthor) see Famularo, Giuseppe, 1669

Blough, David K (coauthor) see Gray, Shelly L, 539

Boedeker, Kimi S (author) Fluconazole Dose Recommendations in Urinary Tract Infection (DIR) 369

Bona, Robert D (coauthor) see Bilgrami, Syed FA, 196

Bonanno, Danielle M Graci (author) Olanzapine-Induced Diabetes Mellitus (CR) 563

Boothby, Lisa A (author) FDA Labeling System for Drugs in Pregnancy (O) 1485

Borcherding, Shawn M (author) book review, 966

Boriani, Giuseppe (author) Nightmares and Sleep Disturbances with Simvastatin and Metoprolol (L) 1292

Bory, Roger Michel (coauthor) see Baty, Vincent, 963

Botts, Sheila R (coauthor) see Bonanno, Danielle M Graci, 563

Boyd, Ian W (author) Comment: History of Drug Induced Hepatitis and Risk of Amoxicillin/Clavulanate-Induced Hepatotoxicity (L) 1677

Brackbill, Marcia L (author) Adjunctive Rifampin Therapy for Central Nervous System Staphylococcal Infections (DIR) 765

Brady, Shannon R (coauthor) see Raji, Mukaila A, 1020

Branch, Robert A (coauthor) see Coley, Kim C, 985

Branzi, Angelo (coauthor) see Boriani, Giuseppe, 1292

Briggs, Gerald G (author) book review, 392; (author) Fatal Fetal Outcome with the Combined Use of Valsartan and Atenolol (CR) 859

Briones, Gabriel R (coauthor) see Quilitz, Rod Everett, 206

Brodeur, Michael R (author) Delirium Associated with Zolpidem (CR) 1562

Brodrick, T Robert (coauthor) see Gilbar, Peter J, 1367

Brooks, Natalie C (coauthor) see Taylor, Charles T, 365

Brown, Raynonda F (coauthor) see Serrano, Maria-Stella, 823

Bruck, Rafael (coauthor) see Scheby, Ron, 1143

Bruno-Joyce, Jeanne (author) Cervistat and Gemfibrozil-Associated Rhabdomyolysis (CR) 1016

Buchanan, Robert J (coauthor) see Smith, Scott R, 155

Buerki, Robert A (author) book review, 510

Bunch, Cheryl L (coauthor) see Vander Zanden, Jeanne A, 1633

Buring, Shauna M (coauthor) see Walker, J Bryan, 113

Burkiewicz, Jill S (author) Impact of an Intravenous Fluconazole Restriction Policy on Patient Outcomes (RR) 9

Buxton, Iain LO (coauthor) see Tangredi, Joseph F, 1205

Buyse, Daniel J (coauthor) see Lenhart, Susan E, 1449

Cakmakci, Ayse (author) Polycythemia in a Patient Treated with Isotretinoin (L) 964

Calderón, Enrique (coauthor) see González de la Puente, Miguel A, 1492

Calvo-Romero, José María (author) Ischemic Heart Disease Associated with Vincristine and Doxorubicin Chemotherapy (CR) 1403; (author) Severe Pancytopenia Associated with Low-Dose Methotrexate Therapy for Rheumatoid Arthritis (CR) 1575

Calza, Leonardo (coauthor) see Manfredi, Roberto, 438

Campbell, R Keith (coauthor) see Levien, Terri L, 1426

Campbell, Suzanne (coauthor) see Younis, Wisam S, 841

Carmona, Alexia (coauthor) see Mateu-de Antonio, Javier, 126

Caron, Michael F (author) Amiodarone in the New AHA Guidelines for Ventricular Tachyarrhythmias (A) 1248

Carr, Andrea (coauthor) see Avripas, Mary Beth A, 262

Carrascosa Porras, Miguel (author) Dalteparin-Induced Extremity Hematoma Complicated by Prolapsed Compartment Syndrome (L) 643; (author) Dalteparin-Induced Retroperitoneal Bleeding (L) 261

Carter, Gary W (coauthor) see Sajbel, Terrie A, 281

Castot, Anne M (coauthor) see Debourdeau, Philippe M, 424

Cawley, Michael J (author) Intravenous Theophylline — An Alternative to Temporary Pacing in the Management of Bradycardia Secondary to AV Nodal Block (CR) 303

Celik, Ismail (coauthor) see Altundag, Özden, 641

Cercos Lletí, Ana-Cristina (coauthor) see Segura Huerta, Angel, 894

Chan, Debora S (author) book review, 967

Chan, Lingtak-Neander (author) book review, 787

Chan, Thomas YK (author) Interaction Between Warfarin and Danshen (*Salvia miltiorrhiza*) (DIR) 501

Chang, Wen-Ho (coauthor) see Lu, Mong-Liang, 1675

Chapman, Stanley W (coauthor) see Slain, Douglas, 720

Chapman, Stephen R (coauthor) see Ashcroft, Darren M, 829

Chaves, Manuel (coauthor) see Salvador Bofill, Javier, 786

Chen, Chi-Hsun (coauthor) see Yuan, Key-Yue, 1045

Cheng, Judy WM (author) L-Arginine in the Management of Cardiovascular Diseases (DIR) 755; (coauthor) see Baldwin, Steven N, 965; (coauthor) see Chu, Valery L, 1278; (coauthor) see Spilner, Sarah A, 589

Cheng, Tsung O (author) Comment: Drug-Herb Interaction (L) 124

Chery, Won-Young (coauthor) see Lee, Ai Young, 1584

Chiodo, Francesco (coauthor) see Manfredi, Roberto, 438

Choiniere, Manon (coauthor) see Perreault, Sylvie, 1588

Chong, Pang H (author) Effect of Acetaminophen in Atherosclerosis (DIR) 1476

Chowbay, Balram (author) High-Dose Methotrexate in Fibroblastic Osteosarcoma (L) 1669

Chu, Valery L (author) Fenoldopam in the Prevention of Contrast Media-Induced Acute Renal Failure (DIR) 1278

Chuc, Nguyen Thi Kim (author) Management of Childhood Acute Respiratory Infections at Private Pharmacies in Vietnam (IR) 1283

Clark, David J (coauthor) see Kelly, John, 1535

Clark, Wendy (coauthor) see Ashcroft, Darren M, 829

Clarke, Amanda K (author) The Debate Regarding Continuous Use of Oral Contraceptives (DIR) 1480

Cleary, John D (coauthor) see Slain, Douglas, 720

Clive, Jonathan M (coauthor) see Bilgrami, Syed FA, 196

Coggan, Peter (coauthor) see Zarowitz, Barbara J, 1661

Cohen, David M (coauthor) see James, Christopher W, 882

Cohen, Hector Isaac (coauthor) see Sbeit, Wisam, 1049

Cohen, Jay S (author) Comparison of FDA Reports of Patient Deaths Associated with Sildenafil and with Injectable Alprostadil (RR) 285; (author) Is the Sildenafil Product Information Adequate to Facilitate Informed Therapeutic Decisions? (A) 337; (author) Peripheral Neuropathy Associated with Fluoroquinolones (RR) 1540; (author) Peripheral Neuropathy Associated with Fluoroquinolones (L) 1673; (author) Reply: Comparison of FDA Reports of Patient Deaths Associated with Sildenafil and with Injectable Alprostadil (L) 1142

Coley, Kim C (author) Lack of Tacrolimus-Induced Cardiomyopathy (RR) 985

Colucci, Vincent J (author) book review, 1500; (author) Increase in International Normalized Ratio Associated with Smoking Cessation (L) 385

Comeau, Donna G (coauthor) see MacCary, Mary E, 852

Condon, John T (coauthor) see Alderman, Christopher P, 1378

Coomb, John H (coauthor) see Erickson, Steven R, 997

Coons, Stephen Joel (coauthor) see Wendel, Christopher S, 1010

Corbacho Bonilla, Begoña (coauthor) see Carrascosa Porras, Miguel, 643

Corzo Delgado, Juan E (coauthor) see Fobelo, Maria J, 128

Cox, Tamara S (coauthor) see Omar, Mohamed A, 1096

Cressman, Michael D (coauthor) see Coley, Kim C, 985

Crickshank, Moira K (coauthor) see Timmuth, Alan H, 669

Cruz Caparrós, Gracia (author) Megestrol-Induced Cushing Syndrome (CR) 1208

Csako, Gyorgy (author) book review, 1500; (author) Exaggerated Levothyroxine Malabsorption Due to Calcium Carbonate Supplementation in Gastrointestinal Disorders (CR) 1578

Culbertson, Vaughn L (coauthor) see Rhodes, Richard S, 675

Culhane, Nicole S (author) Burning Mouth Syndrome After Taking Clonazepam (CR) 874

Cushing, Herbert E (coauthor) see Abraham, Prasad E, 553

Cusson, Jean R (coauthor) see Paquette-Lamontagne, Nicolas, 953

Dager, William E (author) Use of Lepirudin in Patients with Heparin-Induced Thrombocytopenia and Renal Failure Requiring Hemodialysis (CR) 885

Daghig, Behnam (coauthor) see Wazny, Lori D, 1458

Danel, Vincent C (author) Bromide Intoxication and Pseudo-hyperchloremia (L) 386

Dansky, Brad L (coauthor) see Ghani, Sofin, 784

Danziger, Larry H (coauthor) see Pal, Manjunath P, 1255

D'Aprile, Michelle (coauthor) see Russo, Rene L, 576

Darkow, Theodore (coauthor) see Gora-Harper, Mary Lea, 1320

Davis, Elizabeth Anne (author) Psychometric Evaluation of Four HIV Disease-Specific Quality-of-Life Instruments (RR) 546

Davis, George A (author) Pharmacokinetics of Fluconazole in Trauma Patients with Postpyloric Feeding Tubes (L) 1492

Davis, Glenn C (coauthor) see Zarowitz, Barbara J, 1661

Davydov, Liya (coauthor) see Bonanno, Danielle M Graci, 563

Dawson, Andrew H (coauthor) see Ishister, Geoffrey K, 1143; (coauthor) see Ishister, Geoffrey K, 1674

de Boer, Antonius (coauthor) see Schillevoort, Igor, 1517

de Lemos, Mario L (author) Effects of Soy Phytoestrogens Genistein and Daidzein on Breast Cancer Growth (DIR) 1118

Dean, Jr, Joseph O (coauthor) see Kotch, Allison L, 817

Debourdeau, Philippe M (author) Life-Threatening Eosinophilic Pleuropulmonary Effusion Related to Vitamins B₆ and H (CR) 424

DeHart, Renee M (author) Mifepristone (A) 707

Del Pozo, Jesús (author) Linear IgA Bullous Dermatitis Induced by G_mctabine (CR) 891

del Riego Martín, Mónica (coauthor) see Carrascosa Porras, Miguel, 261

Delanty, Norman (coauthor) see Majid, Arshad, 1241

Delgado-Fernández, Marcial (coauthor) see Cruz Caparrós, Gracia, 1208

Dello Buono, Felicia A (coauthor) see Friedman, Jill D, 85

Demers, Jason C (author) Serotonin Syndrome Induced by Fluvoxamine and Mirtazapine (CR) 1217

Demoly, Pascal (coauthor) see Peyrière, Hélène, 1291

Denham, Anne M (coauthor) see Lousberg, Tammy R, 1599

Devitt, Patrick J (coauthor) see Megna, James L, 45

Devlin, John William (author) Sedation Assessment in Critical-Ill Adults (A) 1624

Dewan, Vijay (coauthor) see Zerjav-Lacombe, Sylvia, 180

Dickerson, Lori M (coauthor) see Hamadeh, Ghassan N, 636

Diez, Felipe (coauthor) see Cruz Caparrós, Gracia, 1208

DiGregorio, Robert V (coauthor) see Woodall, Betsy S, 506

Dinour, Dganit (coauthor) see Mayan, Haim, 560

Dix, Suzanne Paige (coauthor) see Quilitz, Rod Everett, 206

Dixon, Amy J (author) Probable Colchicine-Induced Neurotoxicity Not Related to Intentional Overdose (CR) 192

Djezzar, Samira (coauthor) see Debourdeau, Philippe M, 424

Do, Nguyen Thanh (coauthor) see Chuc, Nguyen Thi Kim, 1283

Doering, Paul L (coauthor) see Boothby, Lisa A, 1485; (coauthor) see Monroe, Michelle L, 918

Dolovich, Lisa R (coauthor) see Nieuwstraten, Carmine, 1608

Donn, Folkert (coauthor) see Schulz, Martin, 21

Doucette, Douglas E (author) Reply: Olanzapine-Induced Acute Pancreatitis (L) 507

du Souich, Patrick (coauthor) see Perreault, Sylvie, 1588

Dugas, Jane M (coauthor) see Bruno-Joyce, Jeanne, 1016
 Domo, Peter (coauthor) see Kanji, Salmaan, 249
 Duncan, Pamela W (coauthor) see Rigler, Sally K, 811
 Dursan, Ayse (coauthor) see Kille, Dielehan, 806

E-G

Eales, Richard (coauthor) see Rayner, Craig R, 1391
 Eastham, John H (author) Postpartum Alopecia (DIR) 255
 Edouard, Bruno (author) Comment: Converting Patients from Brand-Name Clozapine to Generic Clozapine (L) 1295
 Edwards, Keith R (coauthor) see Biton, Victor, 173
 Engelhard, Herbert H (coauthor) see Andrews, Carolyn A, 1108
 Elliott, David P (author) Effect of Levothyroxine Administration Time on Serum TSH in Elderly Patients (RR) 529
 Elliott, Jane M (coauthor) see Schrand, Linda M, 1186
 Elmer, Gary W (coauthor) see Lam, Annie Y, 1199
 Empey, Kerry M (coauthor) see Rapp, Robert P, 1289
 Empey, Philip E (author) Levofloxacin Failure in a Patient with Pneumococcal Pneumonia (CR) 687
 Emptage, Ruth E (coauthor) see Spiker, Erin C, 1166
 Enghard, Herbert H (coauthor) see Andrews, Carolyn A, 1108
 English, Brett A (author) Failure of Tolterodine to Treat Clozapine-Induced Nocturnal Enuresis (CR) 867
 Enomoto, Hiromi (coauthor) see Nakamura, Hiroyoshi, 691
 Ensom, Mary HH (coauthor) see Davis, George A, 1492; (coauthor) see John, Leela, 745
 Erb, David R (coauthor) see Avripas, Mary Beth A, 262
 Erickson, Steven R (author) Compliance from Self-Reported vs. Pharmacy Claims Data with Metered-Dose Inhalers (RR) 997
 Erickson-Birkedal, Sherrie (coauthor) see Adson, David E, 1375
 Ernst, Michael E (coauthor) see Koch, Yvonne De Sloover, 1644; (coauthor) see Maynard, Michelle L, 1274; (coauthor) see Weimerskirch, Patti R, 627
 Erramoupe, John (coauthor) see Ratka, Anna, 36
 Erstad, Brian L (author) Antifibrinolytic Agents and Desmopressin as Hemostatic Agents in Cardiac Surgery (A) 1075; (author) Octreotide for Acute Variceal Bleeding (A) 618; (author) Proton-Pump Inhibitors for Acute Peptic Ulcer Bleeding (A) 730; (author) Systemic Hemostatic Medications for Reducing Surgical Blood Loss (A) 925
 Esch, Lori D (coauthor) see Hardy, Helene, 343; (coauthor) see Rayner, Craig R, 1391
 Espinosa, Ricardo (coauthor) see González de la Puente, Miguel A, 1492
 Estival, Jean Louis F (coauthor) see Debourdeau, Philippe M, 424
 Evans, Martin E (coauthor) see Empey, Philip E, 687
 Faix, Yves (coauthor) see Sulem, Patrick, 1292
 Falkenberg, Torleif (coauthor) see Chuc, Nguyen Thi Kim, 1283
 Famularo, Giuseppe (author) Eosinophilic Hepatitis Associated with Cefonicid Therapy (L) 1669
 Fant, Gregory V (coauthor) see Mayer, Michael I, 1548
 Farah, Raymond (coauthor) see Sheit, Wisam, 1049
 Farfel, Zvi (coauthor) see Mayan, Haim, 560
 Farias, Eduardo F (coauthor) see Valsecia, Mabel E, 1495
 Farver, Debra K (author) Zolpidem for Antipsychotic-Induced Parkinsonism (CR) 435
 Fassett, William E (author) book review, 966
 Federico, Michele (coauthor) see Famularo, Giuseppe, 1669
 Feingold, Jay M (coauthor) see Bilgrami, Syed FA, 196
 Fernández-Soria-Pantoja, Rafael (coauthor) see Calvo-Romero, José María, 1403
 Ferrill, Mary J (coauthor) see Fung, Stacey M, 1270; (coauthor) see Shek, Allen, 908
 Fetrow, Charles W (author) Efficacy of the Dietary Supplement SAMe (S-adenosyl-L-methionine) (A) 1414
 Figueras, Albert (coauthor) see Valsecia, Mabel E, 1495
 Fiolet, Bader B (coauthor) see Mayer, Michael I, 1548
 Filizok, Janina (author) book review, 1682
 Finley, Rebecca S (author) Colony-Stimulating Factors in Acute Leukemia: Will We Ever Have an Answer? (O) 120
 Fish, Douglas N (coauthor) see MacLaren, Robert, 1614
 Fisher, Alexander A (author) Intracerebral Hemorrhage Following Possible Interaction Between Celecoxib and Clopidogrel (CR) 1567
 Fitch, J Thomas (author) Are Condoms Effective in Reducing the Risk of Sexually Transmitted Disease? (O) 1136
 Flockhart, David A (coauthor) see Rosebraugh, Curtis J, 1024
 Fobelo, Maria J (author) Aseptic Meningitis Related to Valacyclovir (L) 128
 Fonseca, Eduardo (coauthor) see Del Pozo, Jesús, 891
 Foral, Pamela A (author) Vancomycin Removal During a Plasma Exchange Transfusion (CR) 1400
 Force, Rex W (author) Comment: Blood Pressure Monitoring with Home Monitors Versus Mercury Sphygmomanometer (L) 1676; (coauthor) see Sadler, Melanie A, 1490
 Fouts, Michelle M (coauthor) see Hoehns, James D, 862
 Foy, Aidan (coauthor) see Ishister, Geoffrey K, 1552
 Fraser, Albert D (coauthor) see Pollak, P Timothy, 1371

Fraser, Gilles L (coauthor) see Devlin, John William, 1624
 Frechen, Kathleen A (author) book review, 966
 Friedman, Jill D (author) Opioid Antagonists in the Treatment of Opioid-Induced Constipation and Pruritus (A) 85
 Fufer, Hermann (coauthor) see Kelly, John, 1535
 Fung, Stacey M (author) Treatment of Bulimia Nervosa with Ondansetron (DIR) 1270
 Gabay, Michael P (coauthor) see Mategrano, Vanessa A, 1648
 Garcia, Guadalupe (author) Neuroleptic Malignant Syndrome with Antidepressant/Antipsychotic Drug Combination (L) 784
 Gardner, Stephanie F (coauthor) see Spiker, Sarah A, 589
 Garty, Ben Zion (coauthor) see Marcus, Nufar, 1042
 Geary, Elizabeth A (coauthor) see Reddy, Prabhshri, 682
 Gebauer, Markus G (coauthor) see Alderman, Christopher P, 1378
 Gennari, Carlo (coauthor) see Giordano, Nicola, 1053
 Geraci, Simone (coauthor) see Giordano, Nicola, 1053
 Germain, Marie-Laure Y (coauthor) see Bisschop, Dorothee Y, 311
 Gettman, David A (author) book review, 265
 Ghani, Sofia (coauthor) see Garcia, Guadalupe (L) 784
 Giannamore, Martin R (coauthor) see Spiker, Sarah A, 1166
 Gianni, Laura M (author) Topical Tacrolimus in the Treatment of Atopic Dermatitis (DIR) 943
 Gifford, Allen L (coauthor) see Wendel, Christopher S, 1010
 Gilbar, Peter J (author) Phenytoin and Fluorouracil Interaction (CR) 1367
 Gilbert, Andrew L (coauthor) see Alderman, Christopher P, 1378
 Gil-Cubero, Mercedes (coauthor) see Calvo-Romero, José María, 1403
 Gillespie, John A (author) Comment: Sudden Cardiac Death with Clozapine and Sertraline Combination (L) 1671
 Gimeno-Bayón, Juan-Luis (coauthor) see Mateu-de Antonio, Javier, 126
 Giordano, Nicola (author) Acute Hepatitis Induced by Cyproterone Acetate (CR) 1053
 Gironés Sarrin, Regina (coauthor) see Segura Huerta, Angel, 894
 Goebig, Michelle L (coauthor) see Vivian, Eva M, 452
 Goldschmidt, Neta (author) Compound Cardiac Toxicity of Oral Erythromycin and Verapamil (CR) 1396
 Golubev, Nina (coauthor) see Mayan, Haim, 560
 Gómez-Bellver, María J (coauthor) see Fobelo, María J, 128
 González de la Puente, Miguel A (author) Fatal Hepatotoxicity Associated with Enalapril (L) 1492
 González Ruiz, Mario (coauthor) see Carrascosa Porras, Miguel, 261; (coauthor) see Carrascosa Porras, Miguel, 643
 González-Peralta, Regina P (coauthor) see Besmertny, Olga, 533
 Gora-Harper, Mary Lea (author) Opioid Analgesics vs. Ketorolac in Spine and Joint Procedures: Impact on Healthcare Resources (RR) 1320
 Gotsman, Israel (coauthor) see Goldschmidt, Neta, 1396
 Goulet, Jude (coauthor) see Martineau, Pierre, 71
 Grau Cerrato, Santiago (coauthor) see Mateu-de Antonio, Javier, 126
 Gray, Shelly L (author) Medication Adherence in Elderly Patients Receiving Home Health Services Following Hospital Discharge (RR) 539
 Grillo, Joseph A (author) The Relationship Between Pre-Admission Indicators and Basic Math Skills at a New School of Pharmacy (RR) 167
 Guevel, Caroline (coauthor) see Edouard, Bruno, 1295
 Guglielmo, B Joseph (coauthor) see Burkwicz, Jill S, 9
 Guilarte, Julio (coauthor) see Andrade, Raul J, 783
 Gul, Ulker (coauthor) see Cakmakci, Ayse, 964
 Gums, John G (coauthor) see Smith, Jerry D, 702
 Gürbüz, Nesrin (coauthor) see Tutluoglu, Bülent, 1161
 Gurley, Bill J (coauthor) see Barone, Gary W, 124

H-J

Handl, Wolfgang HA (coauthor) see Westerlund, LO Tommy, 1343
 Hadari, Ruth (coauthor) see Shilo, Lotan, 1339
 Hagmeyer, Kathleen O (author) Hepatotoxicity Associated with Carvedilol (CR) 1364
 Hamadeh, Ghassan N (author) Common Prescriptions in Ambulatory Care in Lebanon (RR) 636
 Hanley, James F (coauthor) see Tholakanahalli, Venkatkrishna N, 432
 Harden, Cynthia L (coauthor) see Biton, Victor, 173
 Hardy, Gaëlle A (coauthor) see Daniel, Vincent C, 386
 Hardy, Hélène (author) Glucose Disorders Associated with HIV and Its Drug Therapy (A) 343
 Harper, John K (coauthor) see English, Brett A, 867
 Hartman, Bert A (coauthor) see Kutscher, Eric C, 1494
 Hartz, Stuart C (coauthor) see Huse, Daniel M, 1173
 Hasegawa, Atsushi (coauthor) see Nakamura, Hiroyoshi, 691
 Hatten, Randy C (coauthor) see Besmertny, Olga, 533
 Havrda, Dawn E (coauthor) see Hope, Kimberly A, 183
 Haynes, George R (author) book review, 130
 Healy, Daniel P (coauthor) see Pass, Steven E, 409
 Heck, Amy M (coauthor) see Tsun, Ellen C, 1471
 Heineman, Susan M (coauthor) see Foral, Pamela A, 1400
 Hemstreet, Brian A (author) Use of Sucralfate in Renal Failure (DIR) 360

Herings, Ron MC (coauthor) see Schillevoort, Igor, 1517
 Herranz Fernandez, Constantino (coauthor) see Segura Huerta, Angel, 894
 Heyneman, Catherine A (coauthor) see Rhodes, Richard S, 675
 Hillaire-Boys, Dominique (coauthor) see Peyrière, Hélène, 1291
 Hilleman, Daniel E (coauthor) see Spiker, Sarah A, 589
 Hilligoss, Nicole M (coauthor) see Littrell, Kimberly H, 1141
 Hifani, Akhitho (coauthor) see Takahashi, Takashi, 642
 Ho, Chun-Sum (coauthor) see Yuan, Rey-Yue, 1045
 Ho, Paul C (author) Stability of Extemporaneously Prepared Gentamicin Ophthalmic Solutions (L) 1293
 Hodges, Brian M (author) Antimicrobial Cycling: the Future or a Fad? (A) 1224; (author) Intravenous Valproate in Status Epilepticus (DIR) 1465
 Hodle, Audrey D (coauthor) see Culhane, Nicole S, 874
 Hoehns, James D (author) Reply: Sudden Cardiac Death with Clozapine and Sertraline Combination (L) 1671; (author) Sudden Cardiac Death with Clozapine and Sertraline Combination (CR) 862
 Hoffman, Gregory (coauthor) see Force, Rex W, 1676
 Holder, E Paul (author) book review, 509
 Holdsworth, Mark T (author) book review, 509; (author) Efficacy of Colony-Stimulating Factors in Acute Leukemia (A) 92
 Hope, Kimberly A (author) Subtherapeutic INR Values Associated with a Switch to Generic Warfarin (CR) 183
 Horn, Susan D (author) Newness of Drugs and Use of HMO Services by Asthma Patients (RR) 990
 Houston, Shelly A (coauthor) see McCune, Jeannine S, 14
 Howard, Grant (coauthor) see Kirkpatrick, Carl MJ, 1295
 Howard, John M (coauthor) see Reniers, Denise E, 1214
 Howard, Patricia A (coauthor) see Spiker, Sarah A, 589
 Hughes, Christine A (author) Metformin in an HIV-Infected Patient with Protease Inhibitor-Induced Diabetic Ketoacidosis (CR) 877
 Huse, Daniel M (author) Physicians' Knowledge, Attitudes, and Practice of Pharmacologic Treatment of Hypertension (RR) 1173
 Hussar, Daniel A (author) Mifepristone—Controversy, Beliefs, and Politics — Issues for Everyone (Opin) 373
 Huston, Sally A (coauthor) see Sleath, Betsy Lynn, 419
 Ibis, Raziye (coauthor) see Tutluoglu, Bülent, 1161
 Ibrahim, Egehan (coauthor) see Kille, Dielehan, 806
 Ippoliti, Cindy M (coauthor) see Quiliza, Rod Everett, 206
 Ishister, Geoffrey K (author) Citalopram-Induced Bradycardia and Presyncope (CR) 1552; (author) Comment: Serotonin Syndrome and 5-HT_{2A} Antagonism (L) 1143; (author) Comment: Serotonin Syndrome Induced by Fluvoxamine and Mirtazapine (L) 1674; (author) Comment: Serotonin Syndrome, Early Management with Cyproheptadine (L) 1672
 Ito, Matthew K (coauthor) see Aldridge, Martha A, 898
 Ivey, Tom D (coauthor) see Pass, Steven E, 409
 Iwamoto, Aikichi (coauthor) see Takahashi, Takashi, 642
 Jacobs, Richard (coauthor) see Burkwicz, Jill S, 9
 James, Christopher W (author) Homicidal Ideation Secondary to Interferon (L) 962; (author) Recurrent Inguinal Hernias Secondary to Indinavir/Ritonavir Combination Therapy (CR) 881
 Jameson, John P (author) Pharmacotherapy Consultation on Polypharmacy Patients in Ambulatory Care (RR) 835
 Jansen, Paul AF (coauthor) see Schillevoort, Igor, 1517
 Jarvis, Catherine L (coauthor) see MacLaren, Robert, 1614
 Jennings, Heath R (coauthor) see Empey, Philip E, 687
 Jimenez-Jimenez, Felix Javier (author) Aggravation of Glaucoma with Fluvoxamine (CR) 1565
 Johansson, Saga (coauthor) see Jørgensen, Tove M, 1004
 John, Leela (author) Role of Therapeutic Drug Monitoring for Protease Inhibitors (A) 745
 Johnson, Carrie J (author) Etanercept in Juvenile Rheumatoid Arthritis (A) 464
 Johnson, Craig G (coauthor) see Littrell, Kimberly H, 1141
 Johnson, Matthew H (coauthor) see Avripas, Mary Beth A, 262
 Jones, Mark E (author) Systemic Adverse Effects from Topical Dexamethasone Cream (L) 505
 Joo, Hyun-Joong (coauthor) see Lee, Ai Young, 1584
 Jordan, Nancy Schuddekuopf (author) book review, 1299
 Jørgensen, Tove M (author) Prescription Drug Use, Diagnoses and Healthcare Utilization Among the Elderly (RR) 1004
 Just, Bernard Y (coauthor) see Bisschop, Dorothee Y, 311

K-L

Kahlenborn, Chris (author) book review, 1681
 Kalhan, Satish (coauthor) see Avram, Anca M, 1381
 Kalus, James S (author) Calcium-Channel Antagonists and Nitrates in Coronary Artery Bypass Patients Receiving Radial Artery Grafts (DIR) 631
 Kazanin, Marc (coauthor) see Biton, Victor, 173
 Kaneda, Yasuhiro (author) Effects of Risperidone on Gonadal Axis Hormones in Schizophrenia (RR) 1523
 Kanik, Arzu (coauthor) see Tutluoglu, Bülent, 1161
 Kanji, Salmaan (coauthor) see Devlin, John William, 1624; (author) The Effect of *Helicobacter pylori* Eradication on NSAID-Induced Gastrointestinal Toxicity (DIR) 249
 Kantor, Jonathan (coauthor) see Majid, Arshad, 1241

Kao, Ching-Rey (coauthor) see Yuan, Rey-Yue. 1045
 Kaplan-Machlis, Barbara (coauthor) see Lucas, Kristy Holmes. 314
 Kapur, Dinesh (coauthor) see Bilgrami, Syed FA. 196
 Kars, Ayse (coauthor) see Altundag, Ozden. 641
 Kawana, Hidetada (coauthor) see Nakamura, Hiroyoshi. 691
 Kearney, Paul A (coauthor) see Davis, George A. 1492
 Kehoe, Jr, William A (author) Treatment of Attention Deficit Hyperactivity Disorder in Children (E) 1130
 Kelley, Kristi W (coauthor) see Taylor, Charles T. 365
 Kelly III, Edward T (coauthor) see Reddy, Prabhshni. 682
 Kelly, H William (coauthor) see Horn, Susan D. 990
 Kelly, Jerome J (author) book review. 1678
 Kelly, John (author) Warfarin Pharmacodynamics Unaffected by Cilomilast (RR) 1535
 Kelly, Kathleen M (author) book review. 1299
 Kelly, Michael W (coauthor) see Hoehns, James D. 862; (coauthor) see Hoehns, James D. 1671
 Kendrick, Michael G (coauthor) see Rotch, Allison L. 817
 Kennedy, LeAnne D (coauthor) see Pegram, Anita A. 935; (coauthor) see Quillit, Rod Everett. 206
 Kennerfalk, Anita (coauthor) see Jorgensen, Tove M. 1004
 Ketch, Beverly L (coauthor) see Barone, Gary W. 124
 Kezele, Robert (coauthor) see Chong, Pang H. 1476
 Khan, Mujeeb H (coauthor) see Farver, Debra K. 435
 Kilbaugh, Todd J (coauthor) see Serrano, Maria-Stella. 823
 Kille, Dielehan (author) Sulfasalazine Decreases Acute Gastrointestinal Complications Due to Pelvic Radiotherapy (RR) 806
 Kilzer, Wanda J (coauthor) see Boedeker, Kimi S. 369
 Kim, Young-Gull (coauthor) see Lee, Ai Young. 1584
 Kintzel, Polly E (author) Prophylaxis for Paclitaxel Hypersensitivity Reactions (DIR) 1114
 Kirking, Duane M (coauthor) see Erickson, Steven R. 997
 Kirkpatrick, Carl MJ (author) Comment: Serum Concentrations of Cefuroxime after Continuous Infusion in Coronary Bypass Graft Patients (L) 1295
 Kirwan, John P (coauthor) see Avram, Anca M. 1381
 Kitada, Mitsukazu (coauthor) see Nakamura, Hiroyoshi. 691
 Klepper, Teresa Bailey (author) book review. 1145
 Kluger, Jeffrey F (coauthor) see Caron, Michael F. 1248
 Knapp, Joseph F (coauthor) see Colucci, Vincent J. 385
 Knoppert, David C (author) Eradication of Severe Neonatal Systemic Candidiasis with Amphotericin B Lipid Complex (CR) 1032
 Koch, Yvonne De Sloover (author) Use of Metformin in Polycystic Ovary Syndrome (DIR) 1644
 Kodama, Yasuo (coauthor) see Ono, Shunsuke. 1122
 Koenig, Harold G (author) Religion and Coping with Serious Medical Illness (A) 352
 Kondo, I. Midori (author) Argatroban for Prevention and Treatment of Thromboembolism in Heparin-Induced Thrombocytopenia (A) 440
 Kophazi, Martha E (coauthor) see Reddy, Prabhshni. 682
 Koranyi, Katalin I (coauthor) see Temple, Mary E. 414
 Kostliuk, Karen A (coauthor) see Burkiewicz, Jill S. 9
 Kotlyar, Michael J (coauthor) see Adson, David E. 1375
 Kovacs, Michael J (author) Reply: Warfarin Resistance Due to Sulfasalazine (L) 506; (coauthor) see Timmuth, Alan H. 669
 Kovatz, Susy (coauthor) see Shilo, Lotan. 1339
 Krivoy, Norberto (coauthor) see Sheit, Wisam. 1049
 Kroesen, Kendall (coauthor) see Wendel, Christopher S. 1010
 Kubler, Paul A (author) Possible Interaction Between Cisapride and Digoxin (L) 127
 Kuhn, John G (author) Fluorouracil and the New Oral Fluorinated Pyrimidines (A) 217
 Kuo, Grace (author) book review. 391
 Kuriyama, Takayuki (coauthor) see Nakamura, Hiroyoshi. 691
 Kushner, Janine M (author) Two Cases of Seizures Associated with Fluoroquinolones (CR) 1194
 Kutscher, Eric C (author) Peripheral Edema Associated with Mirtazapine (L) 1494
 Lafond, Jean-Luc V (coauthor) see Danel, Vincent C. 386
 Lai, Sue Min (coauthor) see Rigler, Sally K. 811
 Lam, Annie Y (author) Possible Interaction Between Warfarin and Lycium barbarum (L) (CR) 1199
 Landers, Amy E (author) book review. 1680
 Lane, Hsien-Yuan (coauthor) see Lu, Mong-Liang. 1675
 Laporte, Joan-Ramon (coauthor) see Valsecia, Mabel E. 1495
 Larson, David B (coauthor) see Koenig, Harold G. 352
 Larson, Susan S (coauthor) see Koenig, Harold G. 352
 Larsson, Mattias (coauthor) see Chue, Nguyen Thi Kim. 1283
 Latif, David A (coauthor) see Grillo, Joseph A. 167
 Latour-Pérez, Jaime (author) Using Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndrome (A) 472
 Le Couteur, David G (coauthor) see Fisher, Alexander A. 1567
 Le Foulgocq, Patrick (coauthor) see Edouard, Bruno. 1295
 Le, Jennifer (author) Implanon: A Critical Review (A) 329
 Lechin, Alex E (coauthor) see Pietrucha-Dilanchian, Paula. 1570
 Lee, Ai Young (author) Photo-Patch Testing in Seven Cases of Photosensitive Drug Eruptions (CR) 1584
 Lee, Audrey J (author) A Case Report of Rhabdomyolysis Secondary to a Drug Interaction Between Simvastatin and Clarithromycin (CR) 26
 Lee, David SC (coauthor) see Knoppert, David C. 1032
 Leinonen, Esa VJ (coauthor) see Anttila, Sami AK. 1221

Lemaire, Jane B (coauthor) see Bates, Duane E. 782
 Lenhart, Susan E (author) Treatment of Insomnia in Hospitalized Patients (A) 1449
 Leufkens, Hubert G M (coauthor) see Schillevoort, Igor. 1517
 Levien, Terri L (author) Nateglinide Therapy for Type 2 Diabetes Mellitus (A) 1426
 Lewis, Russell E (coauthor) see Pietrucha-Dilanchian, Paula. 1570
 Lightfoot, Meredith L (coauthor) see Barone, Gary W. 124
 Lim, Siew M (coauthor) see Ho, Paul C. 1293
 Lin, Annica Y (coauthor) see Bishara, Jihad. 308
 Lindley, Celeste M (coauthor) see McCune, Jeannine S. 14
 Littrell, Kimberly H (author) Weight Loss with Topiramate (L) 1141
 Liu, Chin Y (author) Anticoagulation Therapy for Radiation-Induced Myelopathy (CR) 188
 Lloyd, Stanley (coauthor) see Thomas, Michael L. 123
 Lober, Cheryl A (coauthor) see Kalus, James S. 631
 Loewen, Peter S (coauthor) see Zed, Peter J. 1528
 López Tendero, Pedro (coauthor) see Segura Huerta, Angel. 894
 Lopez, Larry M (coauthor) see Spinler, Sarah A. 589
 Lousberg, Tammy R (author) A Comparison of Clinical Outcome Studies Among Cholesterol-Lowering Agents (A) 1599
 Lu, Mong-Liang (author) Comment: Unanticipated Plasma Concentrations in Two Clozapine-Treated Patients (L) 1675
 Lu, Weidong (coauthor) see Riedinger, June E. 228
 Lucas, Kristy H (author) Orlistat—A Novel Weight Loss Therapy (A) 314; (coauthor) see Metz, Charity A. 496
 Lucena, M Isabel (coauthor) see Andrade, Raul J. 783
 Lucich, Jeanne L (coauthor) see Quillit, Rod Everett. 206
 Lund, Brian C (coauthor) see Kutscher, Eric C. 1494
 Lyman, Jr, Alfred E (author) Pregnancy Categories of Nicotine Replacement Products (L) 1496

M-O

MacCarra, Mary E (author) Impact of a Limited Fluoroquinolone Reimbursement Policy on Antimicrobial Prescription Claims (RR) 852
 MacCausland, Owen E (coauthor) see Bruno-Joyce, Jeanne. 1016
 Mack, James E (coauthor) see Reeves, Roy R. 698
 MacLaren, Robert (author) Use of Enteral Nutrition for Stress Ulcer Prophylaxis (A) 1614
 Maddis, Daniel S (coauthor) see Lee, Audrey J. 26
 Madhavan, S Suresh (coauthor) see Scott, Virginia G. 289
 Mahoney, Jane E (coauthor) see Gray, Shelly L. 539
 Maidment, Ian D (author) Gabapentin Treatment for Bipolar Disorders (DIR) 1264
 Majid, Arshad (author) Antiplatelet Agents for Secondary Prevention of Ischemic Stroke (A) 1241
 Major, Stella C (coauthor) see Hamadeh, Ghassan N. 636
 Malek-Ahmedi, Parviz (author) Mood Disorders Associated with Interferon Treatment: Theoretical and Practical Considerations (A) 489; (author) Olanzapine in Pregnancy (L) 1294
 Malgor, Luis A (coauthor) see Valsecia, Mabel E. 1495
 Mallaret, Michel P (coauthor) see Danel, Vincent C. 386
 Malone, Daniel C (author) Adherence to ATS Guidelines for Hospitalized Patients with Community-Acquired Pneumonia (RR) 1180
 Malone, Margaret (coauthor) see Demers, Jason C. 1217
 Manfredi, Roberto (author) Gynecomastric Associated with Highly Active Antiretroviral Therapy (CR) 438
 Mannick, Elizabeth E (coauthor) see Serrano, Maria-Stella. 823
 Marcus, Nufar (author) Transient Hypoparathyroidism Due to Amphotericin B-Induced Hypomagnesemia in a Patient with β -Thalassemia (CR) 1042
 Markelon, Jennifer D (coauthor) see Reddy, Prabhshni. 682
 Marklund, Bertil R G (coauthor) see Westerlund, LO Tommy. 1343
 Marra, Carlo A (coauthor) see Zed, Peter J. 1528
 Marra, Fawiah (coauthor) see John, Leela. 745
 Martineau, Pierre (author) New Competition in the Realm of Renin-Angiotensin Axis Inhibition: The Angiotensin II Receptor Antagonists in Congestive Heart Failure (A) 71
 Martinez, Walter (coauthor) see Del Pozo, Jesús. 891
 Martiradonna, Carlo (coauthor) see Famularo, Giuseppe. 1669
 Mason, Barbara J (author) book review. 1298
 Masters-Harte, Lory D (author) Sucrose Analgesia for Minor Procedures in Newborn Infants (DIR) 947
 Mategrano, Vanessa A (author) Misoprostol in the Prevention of Postpartum Hemorrhage (DIR) 1648
 Materne, Isabelle (coauthor) see Edouard, Bruno. 1295
 Mateu-de Antonio, Javier (author) Ritonavir-Induced Carbamazepine Toxicity (L) 126
 Mathew, Prasad (coauthor) see Holdsworth, Mark T. 92
 Mathur, Vijay Shanker (coauthor) see Al Khaja, Khalid Ahmed Jassim. 1350
 Mathys, Monica L (coauthor) see Thompson, Dennis F. 126
 Mauro, Vincent F (coauthor) see Spinler, Sarah A. 589
 Mayan, Haim (author) Lithium Intoxication Due to Carbamazepine-Induced Renal Failure (CR) 560
 Mayer, Michael I (author) Stability of Cisplatin, Doxorubicin, and Mitomycin Combined with Ioversol for Chemoembolization (RR) 1548

Maynard, Michelle L (author) Leukotriene Receptor Antagonists in the Treatment of Allergic Rhinitis (DIR) 1274
 Mazur, Joseph E (coauthor) see Hodges, Brian M. 1465
 McClintock, Claudia (coauthor) see Rettman, Kristina S. 1559
 McClure, Robert (coauthor) see Alfaro, Cara L. 1028
 McCune, Jeannine S (author) Evaluation of Outcomes in Converting from Intravenous Ondansetron to Oral Granisetron: An Observational Study (RR) 14
 McDaniel, William W (author) Reply: Serotonin Syndrome, Early Management with Cyproheptadine (L) 1672; (author) Serotonin Syndrome, Early Management with Cyproheptadine (CR) 870
 McGriff, Nayahmka J (coauthor) see Csako, Gyorgy. 1578
 McKay, Jenny R (coauthor) see Kubler, Paul A. 127
 McLean, William M (coauthor) see Paquette-Lamontagne, Nicolas. 953
 McNally, Daniel (coauthor) see Bilgrami, Syed FA. 196
 McNamara, Dennis M (coauthor) see Coley, Kim C. 985
 McNelis, Kelly C (coauthor) see James, Christopher W. 882
 McNicholl, Ian Richard (author) Neutrinamide Inhibitors: Zanamivir and Oseltamivir (A) 57
 McNicholl, Joan Jovero (coauthor) see McNicholl, Ian Richard. 57
 Medicus-Bringa, Maggie (author) book review. 1499
 Megna, James L (author) Treatment of Bipolar Depression with Twice Weekly Fluoxetine: Management of Antidepressant-Induced Mania (CR) 45
 Mehlhorn, Alana J (coauthor) see Wagner, Mary L. 116
 Mehta, Jayesh (coauthor) see Quillit, Rod Everett. 206
 Melde, Stephen L (author) Olfaxin: A Probable Cause of Toxic Epidermal Necrolysis (CR) 1388
 Menzin, Joseph H (coauthor) see Vera-Llonch, Montserrat. 846
 Merliss, Andrew D (coauthor) see Tholakanahalli, Venkatakrishna N. 432
 Messmer, Karen J (author) Verteporfin for Age-Related Macular Degeneration (A) 1593
 Metersky, Mark L (coauthor) see Bilgrami, Syed FA. 196
 Metz, Charity A (author) Alternate-Day Dosing of HMG-CoA Reductase Inhibitors for Cholesterol Reduction (DIR) 496
 Millart, Hervé G (coauthor) see Bioschoop, Dorothée Y. 311
 Miller, Lisa J (author) Gabapentin for Treatment of Behavioral and Psychological Symptoms of Dementia (CR) 427
 Miller, Sarah J (coauthor) see Clarke, Amanda K. 1480
 Millson, David (coauthor) see Ashcroft, Darren M. 829
 Mitropoulos, Fotios A (author) Trovafloxacin-Associated Leukopenia (CR) 41
 Miyagawa, Clyde I (coauthor) see Pass, Steven E. 409
 Mohler, III, Emilie R (coauthor) see Reilly, Muredach P. 48
 Mohler, M Jane (coauthor) see Wendel, Christopher S. 1010
 Mohutsky, Michael A (coauthor) see Lam, Annie Y. 1199
 Monroe, Michelle L (author) Effect of Common OTC Medications on Blood Alcohol Levels (A) 918
 Montastruc, Jean Louis (coauthor) see Sulem, Patrick. 1292
 Montouris, Georgia D (coauthor) see Bilton, Victor. 173
 Moore, P Mary (coauthor) see Timmuth, Alan H. 669
 Morehead, M Shawn (coauthor) see DeHart, Renee M. 707
 Moreno, Jose Andres (coauthor) see Salvador Bofill, Javier. 786
 Morrow, Beverly H (coauthor) see Timmuth, Alan H. 669
 Morse, Gene D (coauthor) see Hardy, Helene. 343
 Moulin, Dwight E (coauthor) see Sumpton, Janice E. 557
 Mukherjee, S Mimi (coauthor) see Roefaro, John. 300
 Mukherjee, Som D (coauthor) see Pollak, P Timothy. 1371
 Muma, Bruce K (coauthor) see Zarowitz, Barbara J. 1661
 Mumford, James (coauthor) see See, Sharon. 694
 Munger, Mark A (coauthor) see Spinler, Sarah A. 589
 Murdoch, Robert D (coauthor) see Kelly, John. 1335
 Murray, Kim M (coauthor) see Johnson, Carrie J. 464
 Muskat, Mordechai (coauthor) see Goldschmidt, Neta. 1396
 Mutnick, Alan H (coauthor) see Schrand, Linda M. 1186
 Nagao, Taku (coauthor) see Ono, Shunsuke. 1122
 Nageotte, Michael P (coauthor) see Briggs, Gerald G. 859
 Nahata, Milap C (author) Alternative, Complementary, or Integrated Pharmacotherapy (E) 959; (author) Publication of Clinical Drug Trials (E) 780; (coauthor) see Robinson, Renee F. 1327; (coauthor) see Temple, Mary E. 414
 Nakamura, Hiroyoshi (author) Effect of Levofloxacin on Theophylline Clearance During Theophylline and Clarithromycin Combination Therapy (CR) 691
 Nakamura, Tetuya (coauthor) see Takahashi, Takashi. 642
 Nappi, Jean M (coauthor) see Spinler, Sarah A. 589; (coauthor) see Turcasso, Nannette M. 1233
 Naqvi, Bilal H (coauthor) see Bilgrami, Syed FA. 196
 Nardi, Paolo (coauthor) see Giordano, Nicola. 1053
 Netski, Alison I (author) Lithium-Induced Exacerbation of Sutter (L) 961
 Nguyen-Khoa, Bao-Anh (author) book review. 1679
 Nice, Frank J (author) book review. 1680
 Nicolas, Joëlle (coauthor) see Peyrière, Hélène. 1291
 Nicotro, Giulio Cesare (coauthor) see Famularo, Giuseppe. 1669
 Nieuwenstraten, Carmine (author) Bupropion versus Selective Serotonin Reuptake Inhibitors for Treatment of Depression (A) 1608
 Nir-Paz, Ran (coauthor) see Goldschmidt, Neta. 1396
 Nix, David E (coauthor) see Polocini, Charles A. 1332
 North, Ginnie Lee T (author) Celecoxib as Adjunctive Therapy for Treatment of Colorectal Cancer (DIR) 1638

Oertel, Maryann D (author) see McCune, Jeannine S, 14
 Ohmori, Shigeru (author) see Nakamura, Hiroyoshi, 691
 Ohtsuka, Tomoko (author) see Nakamura, Hiroyoshi, 691
 Olson, Kari L (author) Combined Aspirin/ACE Inhibitor Treatment for CHF (DIR) 1653
 Omar, Mohamed A (author) Correction: Rhabdomyolysis and HMG Co-A Reductase Inhibitors (L) 1296; (author) Rhabdomyolysis and HMG Co-A Reductase Inhibitors (A) 1096
 Onder, Meltem (author) see Öztas, Pinar, 961
 Ono, Shunsuke (author) Infrastructure of Pharmaceutical Research and Development in Japan (IR) 1122
 Oppelt, Thomas F (author) see Bair, Jennifer D, 1202
 Orti-Pareja, Miguel (author) see Jimenez-Jimenez, Felix Javier, 1565
 Oster, Gerry (author) see Vera-Llonch, Montserrat, 846
 Ozenirler, Seren (author) see Kiliç, Dieçhan, 861
 Öztas, M Orhan (author) see Öztas, Pinar, 961
 Öztas, Pinar (author) Severe Acne with Lithium (L) 961
 Özyükan, Esin (author) see Cakmakci, Ayse, 964

P-Q

Pai, Manjunath P (author) Antimicrobial-Coated/Bonded and -Impregnated Intravascular Catheters (A) 1255
 Pakes, Gary E (author) Writing Manuscripts Describing Clinical Trials: A Guide for Pharmacotherapeutic Researchers (A) 770
 Paladino, Joseph A (author) Is More Than One Quinolone Needed in Clinical Practice? (A) 1085
 Paquette-Lamontagne, Nicolas (author) Evaluation of a New Integrated Discharge Prescription Form (RR) 953
 Park, Charles W (author) Disulfiram-Ethanol Induced Delirium (CR) 33
 Park, Sang C (author) see Coley, Kim C, 985
 Pass, Steven E (author) Serum Concentrations of Cefuroxime after Continuous Infusion in Coronary Bypass Graft Patients (RR) 409
 Patatiani, Leslie K (author) see Thompson, Dennis F, 126
 Patel, Atul T (author) see Rigler, Sally K, 811
 Patel, Vinod (author) see Avram, Anca M, 1381
 Pathak, Dev S (author) see Davis, Elizabeth Anne, 546
 Peabody, Carol D (author) see Littrell, Kimberly H, 1141
 Pearson, Vincent E (author) Galantamine: A New Alzheimer Drug with a Past Life (A) 1406
 Peckman, Howard J (author) see Kushner, Janine M, 1194
 Pedersen, Craig A (author) see Spiker, Erin C, 1166
 Pegram, Anita A (author) Prevention and Treatment of Venous Occlusive Disease (A) 935
 Peloquin, Charles A (author) Pharmacokinetics of para-Aminosalicylic Acid Granules Under Four Dosing Conditions (RR) 1332
 Peña Gómez, Elena (author) see Carrascosa Porras, Miguel, 643
 Peña-Penabaz, Carmen (author) see Del Pozo, Jesús, 891
 Pendland, Susan L (author) see Pai, Manjunath P, 1255
 Pérez Fidalgo, Jose A (author) see Segura Huerta, Angel, 894
 Perlman, Jay I (author) see Vander Zanden, Jeanne A, 1633
 Perreault, Sylvie (author) Pharmacokinetics of Morphine and Its Glucuronidated Metabolites in Burn Injuries (CR) 1588
 Peters, Byron G (author) see Quillitz, Rod Everett, 206
 Peterson, Kristi E (author) see Bartels, Cathy L, 109
 Petty, Richard G (author) see Littrell, Kimberly H, 1141
 Peyrière, Hélène (author) Hypersensitivity Reaction Related to Avacavir in Two Members of the Same Family (L) 1291
 Pfeiffer, Dennis (author) see McCune, Jeannine S, 14
 Phatak, Hemant M (author) see Rhodes, Richard S, 675
 Piasecki, Melissa P (author) see Netski, Alison L, 961
 Pietrucha-Dilanchian, Paula (author) *Candida lusitanae* Catheter-Related Sepsis (CR) 1570
 Pillans, Peter Ian (author) see Kubler, Paul A, 127
 Pitlik, Silvio D (author) see Bishara, Jihad, 308
 Polchi, Sandra (author) see Famularo, Giuseppe, 1669
 Pollak, P Timothy (author) Sertraline-Induced Hypoglycemia (CR) 1371
 Pontikes, Pamela J (author) see Chong, Pang H, 1476
 Potti, Anil (author) see Tholakanahalli, Venkatakrishna N, 432
 Poveda, Rene A (author) see Ghani, Sofin, 784
 Prior, Felicity H (author) see Isbister, Geoffrey K, 1552
 Pucino, Frank (author) see Csako, Gyorgy, 1500; (author) see Csako, Gyorgy, 1578
 Puzantian, Talia (author) book review, 1678
 Qasim, Mahmood (author) see Shilo, Lotan, 1678
 Quillitz, Rod Everett (author) Practice Guidelines for Lipid-Based Amphotericin B in Stem Cell Transplant Recipients (A) 206

R

Rabinovici, Reuven (author) see Mitropoulos, Fotios A, 41
 Raebel, Marsha A (author) see Lyman, Jr, Alfred E, 1496
 Ragucci, Kelly R (author) Olanzapine-Induced Diabetic Ketoacidosis (CR) 1556
 Raible, Donald (author) see Bilgrami, Syed FA, 196
 Raji, Mukaila A (author) Mirtazapine for Treatment of Depression and Comorbidities in Alzheimer Disease (CR) 1020

Rapp, Robert P (author) Antimicrobial Cycling to Control Bacterial Resistance (E) 1289; (author) see Davis, George A, 1492; (author) see Empey, Philip E, 687
 Rasanen, Ilpo (author) see Anttila, Sami AK, 1221
 Rasmussen, Jon R (author) see Lousberg, Tammy R, 1599
 Ratka, Anna (author) Intrameningeal Ceftriaxone in the Treatment of Childhood Meningitis Due to *Haemophilus influenzae* Type F (CR) 36
 Ray-Coquard, Isabelle (author) see Baty, Vincent, 963
 Rayner, Craig R (author) Symptomatic Hyperbilirubinemia with Indinavir/Ritonavir-Containing Regimen (CR) 1391
 Razgallah, Ibrahim (author) see Böschop, Dorothee Y, 311
 Record, Kenneth E (author) see Gora-Harper, Mary Lea, 1320
 Reddy, Prabhashni (author) Medicaid's β_2 -Agonist Recipients and their Treatment by National Standards (RR) 682
 Reeves, Roy R (author) Neuroleptic Malignant Syndrome During a Change from Haloperidol to Risperidone (CR) 698
 Reilly, Kathleen M (author) see Johnson, Carrie J, 464
 Reilly, Muredach P (author) Cilostazol: Treatment of Intermittent Claudication (A) 48
 Reissner, Lori A (author) book review, 647
 Reist, Christopher (author) see Frechen, Kathleen A, 966
 Reniers, Denise E (author) Isotretinoin-Induced Inflammatory Bowel Disease in an Adolescent (CR) 1214
 Reshef, Ron (author) see Sheit, Wisam, 1049
 Rettman, Kristina S (author) Hepatotoxicity After Short-Term Trastuzumab Therapy (CR) 1559
 Reynes, Jacques (author) see Peyrière, Hélène, 1291
 Rhodes, Richard S (author) Topical Phenytoin Treatment of Stage II Decubitus Ulcers in the Elderly (RR) 675
 Richard, René C (author) see Debourdeau, Philippe M, 424
 Richner, Ramiel E (author) see Vera-Llonch, Montserrat, 846
 Riedinger, June E (author) Ping Wei San, a Traditional Chinese Medicine Approach for Gastrointestinal Disorders (A) 228
 Riggio, Silvana (author) see Park, Charles W, 33
 Rigler, Sally K (author) Use of Antihypertensive and Antithrombotic Medications After Stroke in Community-Based Care (RR) 811
 Riker, Richard R (author) see Devlin, John William, 1624
 Rincón, Manuel (author) see González de la Puente, Miguel A, 1492
 Rivey, Michael P (author) see Struckman, Daniel R, 242
 Robertson, Patrick S (author) see Doucette, Douglas E, 507
 Robinson, Renee F (author) Safety of Intravenous Bolus Administration of Gentamicin in Children (RR) 1327
 Roelfaro, John (author) Olanzapine-Induced Hyperglycemic Nonketotic Coma (CR) 300
 Rogers, P David (author) see Slain, Douglas, 720
 Roht, Lewis H (author) see Huse, Daniel M, 1173
 Rojas-Fernandez, Carlos H (author) Successful Use of Donepezil for the Treatment of Dementia with Lewy Bodies (CR) 202
 Roman, Sabine (author) see Baty, Vincent, 963
 Romero Alonso, Alberto (author) see Fobelo, Maria J, 128
 Roos, Raymond AC (author) see Schillevoort, Igor, 1517
 Rosebraugh, Curtis J (author) Olanzapine-Induced Rhabdomyolysis (CR) 1024
 Ross, Mary B (author) see Schrand, Linda M, 1186
 Rotch, Allison L (author) Blood Pressure Monitoring with Home Monitors Versus Mercury Sphygmomanometer (RR) 817
 Rotman-Pikielny, Pnina (author) see Csako, Gyorgy, 1578
 Rubin, Richard H (author) see Sleath, Betsy Lynn, 419
 Rudd, Gene (author) Condoms and Sexually Transmitted Diseases (O) 1135; (author) Mifepristone: Less Obvious Adverse Effects (O) 381
 Russo, René L (author) The Role of Antimicrobial Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (A) 576

S

Saab, Basssem R (author) see Hamadeh, Ghassan N, 636
 Sackellares, J Chris (author) see Biton, Victor, 173
 Sadler, Melanie A (author) Suspected *Tegenaria agrestis* Envenomation (VO) 1490
 Sajbel, Terrie A (author) Converting Patients from Brand-Name Clozapine to Generic Clozapine (RR) 281
 Saklad, Stephen R (author) see English, Brett A, 867
 Salama, Husam EM (author) see Knoppert, David C, 1032
 Salmerón, F Javier (author) see Andrade, Raul J, 783
 Salvador Boffill, Javier (author) Reply: Fluorouracil-Induced Aphasia (L) 786
 Sansom, Dennis I (author) book review, 1498
 Santacrose, Clorinda (author) see Giordano, Nicola, 1053
 Sarlis, Nicholas J (author) see Csako, Gyorgy, 1578
 Savini, Carolyn J (author) see James, Christopher W, 962
 Savic, Philippe F (author) see Daniel, Vincent C, 386
 Sawyer, William Theron (author) see McCune, Jeannine S, 14
 Sheit, Wisam (author) Nimesulide-Induced Acute Hepatitis (CR) 1049
 Schey, Ron (author) History of Drug-Induced Hepatitis and Risk of Amoxicillin/Clavulanate-Induced Hepatotoxicity (L) 1142
 Schillevoort, Igor (author) Risk of Extrapyrasidal Syndromes with Haloperidol, Risperidone or Olanzapine (RR) 1517

Schmidt, Siegfried OF (author) see Smith, Jerry D, 702
 Schmidt-Sommerfeld, Eberhard (author) see Serrano, Maria-Stella, 823
 Schmoldt, Achim (author) see Schulz, Martin, 21
 Schrand, Linda M (author) A Cost-Benefit Analysis of RSV Prophylaxis in High-Risk Infants (RR) 1186
 Schulz, Martin (author) Lack of Methemoglobinemia with Flutamide (RR) 21
 Scott, Virginia G (author) Pharmacists' Preferences for Continuing Education and Certificate Programs (RR) 289
 See, Sharon (author) Trimethoprim/Sulfamethoxazole-Induced Toxic Epidermal Necrolysis (CR) 694
 Segarra-Newnham, Marisel (author) Use of Cidofovir in Progressive Multifocal Leukoencephalopathy (A) 741
 Segars, Larry W (author) book review, 1681
 Segura Huerta, Angel (author) Pulmonary Fibrosis Induced by Cyclophosphamide (CR) 894
 Sequeira, Reginald Paul (author) see Al Khaja, Khalid Ahmed Jassim, 1350
 Serrano, Maria-Stella (author) Use of Infliximab in Pediatric Patients with Inflammatory Bowel Disease (RR) 823
 Serrano-Castro, Pedro J (author) Comment: Fluorouracil-Induced Aphasia: Neurotoxicity Versus Cerebral Ischemia (L) 785
 Shaban, Hanan M (author) see Malone, Daniel C, 1180
 Sharkey, Phoebe D (author) see Horn, Susan D, 990
 Shek, Allen (author) Statin-Fibrate Combination Therapy (A) 908
 Shenkman, Louis (author) see Shilo, Lotan, 1339
 Sherman, Justin J (author) Comment: Warfarin Resistance due to Sulfasalazine (L) 506
 Shen, Jun-Juan (author) see Yuan, Rey-Yue, 1045
 Shiller, Moshe (author) see Sheit, Wisam, 1049
 Shilo, Lotan (author) Appropriateness of Nitrate Use in a General Medical Population (RR) 1339
 Shirin, Haim (author) see Schey, Ron, 1143
 Shiffert, Martine (author) see Peyrière, Hélène, 1291
 Singleton, Michael (author) see Pelequin, Charles A, 1332
 Siong, Khoo Kel (author) see Chowbay, Balram, 1669
 Skachell, Penny A (author) Tacrolimus in Dermatologic Disorders (A) 582
 Skaufle, Monte L (author) see Jones, Mark E, 505
 Skeris, Ingrid S (author) see MacCarra, Mary E, 852
 Skidmore, Jr, Robert A (author) book review, 130
 Slack, Marion K (author) see Younis, Wisam S, 841
 Slain, Douglas (author) Intravenous Itraconazole (A) 720
 Slavik, Richard S (author) see Zed, Peter J, 1528
 Sleath, Betsy L (author) Antidepressant Prescribing to Hispanic and non-Hispanic White Patients in Primary Care (RR) 419
 Smith, Jerry D (author) Relief of Fibromyalgia Symptoms Following Discontinuation of Dietary Excitoxins (CR) 702
 Smith, Scott R (author) The AIDS Drug Assistance Programs and Coverage of HIV-Related Medications (RR) 155
 Smythe, Maureen A (author) see Avripas, Mary Beth A, 262
 Snyder, Clyde R (author) see Kushner, Janine M, 1194
 Soh, Hwei (author) see Ho, Paul C, 1293
 Solbrig, Ronald M (author) see Sadler, Melanie A, 1490
 Solimando, Jr, Dominick A (author) see Mayer, Michael I, 1548
 Sommer, Stefan (author) see Sadler, Melanie A, 1490
 Song, Jessica C (author) Do HMG-CoA Reductase Inhibitors Affect Fibrinogen? (A) 236
 Sorensen, Suellyn J (author) see Abraham, Prasad E, 553
 Spiker, Erin C (author) Potential Adverse Drug Events in an Indigent and Homeless Geriatric Population (RR) 1166
 Spinler, Sarah A (author) New Recommendations from the 1999 American College of Cardiology/American Heart Association AHA Guidelines (A) 589; (author) see El-Beyrousty, Claudine, 1108
 Stein, Jenny (author) see Hagnmeyer, Kathleen O, 1364
 Still, Daniel J (author) see English, Brett A, 867
 Stirling, Alexandra L (author) see Brodeur, Michael R, 1562
 Stoltz, Scott K (author) see Grillo, Joseph A, 167
 Stone, Elizabeth A (author) see Cawley, Michael J, 303
 Strocchi, Enrico (author) see Boriani, Giuseppe, 1292
 Strom, Brian L (author) Comment: Comparison of FDA Reports of Patient Deaths Associated with Sildenafil and with Injectable Alprostadil (L) 1143
 Struckman, Daniel R (author) Combined Therapy with an Angiotensin II Receptor Blocker and an ACE Inhibitor in Heart Failure (DIR) 242
 Struminger, LBB (author) see Sheit, Wisam, 1049
 Stull, Dawn M (author) see Holdsworth, Mark T, 509
 Sulem, Patrick (author) Atorvastatin-Induced Diaphragmatic Muscle Impairment (L) 1292
 Sulli, Maria M (author) see Gianni, Laura M, 943
 Sullivan, Donald L (author) Information in Consumer Advertisements of Prescription Drugs (L) 1494
 Sumpston, Janice E (author) Treatment of Neuropathic Pain with Venlafaxine (CR) 557
 Sutherland, Brian (author) see Walker, J Bryan, 1297
 Svärdsudd, Kurt (author) see Jørgensen, Tove M, 1004
 Szabo, Susan (author) see James, Christopher W, 882

T

Takahashi, Takashi (author) Desensitization to Fluconazole in an AIDS Patient (L) 642

Tan, Phyllis W (coauthor) see Riedinger, June E, 228
 Tangredi, Joseph F (author) Hypertension as a Complication of Topical Testosterone Therapy (CR) 1205
 Taylor, Charles T (author) Adrenocorticotropic Hormone for Acute Management of Gout (DIR) 365
 Taylor, Geoffrey D (coauthor) see Hughes, Christine A, 877
 Taylor, Harris C (coauthor) see Avram, Anca M, 1381
 Taylor, Jerry W (author) book review, 648
 Taylor, Karyn L (coauthor) see Bartels, Cathy L, 109
 Teefy, Anna M (coauthor) see Kovacs, Michael J, 506
 Temple, Mary E (author) Gastrostomy Tube Placement in Non-adherent HIV-Infected Children (RR) 414
 Terpening, Chris M (author) Mediators of Chronic Heart Failure: How Drugs Work (A) 1066; (coauthor) see Smith, Jerry D, 702
 Tholakanahalli, Venkatakrishna N (author) Fluconazole-Induced Torsades De Pointes (CR) 432
 Thomas, Michael L (author) Pulmonary Edema Associated with Rosiglitazone and Troglitazone (L) 123
 Thompson, Dennis F (author) Publication Rates in Australia, Canada, UK and US Pharmacy Schools (L) 126
 Thornton, Alice C (coauthor) see Empey, Philip E, 687
 Thunberg, Margareta E (coauthor) see Westerlund, LO Tommy, 1343
 Tibbs, Phillip A (coauthor) see Gora-Harper, Mary Len, 1320
 Tice, David S (coauthor) see Quillit, Rod Everett, 206
 Tillotson, Glenn S (author) Comment: Peripheral Neuropathy Associated with Fluoroquinolones (L) 1673
 Timmuth, Alan H (author) Dalteparin as Periprocedure Anticoagulation for Patients on Warfarin and at High Risk of Thrombosis (RR) 669
 Tomson, Goran B (coauthor) see Chuc, Nguyen Thi Kim, 1283
 Torres, Rafael A (coauthor) see Reeves, Roy R, 698
 Trappier, Brian (author) book review, 1146
 Trenque, Thierry C (coauthor) see Bisschop, Dorothee Y, 311
 Trissel, Lawrence A (coauthor) see Zhang, Yanping, 1360
 Tsourounis, Candy (coauthor) see Le, Jennifer, 329
 Tsun, Ellen C (author) Intermittent Dosing of Alendronate (DIR) 1471
 Tu, Katie B (coauthor) see Hoches, James D, 862
 Turcasso, Nannette M (author) Tenecteplase for Treatment of Acute Myocardial Infarction (A) 1233
 Tutluoglu, Bulent (author) Effects of Heparin on Hypertonic Potassium Chloride Induced Bronchoconstriction (RR) 1161

U-Z

Udall, Jr, John N (coauthor) see Serrano, Maria-Stella, 823
 Uden, Donald L (coauthor) see Horn, Susan D, 990
 Valdecia, Mabel E (author) Interaction Between Orlistat and Antihypertensive Drugs (L) 1495
 Vanuck, Robert J (coauthor) see Vander Zanden, Jeanne A, 1633
 Vander Zanden, Jeanne A (author) Systemic Adverse Effects of Ophthalmic β -Blockers (A) 1633
 VanNoord, Glenn R (coauthor) see Jameson, John P, 835
 Varela, José M (coauthor) see González de la Puente, Miguel A, 1492
 Vella-Brincat, Jane (coauthor) see Kirkpatrick, Carl MJ, 1295
 Vera-Llonch, Montserrat (author) Cost-Effectiveness Results from the US Carvedilol Heart Failure Trials Program (RR) 846
 Verrico, Margaret M (coauthor) see Coley, Kim C, 985
 Vertrees, Julia E (coauthor) see Alfaro, Cara L, 1028
 Vivian, Eva M (author) Slowing the Progression of Renal Disease in Diabetic Patients (A) 452
 Vodolo, Kristen M (coauthor) see Segarra-Newnham, Marisol, 741
 Wagner, Bertil KJ (coauthor) see Kelly, Kathleen M, 1299
 Wagner, Mary L (author) Comparison of Internet and Community Pharmacies (A) 116
 Walker, J Bryan (author) book review, 1297; (author) NSAID Impairment of Orthodontic Tooth Movement (DIR) 113
 Wall, Geoffrey C (coauthor) see Dixon, Amy J, 192
 Wallander, Mari-Ann (coauthor) see Jorgensen, Tove M, 1004
 Ward, K Allan (author) book review, 265
 Wazny, Lori D (author) Desensitization Protocols for Vancomycin Hypersensitivity (A) 1458
 Webb, Melissa J (coauthor) see Rigler, Sally K, 811
 Webber, Dawn M (coauthor) see Kelly, John, 1535
 Webster, Kathy D (author) book review, 787
 Weerasinghe, Swarna DS (coauthor) see MacCara, Mary E, 852

Weickum, Ricke J (coauthor) see Mayer, Michael I, 1548
 Weimerskirch, Patti R (author) Newer Dopamine Agonists in the Treatment of Restless Legs Syndrome (DIR) 627
 Weinberger, Miriam (coauthor) see Bishara, Jihad, 308
 Wells, Brian J (coauthor) see Ragucci, Kelly R, 1556
 Weiler, Karissa (coauthor) see Reddy, Prabhshni, 682
 Wendel, Christopher S (author) Barriers to Use of Electronic Adherence Monitoring in an HIV Clinic (A) 1010
 Westerlund, LO Tommy (author) Nonprescription Drug-Related Problems and Pharmacy Interventions (RR) 1343
 White, C Michael (coauthor) see Caron, Michael F, 1248; (coauthor) see Song, Jessica C, 236
 White, Jr, John R (coauthor) see Levien, Terri L, 1426
 White, Richard H (coauthor) see Dager, William E, 885
 White, Roger L (coauthor) see Hodges, Brian M, 1224
 Whitney, Jr, Harvey AK (author) George F. Archambault, JD, ScD, PharmD 1909-2001: A Salute to My Coach (TRIB) 383
 Whyte, Ian M (coauthor) see Isbister, Geoffrey K, 1143; (coauthor) see Isbister, Geoffrey K, 1674
 Wiggins, Barbara S (coauthor) see Kondo, I. Midori, 440
 Wiley, Roy B (coauthor) see Sajbel, Terrie A, 281
 Wilkie, John C (author) Mifepristone — A Boom or a Bust? (O) 389
 Wilson, LTC, James P (coauthor) see Omar, Mohamed A, 1096
 Wilson, Susan E (coauthor) see Rhodes, Richard S, 675
 Witthrodt, Eric T (coauthor) see Bain, Kevin T, 566
 Wittkowsky, Ann K (coauthor) see Kondo, I. Midori, 440
 Wong, Siu-Fun (author) Oral Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma (A) 1056
 Woodall, Betsy S (author) Comment: Olanzapine-Induced Acute Pancreatitis (L) 506
 Woolley, Thomas W (coauthor) see Rotch, Allison L, 817
 Woosley, Jr, Raymond L (coauthor) see Rosebraugh, Curtis J, 1024
 Wortman, George I (coauthor) see Vander Zanden, Jeanne A, 1633
 Wozniak, Antonette J (coauthor) see Liu, Chin Y, 188
 Wright, Stephanie Gooch (coauthor) see Rotch, Allison L, 817
 Wynn, Heather E (coauthor) see Rayner, Craig R, 1391
 Yamada, Harumi (coauthor) see Takahashi, Takashi, 642
 Yasuda, Sally U (coauthor) see Rosebraugh, Curtis J, 1024
 Yebra-Pimentel, Maria T (coauthor) see Del Pozo, Jesús, 891
 Yilmaz, A Sema (coauthor) see Cakmakci, Ayse, 964
 Yin, Barbara T (coauthor) see Liu, Chin Y, 188
 Younis, Wisam S (author) Pharmacists' Attitudes Toward Diabetes and Their Involvement in Diabetes Education (RR) 841
 Yow, Kai L (coauthor) see Ho, Paul C, 1293
 Yuan, Rey-Yue (author) Delirium Following a Switch from Cimetidine to Famotidine (CR) 1045
 Yuste Izquierdo, Ana Lucia (coauthor) see Segura Huerta, Angel, 894
 Zambrana, Jose L (coauthor) see Cruz Caparrós, Gracia, 1208
 Zammil, Christine M (coauthor) see Debourdeau, Philippe M, 424
 Zarowitz, Barbara J (author) Managing the Pharmaceutical Industry-Health System Interface (E) 1661
 Zed, Peter J (author) Meta-Analysis of Proton Pump Inhibitors in Treatment of Bleeding Peptic Ulcers (RR) 1528
 Zerjav-Lacombe, Sylvia (author) Possible Serotonin Syndrome Associated with Clomipramine after Withdrawal of Clozapine (CR) 180
 Zhang, Yanping (author) Stability of Piperacillin and Ticarcillin in AutoDose Infusion System Bags (RR) 1360
 Zhu, Min (coauthor) see Peloquin, Charles A, 1332
 Zolezzi, Monica (author) Seizures with Intravenous Codeine Phosphate (CR) 1211
 Zurdo, Jose Martin (coauthor) see Jimenez-Jimenez, Felix Javier, 1565

ADVERTISER INDEX

Bayer Corporation, Cipro, otc-Jan, otc-Mar, otc-May, otc-J/A, otc-Sept, otc-Nov
 Christian Medical & Dental Associations, 2001 National Convention, 426, 661
 Christian Pharmacists Fellowship International, Christianity & Pharmacy, 1583
 College of Psychiatric and Neurologic Pharmacists, CPNP 2001, 143, 273, 401

Harvey Whitney Books Company, Books and Journals for Pharmacy and Pharmacotherapy, 6, 152, 406, 666; Certification Review for Pharmacy Technicians, 660; Journal of Pharmacy Technology, reprints available, 191, 307, 431, 562, 740, 1547; subscriptions, 129, 359; Medical Abbreviations, 10th Ed., 626, 942, 1309, 1448, 1539; Pediatric Drug Formulations, 4th Ed., 132, 274, 388, 514, 649, 798, 984, otc-Nov, otc-Dec; Pharmacoeconomics, An Introduction, 3rd Ed., 142, 393, 522, otc-May, 800; Pharmacy and Pharmacotherapy References to Meet Today's Health Care Demands, 1316; Principles of Pharmacoeconomics, 2nd Ed., 400; The Annals of Pharmacotherapy, bound volumes, 172, 380, 488, 588, 701, 907, 1023, 1193, 1359; full text now available online, 20, 166, 273, 288, 423, 532, 690, 840, 1052, 1172; PharmaCE, 136, 272, 396, 521, 652, 796, 975, 1154, 1308, 1504, 1686; subscriptions, 5, 145, 151, 259, 280, 389, 405, 515, 528, 653, 665, 791, 802, 977, 980, 1139, 1160, 1301, 1314, 1511, 1516; Therapeutics in the Elderly, 3rd Ed., otc-Jan, 264, otc-Mar, otc-April, 646, otc-J/A, otc-Sept, otc-Oct
 Personnel Placement, Israel, Hebrew University, 523; Wisconsin, The University of Wisconsin School of Pharmacy, 1155
 Pfizer, Inc., Zolof, otc-Feb, otc-April, otc-June, otc-Oct, otc-Dec
 Pharmacia Corp., Axert, otc-June
 Wyeth-Ayerst Laboratories, Cordarone IV, otc-Jan, otc-Feb; Zosyn, otc-Mar, otc-May, otc-J/A, otc-Sept, otc-Nov

INDEX ABBREVIATIONS

A: Article
 CR: Case Report
 E: Editorial
 ibc: inside back cover
 ifc: inside front cover
 IR: International Report
 L: Letter
 NC: News and Comments
 O: Opinion
 RR: Research Report
 SC: Special Contribution
 VO: Visual Observation

Statement of ownership, management, and monthly circulation (11 issues, \$249.00 annually) of The Annals of Pharmacotherapy, publication no. 1060-0280. Owner, Harvey Whitney Books Company, Publisher, editor, and managing editor: Harvey AK Whitney Jr, Headquarters of publisher, owner, and publication: 8044 Montgomery Road, PO Box 42696, Cincinnati, OH 45242. Known bondholders, mortgages, and other security holders: none. Average no. of copies of each issue from October 2000 to October 2001 and no. of copies of October 01 issue: A, total no. copies printed (net press run) 4800, 4700; B, paid and/or requested circulation (1) sales through dealers and carriers, street vendors, and counter sales 0, 0; (2) paid or requested mail subscriptions 2500, 2600; C, total paid and/or requested circulation 3650, 3781; D, free distribution by mail 300, 294; F, total free distribution 300, 294; G, total distribution 3950, 4075; H, copies not distributed (1) office use, leftovers, spoiled 850, 625; I, Total 4800, 4700. No. of issues published annually: 11. Date of filing 1 October 2001. Signed: Harvey AK Whitney Jr, publisher.

